Genetic and environmental determinants of lung function in the general population by Siedlinski, Mateusz Iwo
  
 University of Groningen
Genetic and environmental determinants of lung function in the general population
Siedlinski, Mateusz Iwo
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Siedlinski, M. I. (2009). Genetic and environmental determinants of lung function in the general population.
[S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019

Genetic and environmental determinants of lung function 
in the general population 
Mateusz Siedlinski 
M. Siedlinski 
Genetic and environmental determinants of lung function in the general 
population 
Thesis University of Groningen with summary in Dutch 
The studies described in this thesis were financially supported by the Groningen 
University Institute for Drug Exploration (GUIDE) and the Dutch Asthma 
Foundation. 
Printing of this thesis was financially supported by: Rijksuniversiteit Groningen, 
University Medical Center Groningen, Groningen University Institute for Drug 
Exploration (GUIDE), Stichting Astma Bestrijding, AstraZeneca BV, Pfizer BV, 
Boehringer lngelheim BV, GlaxoSmithKline BV. 
Cover design inspired by a theme from The Matrix movie. 
Printed by EIKON PLUS (Krakow, Poland). 
© 2009 M. Siedlinski. All rights reserved. No part of this book may be 
reproduced or transmitted in any form or by any means without permission of 
the author. 
ISBN: 978-90-3 67-3912-2 
Stellingen behorende bij het proefschrift: 
"Genetic and environmental determinants of lung function 
in the general population" 
1. Two Single Nucleotide Polymorphisms in the 3' region of ABCCl 
significantly associate with the level of FEV1 in two independent 
cohorts (this thesis}. This may still represent genetic variation in the 
ABCC6 gene. 
2. Polymorphisms in the 5' region of GCLC are important for the level of 
lung function, yet only in interaction with smoking. This thesis 
3. It is better to drink white wine than red wine if one wishes to have a 
higher lung function. This thesis 
4 .  Though oxidative stress is important in FEV1 decline and COPD 
development, variations in genes involved in the regulation of the 
redox balance in vivo, such as NFE2L2, KEAPl or EPHXl, do not 
associate with the course of lung function over time. This thesis 
5. Correlation does not imply causation. 
6. The lack of significant association of a SNP with a trait does not imply 
that the gene is not important for this trait. 
7. Functional genetic studies facilitate understanding of epidemiological 
findings and vice versa. 
8. "Science is the great antidote to the poison of enthusiasm and 
superstition." Adam Smith 
9. "The whole of science is nothing more than a refinement of everyday 
thinking." Albert Einstein 
10. "I know, through not knowing." adapted from Socrates 











Genetic and environmental determinants of lung function 
in the general population 
Proefschrift 
ter verkrijging van het doctoraat in de 
Medische Wetenschappen 
aan de Rijksuniversiteit Groningen 
op gezag van de 
Rector Magnificus, dr. F. Zwarts, 
in het openbaar te verdedigen op 
woensdag 28 oktober 2009 
om 16.15 uur 
door 
Mateusz lwo Siedlinski 
geboren op 29 April 1981 









Promotores: Prof. Dr. H.M. Boezen 
Prof. Dr. D.S. Postma 
Prof. Dr. H.A. Smit 
Beoordelingscommissie: Prof. Dr. N.M. Probst-Hensch 
Prof. Dr. H. Snieder 
Prof. Dr. J. Vestbo 





1. General introduction and aims of the thesis 
2. Lung function loss, smoking, vitamin C intake and 
polymorphisms of the glutamate-cysteine ligase genes 
3. The wine-resveratrol-S/RTl pathway and the level 
of lung function of the general population 
4. ABCCl polymorphisms contribute to level and decline of 






5. Level and course of FEV1 in relation to polymorphisms 97 
in NFE2l2 and KEAPl in the general population 
6. Superoxide dismutases, lung function and bronchial 117 
responsiveness in a general population 
7. No effects of EPHXl polymorphisms on the level or change 137 
of FEV 1 in the general population 
8. Heme Oxygenase l variations and lung function decline 
in smokers: proof of replication 
9. Level and course of lung function and variations in the 
GSTOl/GST02 cluster in the general population 
10. Summary, conclusions and future perspectives 











Chronic Obstructive Pulmonary Disease (COPD) is a worldwide prevalent disease with 
increasing mortality and morbidity. The disease has great economical and societal impact 
and is projected to be the fifth cause of disease related mortality worldwide in 2020 1. 
Tobacco smoking is the major risk factor for COPD, however numerous other behavioral, 
environmental and genetic factors contribute to the development of COPD as well. 
COPD is a disease characterized by a low level of lung function and abnormally accelerated 
lung function decline. The worldwide adopted criteria for a COPD diagnosis were 
developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1. These 
criteria define the presence of COPD as a ratio of postbronchodilator measurements of 
Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) below 0.70. 
Furthermore, the stages of COPD severity are defined according to the level of FEV1, 
normalized for sex, height, and age (table 1). 
Table 1: Stages of Chronic 
Obstructive Pulmonary Disease 
according to the Global Initiative for 





IV -Very Severe 
Postbronchodilator Spirometry: 
FEVJFVC < 0.70 and FEV1 ;:: 80% predicted 
FEVJFVC < 0.70 and 50% S FEV1 < 80% predicted 
FEVJFVC < 0.70 and 30% s FEV1 < 50% predicted 
FEVJFVC < 0.70 and FEV1 < 30% predicted, 
or FEV1 < 50% predicted plus chronic respiratory failure 
Lung function is affected by the aging process, which is reflected by the decline in FEV1 
level and FEV1/FVC ratio throughout lifetime. Since the decline in lung function is a normal 
physiological phenomenon, using a fixed 0.70 cutoff of FEV1/FVC ratio as definition of 
COPD may overestimate the prevalence of the disease in the older ages and consequently 
underestimate it in younger subjects 1. Therefore another method to define COPD has 
been advocated, i.e. the Lower Limit of Normal FEVi/FVC ratio, accounting for this 
misclassification 2• Briefly, the LLN method defines the presence of airway obstruction in 
the lowest 5th percentile of lung function measurements within never-smoking subjects 
who are generally not exposed to risk factors for COPD development. The subsequently 
calculated prediction equation for the level of FEV 1 and FEV 1/FVC ratio is used to define 
the status of airway obstruction for all subjects within the studied cohort. 
Since the clinical expression of COPD occurs predominantly after the age of 50 years, it is 
important to search, define and study phenotypes that may help to predict whether a 
subject will develop COPD in the future. Lung growth starts at prenatal stage, and reaches 
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a plateau phase that ends approximately at the age of 30 years. After this period lung 
function, reflected by FEV1 measurement, starts to decline with a rate of 20-30 ml per year 
(figure 1). It has been shown that abnormally accelerated FEV1 decline leads to 
development of COPD 3, thus the identification of risk factors for the accelerated FEV1 
decline is one of the milestones in studies aiming to predict and prevent development of 
COPD. The level of lung function is another phenotype that is useful in studies focusing on 
COPD development, since it may reflect a reduced, abnormal growth of the lungs in youth, 
irrespective of the normal lung function decline that occurs thereafter. 
Figure 1: Lifetime course of Forced Expiratory Volume in 1 second adapted from Fletcher et al. 4, with indicated 
GOLD-defined COPD stages 
100 
80 
% of FEV1 
level Moderate COPD 
at age 25 SO 
30 
25 
Very severe COPD 
40 55 
Age 




The GOLD-defined stages of COPD severity are depicted for an FEVJFVC ratio below 0. 70 and according to the 
thresholds of% predicted FEV 1, assuming a 100% level at age 25. Another, not depicted in the figure, scenario 
leading to the abnormal lung function level, and development of COPD might be an impaired lung growth, 
resulting in low maximal FEV1 level attained in plateau phase, i.e. presumably before the age of 30. 
Environmental risk factors for COPD 
It has been shown that, apart from smoking, many other behavioral and environmental 
factors affect lung function and consequently the development of COPD. Second-hand 
smoking is a risk factor for many human disorders including COPD 5, and therefore several 
European countries have recently introduced a "free of tobacco smoke" policy concerning 
public places. Several types of occupations, and especially those related to the exposure to 
vapors, gas or dust, have been shown to substantially contribute to the occurrence of the 
disease, with a 20-30% population attributable fraction 6• It was shown that the 
prevalence of COPD symptoms and emphysema is higher in areas with higher particulate 
air pollution 7, which therefore often is considered to be another environmental risk factor 
for COPD development. 
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Dietary intake has been one of the most intensively studied fields in the epidemiology of 
pulmonary function in the general population and consequently in the development of 
COPD. Prospective cohort studies showed that both women and men with a diet rich in 
vegetables, fruits and fish (i.e. prudent dietary pattern} have a lower risk for COPD 
development, COPD symptoms and higher FEV1 level, whereas a diet rich in red and cured 
meat, sweets and deserts (i.e. Western dietary pattern} predisposes for COPD 
development 8'9• 
The large cross-sectional MORGEN study aimed to identify single dietary items that are 
associated with lung function, respiratory symptoms and COPD. The intake of vitamin C 
was associated with a higher level of FEV1 and FVC and lower prevalence of chronic 
coughing, which is one of the symptoms accompanying COPD 10• Numerous other studies 
have consistently shown a beneficial effect of this vitamin on lung function in the general 
population 11• Interestingly, higher vitamin C intake was also associated with a slower FEV1 
decline, which further stresses the preventive potential of this antioxidant in the 
development of COPD 12• Vitamin C is an exogenous antioxidant constituent of the 
epithelial lining fluid in lungs, present in much higher levels than in plasma 13• This 
suggests an important role of vitamin C in lung protection against exogenous toxins, like 
reactive oxygen and nitrogen species found in cigarette smoke. A molecular mechanism of 
the beneficial effects of vitamin C on lung function likely involves direct neutralization of 
toxic cigarette smoke compounds or an indirect mechanism driven via endogenous 
antioxidant systems like the glutathione cycle 14• This further implies a possible 
involvement of certain genes, like glutathione synthetases or glutathione transferases in 
the vitamin C antioxidant cycle in vivo. 
Another dietary antioxidant, �-carotene, a vitamin A precursor found in many fruits and 
vegetables, has been associated with a higher level of lung function, but not with 
respiratory symptoms in the MORGEN study 10. However, another cross-sectional study 
did not show an association of total carotene (i.e. a- and �- isoforms} intake with lung 
function 15, which implicates that the effects of carotene on lung function depends on a 
specific form of this molecule. 
Apart from antioxidant vitamins, plant polyphenols were suggested to protect against 
COPD development. In particular the intake of catechins, members of the flavonoids 
family, showed convincing association with a lower risk of COPD symptoms, i.e. chronic 
cough, chronic phlegm production and breathlessness, in the MORGEN study 16• Since the 
intake of tea, which is the major dietary source of flavonoids, was neither associated with 
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FEV1 level, nor with COPD symptoms, the direct causative effect of flavonoids intake on 
lung function still requires further investigation. 
Both, low (<lg/day) and high (>30g/day) intake of alcohol was found to be associated with 
a lower level of lung function and higher prevalence of COPD symptoms as compared to 
moderate alcohol intake (1-30 g/day) 17• Moreover, subjects with moderate alcohol 
consumption (i.e. approximately between 1-3 drinks per day) showed a lower risk of COPD 
mortality in a longitudinal study involving 3 European countries 18• Interestingly, the study 
performed on 1,555 New York residents suggested that the effect of alcohol intake on 
lung function level depends on the type of alcoholic beverage 19• Thus the intake of wine, 
but not of beer or liquor, is associated with higher levels of FEV1 and FVC. Remarkably, 
white wine intake showed a much stronger association with lung function than red wine 
intake, which could possibly be explained by confounding effects of lifestyle factors 
associated with the intake of a specific type of wine 19• Wine is a rich source of grape­
derived polyphenols that provide anti-inflammatory and antioxidants effects in vitro. The 
production process differs according to the type of wine, and causes red wine to contain 
much higher levels of polyphenolic molecules as compared to white wine. Thus the 
observed effect of white wine intake might be driven by yet unknown or unidentified 
molecules. For example it has been recently shown that polyphenols hydroxytyrosol and 
tyrosol may be responsible for the beneficial effects of white wine 20• 
Other dietary compounds that are associated with the level of lung function are whole 
grain products. Higher intake of these products was associated with higher lung function 
level and lower prevalence of COPD-specific symptoms in the MORGEN study 17• It has 
been suggested that whole grain components like fibre, unsaturated fatty acids, 
antioxidant nutrients, tocotrienols, lignans and phenolic compounds are responsible for 
beneficial effects of these products in a wide range of diseases including lung disorders 21• 
Importantly not all grain products are equally beneficial for human health since the 
process of grain refining depletes contents of fibre, minerals and vitamins 21 • 
The biological mechanism of the dietary compounds' action includes the phase of 
absorption in the gastrointestinal tract, when the compounds are transferred to the blood 
and further to tissues. Therefore the level of exogenous vitamins and micronutrients in 
blood depends on the level of dietary intake, and it likely better reflects the micro-/macro­
nutrients status of the organism than data on the reported dietary intake. A recent study 
showed that elevated levels of vitamin A, �-cryptoxanthin (a vitamin A precursor), vitamin 
C and vitamin E are independently associated with a higher FEV1 level in a cohort of over 
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14 ,000 subjects from the Third National Health and Nutrition Survey 22• Interestingly a 
positive association of blood selenium level, a cofactor of antioxidant enzymes like 
glutathione peroxidases and thioredoxin reductase, with lung function was reported by 
two studies 22'23 • 
Genetic risk factors for COPD 
The human genome consists of deoxyribonucleic acid (DNA}, and contains information on 
protein and ribonucleic acid content of the cell. The whole genome consists of 
approximately 3 billions base pairs (adenine, thymine, guanine or cytosine} organized in 
23 chromosome pairs located in the nucleus and inherited from both parents and in 
maternally inherited mitochondrial DNA. Although over 99% of the genome has a similar 
structure in humans, certain base pairs may differ between subjects and these are called 
Single Nucleotide Polymorphisms (SNPs}. Over 15  millions SNPs in the human genome are 
currently known, yet only a minority is functional. A functional SNP has a direct effect on 
the rate of gene transcription (e.g. polymorphisms in the promoter region} or alters the 
function of translated protein (e.g. nonsynonymous polymorphisms altering amino acid 
sequence in protein}. Apart from SNPs, other modifications of the genome are known. 
These involve copy number variations, deletions, or insertions altering DNA sequence or 
epigenetic phenomena, like DNA methylation, which do not alter DNA sequence, but still 
are able to completely silence or increase gene transcription. 
There is substantial evidence that lung function and susceptibility to COPD are partially 
determined by genetic factors. Familial and twin studies have provided evidence that lung 
function and susceptibility to COPD cluster within members of the same family 24'25, who, 
per definition, share similar genome parts. The Framingham study suggested a relatively 
high ("'4 0%} heritability (i.e.% of variance explained by genetic component} of the level of 
FEV1 and FVC in the general population, yet the heritability of FEV1 decline was 
considerably lower ("'15%} 26• 
al-antitrypsin deficiency 
An established genetic risk factor for early onset COPD and accelerated lung function 
decline is al-antitrypsin deficiency caused by polymorphisms in SERPINAl locus on 
chromosome 14. SERPINAl codes al-antitrypsin (AAT) protein that inhibits activity of 
serine proteases such as neutrophil elastase, which has a direct contribution to the loss of 
elastic tissue in lung parenchyma observed in COPD. Rare variations, including null alleles 
within SERPINAl locus have been identified and the homozygosity for the Lys3 42Glu 
substitution, known as a Z allele, results in low (10% of normal values or less} AAT levels 
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and is a risk factor for COPD, yet with a low population attributable risk 3 • It has been 
found that heterozygosity for the Z allele may increase the risk for COPD as well 27 • 
Interestingly, there exist numerous, rare haplotypes in the SERPINA1 locus not linked with 
the Z allele and six of them have been associated with COPD in Caucasians 28• Remarkably, 
these haplotypes contain functional SNPs, which affect SERPINA1 expression in response 
to cytokines 29• 
Polymorphisms in antioxidant and detoxifying enzymes 
An imbalance between oxidants and antioxidants is considered to be an important 
causative factor in the onset and progression of COPD. Cigarette smoke contains more 
than 4 000 different chemical molecules including a large amount of highly reactive free 
radicals 30, which disturb the redox balance in the lungs, leading to the elevation of 
oxidative burden 31• Such an oxidant overdose can injure lung tissue directly by oxidation 
of cellular components 31 or indirectly by promoting inflammation or tissue degradation 32• 
When the lungs are chronically exposed to cigarette smoke a more efficient protection 
against this oxidative stress is needed. Such a protection can be provided by endogenous 
factors like antioxidant enzymes that are capable to neutralize certain toxic cigarette 
smoke compounds. Therefore, variations in enzymes involved in tissue redox balance and 
detoxification processes have been intensively studied in smoking-related disorders like 
COPD. 
One of the first described candidate genes for COPD is a phase II detoxification enzyme 
Epoxide Hydrolase 1 33 • The prevalent nonsynonymous polymorphisms Tyrll3His and 
Arg139His affect EPHXl enzymatic activity 34, providing a direct mechanism explaining 
their association with COPD development. Nevertheless, further replication studies 
provided contradictory findings concerning the role of EPHX1 polymorphisms in COPD 
development across different races, and a recent meta-analysis suggested that EPHX1 
variations associate with COPD in Asian, rather than in Caucasian subjects 35• Therefore, 
more prospective cohort studies are needed to determine the role of EPHX1 SNPs in the 
development of COPD in Caucasians. 
The large prospective Copenhagen General Population Study and Copenhagen City Heart 
study showed that three SNPs in Superoxide Dismutase 3 (5003) gene were associated 
with lung function, COPD prevalence and COPD hospitalization 36'37 • SOD3 is an 
extracellular antioxidant enzyme responsible for conversion of highly reactive superoxide 
anion into hydrogen peroxide. The Arg213Gly substitution in SOD3 decreases the affinity 
of the enzyme to extracellular heparin and additionally protects against protease 
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degradation, which eventually leads to the elevation of 50D3 level in plasma 38'39• These 
findings may explain a protective role of the Arg213 Gly substitution in COPD development 
as found in the Copenhagen City Heart study and in a subsequent case-control study from 
New Zealand 37A0• The two other, completely linked, 5003 polymorphisms, located in the 
intronic and 5' untranslated region of 5003, were associated with increased risk for COPD 
and lower FVC level 36• However, their functional implications still remain unknown. Two 
other members of the superoxide dismutase family have been described, but their 
functional polymorphisms, i.e. Ala16Val located in mitochondrial targeting sequence of 
5002 and +3 5A/C SNP, located adjacently to a splice site in 5001, were not associated 
with COPD in Chinese and Caucasians 40'41• Therefore, definite conclusions about the role 
of these polymorphisms in lung function of the general population cannot be drawn so far. 
Another enzyme in which variations may play a role in COPD is Heme 0xygenase 1 
(HM0X1). HM0X1 degrades heme to biliverdin, carbon monoxide and free iron, and all 
these molecules possess various functions including neutralization of reactive oxygen 
species or cytoprotection in vivo. Importantly, alveolar macrophages of COPD patients 
contain less HMOXl protein as compared to controls 42• The HM0X1 promoter region 
contains polymorphism consisting of varying number of di nucleotide GT repeats between 
subjects. It has been shown that the long (>32 GT repeats) variant results in lower 
expression of HM0X1 in response to oxidative stress, thus it may be directly involved in 
the pathogenesis of smoking related disorders like COPD 43• The same study showed that 
the presence of the long allele is associated with a higher COPD prevalence in Japanese 43, 
which is in agreement with results provided by the subsequent study associating the 
presence of the long allele with accelerated lung function decline in Caucasian smokers 44• 
Expression of HMOXl and other antioxidant enzymes in vivo is regulated by transcription 
factor NFE2L2 (Nuclear Factor (Erythroid-derived 2)-Like 2). Oxidative stress causes 
disruption of the NFE2L2 complex with its cytosolic repressor Kelch-like ECH-associated 
protein-1 (KEAPl), translocation of NFE2L2 to the nucleus and a subsequent induction of 
the expression of antioxidant genes 45• It has been shown that NFE2L2 protects mice 
against elastase-induced 46 and tobacco-induced 47 emphysema. Recent studies showed 
that a homeostasis of the NFE2L2 pathway is disturbed in lung tissue of COPD patients 48-
50
. Additionally, the expression pattern of both KEAP1 and NFE2L2 is different in COPD 
patients as compared to healthy never- or former- smokers 48,49 and the expression of 
NFE2L2-regulated antioxidant genes is lower in COPD subjects than in non-diseased 
controls 50• So far, genetic studies concerning the role of NFE2L2 and KEAP1 in COPD are 
lacking. 
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Other phase II detoxification enzymes, widely studied in the field of COPD genetics, are 
Glutathione S-Transferases {GSTs) and particularly GSTPl, GSTTl and GSTMl members of 
the GSTs family. The genes coding the two latter enzymes are absent in approximately 
20%, respectively 60% of the Caucasian population, due to deletions (null genotype) 
occurring likely during the crossing-over process. It has been shown in the general 
population-based SAPALDIA cohort that males carrying the GSTT1 null genotype are at risk 
for accelerated FEV1 decline 
51
• Contrary, a recent meta-analysis suggested that the 
GSTM1 null genotype is a risk factor for COPD in non-Asian populations while the GSTTl 
null genotype has no effect in this respect 52• 
Summary of candidate gene studies on COP D  so far 
The genetics of COPD has been studied predominantly using case-control approaches. 
Therefore, population-based cohort studies are required in order to more deeply 
characterize identified candidate genes for COPD development. Such prospective studies 
put new insight into the progressive lung function loss that is determined by the genetic 
component, and ultimately contribute to better understanding of the etiology of COPD. 
Moreover, there is a need to analyze variations within genes not previously studied, yet 
postulated to play an important role in the lung due to results of in vivo and in vitro 
studies. The analysis of gene by environment interactions in the cohort studies 
additionally helps to identify subjects being at the more than average risk for accelerated 
lung function decline and development of COPD, due to the presence of both 
environmental and genetic risk factors. Such studies are still lacking, though they are 
crucial for a complete overview of genetic and environmental interactive networks in the 
lung. 
AIMS OF THE THESIS 
The major purpose of studies described in this thesis is to identify and describe genetic 
variations affecting lung function in the general population, with additional characteristics 
of possible gene by environment interactions. The majority of genes described in the 
thesis participate in the regulation of redox balance in lung tissue, which is of special 
importance in smoking related disorders like Chronic Obstructive Pulmonary Disease 
{COPD). 
Chapters 2 and 3 describe two biological pathways containing both genetic and dietary 
components, which are hypothesized to play an important role in the course of lung 
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function and COPD development. Chapter 2 focuses on the functional polymorphisms in 
genes coding subunits of glutamate cysteine ligase, the rate limiting enzyme in the 
synthesis of major endogenous lung antioxidant glutathione. The main purpose of this 
chapter was to describe the potential interactions between these variations and 
exogenous modulators of the red ox state in the lung i.e. cigarette smoking and vitamin C 
intake. Chapter 3 describes in detail the role of the anti-inflammatory polyphenol 
resveratrol intake in the level of lung function and presence of COPD in the general 
population. Furthermore it investigates whether variations in Sirtuin 1, a deacetylase gene 
induced by resveratrol, affect the level and decline of lung function in two independent 
cohorts. 
Chapters 4 and 5 focus on genetic variations in candidate genes, not previously studied in 
the context of lung function genetics. The main purpose of chapter 4 was to investigate in 
detail Single Nucleotide Polymorphisms (SNPs} located in the ABCC1 gene coding 
Multidrug Resistance-associated Protein 1. This study includes investigation of all ABCC1 
tagging SNPs in relation to the level and decline of Forced Expiratory Volume in 1 second 
(FEV1} in two general population-based cohorts. Chapter 5 is focused on SNPs located in 
the key transcriptional regulators of antioxidant enzymes - transcription factor NFE2L2 and 
its cytosolic repressor KEAP1 . This chapter includes analysis concerning all available FEV1 
measurements across all surveys in the Doetinchem cohort and the Vlagtwedde­
Vlaardingen cohort. 
Chapters 6, 7, 8, and 9 aim to broaden the current knowledge about genetic variations 
previously identified as candidate genes for the level or decline lung function, or 
development of COPD in the general population. Chapter 6 describes a potential role of 
variations in superoxide dismutase (SOD} genes in the development of COPD and 
bronchial hyperresponsiveness, a risk factor for COPD, and the level and course of lung 
function in the Vlagtwedde-Vlaardingen cohort. The main purpose of this study is to 
investigate in details the role of SNPs in extracellular enzyme 5003, a gene, which has 
been previously associated with a lower risk for COPD by two independent studies. An 
additional aim was to extend these findings by analyzing SNPs in the mitochondrial 
enzyme 5002. Chapter 7 includes a study concerning level and course of FEV1 in relation 
to SNPs in Epoxide Hydrolase 1, a detoxifying gene identified as a COPD susceptibility 
candidate by multiple studies across different races. Another, previously described 
candidate gene for COPD development is Heme Oxygenase 1, and the impact of a 
promoter GT repeats in this gene on FEV1 decline is described in chapter 8. The additional 
aim of this chapter was to study all prevalent genotypes determined by this repeat in the 
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general population and to assess whether and how these genotypes affect the rate of FEV1 
decline in smokers. The major purpose of chapter 9 was to check for replication of the 
association, reported in the Framingham Heart whole genome association study, between 
SNP in the Glutathione Omega Transferase-2 {GST02) gene and the level of FEV1 and 
Forced Vital Capacity in a general population. This chapter elaborates on the Framingham 
study by analysis of all SNPs tagging GST02, and it additionally includes the analysis 
concerning variations in the adjacently located GSTOl gene. 
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ABSTRACT 
Rationale: Smoking induced oxidative stress contributes to COPD, a lung disease 
characterized by low lung function and increasing mortality worldwide. The 
counterbalance for this effect may be provided by e.g. increased intake of the antioxidant 
vitamin C or endogenously acting antioxidant enzymes like glutamate cysteine ligase (GCL) 
that is responsible for glutathione biosynthesis. 
Objectives: To investigate associations of functional polymorphisms in GCL subunits 
(GCLM and GCLC) with lung function level and its longitudinal course, with vitamin C and 
smoking habits as potential interactive factors. 
Methods: Two independent general population samples (Doetinchem, n=l,152 and 
Vlagtwedde-Vlaardingen, n=l,390) with multiple lung function (FEV1, FVC) measurements 
were genotyped for three polymorphisms (C(-129)T, C(-588)T, and a trinucleotide GAG 
repeat (TN R)) in the subunits of GCL. Genetic effects on lung function level and decline 
were estimated using linear regression and linear mixed effect models adjusted for 
confounders. Findings were further investigated for interactions with vitamin C intake in 
the Doetinchem cohort. 
Measurements and Main Results: GCLC polymorphisms were significantly associated with 
lower lung function levels in interaction with packyears smoked in both cohorts. TNR 
variants in GCLC were associated with accelerated FEV1 decline in both cohorts in 
interaction with packyears. All significant effects were specifically present in subjects 
within the lowest tertile of vitamin C intake. 
Conclusions: GCLC is a novel susceptibility gene for low level of lung function in two 
independent populations. We provide suggestive evidence that this occurs due to an 
interaction between GCLC polymorphisms, smoking, and low vitamin C intake, which all 
contribute to the oxidative burden. 
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INTRODUCTION 
Lung function loss leads to the development of Chronic Obstructive Pulmonary Disease 
(COPD) that is accompanied by increasing morbidity and mortality worldwide 1. The 
disease has a large personal, societal, and economic impact. COPD is characterized by a 
slow, progressive airflow limitation that is mainly caused by cigarette smoking and it is 
predicted to predominantly account for tobacco-caused deaths worldwide 2• The fact that 
some smokers are resistant to cigarette smoke and thus do not develop clinically relevant 
COPD suggests that other environmental factors and genetic variations can predispose to 
COPD development 3• 
Cigarette smoke contains a large amount of free radicals 4, which disturbs the redox 
balance in the lungs, leading to the elevation of oxidative burden 5• Such an oxidant 
overdose can injure lung tissue directly by oxidation of cellular components 5 or indirectly 
by promoting inflammation and tissue degradation 6• When the lungs are chronically 
exposed to cigarette smoke a more efficient protection against this oxidative stress is 
needed. The latter can take place via antioxidants consumed with food 5,7•9 and via 
endogenous factors like antioxidant enzymes that are capable to neutralize certain toxic 
cigarette smoke compounds 5' 10'11 . Vitamin C, that is abundantly present in the lung 
epithelial lining fluid, has been linked to a beneficial effect on lung function in several 
epidemiological studies 12 • Of all endogenous antioxidants, glutathione (GSH) has been 
shown to be present in the lung in uniquely high concentrations, which are even further 
increased in smokers 13• 
GSH plays a crucial role in systems like multidrug resistance proteins and the GSH 
transferases that neutralize a variety of xenobiotics 11• De nova GSH synthesis is a two-step 
reaction, with the first step being a rate-limiting one, i.e. this step is the bottleneck of the 
whole process 14• Within this step two aminoacids are conjugated by the glutamate­
cysteine ligase (GCL). GCL is a heterodimeric enzyme containing catalytic and modifier 
subunits, coded by the GCLC and GCLM genes respectively. Three polymorphisms in the 
GCLM and GCLC genes have been identified to have a functional role 15·19 and thus are of 
interest to study in the context of smoking-related lung function loss. 
We investigated whether previously identified and functional polymorphisms in GCLC and 
GCLM contribute to the level of lung function and its change over time in a prospective 
Dutch cohort study, i.e. the Doetinchem cohort. Additionally, we had the opportunity to 
assess interactions between genotypes and environmental factors (i.e. vitamin C intake 
and smoking habits) with respect to lung function parameters in this cohort. A replication 
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study in another population-based cohort, i.e. the Vlagtwedde-Vlaardingen cohort, was 




Subjects from the Doetinchem cohort study, a prospective part of the larger MORGEN 
study, were included 7'9• All subjects were tested for lung function two times with a 5-year 
interval : measurements of Forced Expiratory Volume in one second (FEV1) and Vital 
Capacity (VC, performed with forced expiratory maneuver) were performed with a heated 
pneumotachometer (Jaeger, Germany). A sub-sample (n=l,152) was randomly selected 
from the total cohort (n=3 ,224 ) with no significant differences in population 
characteristics (table E2 in the on line supplement). Vitamin C intake at the last survey was 
calculated using a semi-quantitative food frequency questionnaire as described 
previously 7• 
The Vlagtwedde-Vlaardingen cohort (n=l,3 90) was described previously in detail 20•21 and 
included as a replication sample. This cohort was prospectively followed for 25 years with 
FEV1 and VC (slow inspiratory maneuver) measurements every 3 years using a water­
sealed spirometer (Lode Instruments, the Netherlands). There was no overlap in subjects 
whatsoever between the two cohorts, due to different sampling time frames and sampling 
from different cities. 
The study protocol was approved by the local university hospital medical ethics committee 
and all participants gave their written informed consent. 
Genotyping 
We genotyped one single nucleotide polymorphism (SNP), C(-129}T (rs17883 901), and a 
trinucleotide GAG repeat (TNR, located in the 5' untranslated region (5'UTR)) in GCLC and 
one SNP, C(-588}T (rs4 1303 970), in GCLM (see the online supplement for details). To check 
for genotyping quality we regenotyped all polymorphisms in 100 DNA samples, taken from 
the stock vials, with no genotyping errors detected. 
- 24 -
Chapter 2 - GCL polymorphisms and lung function 
Statistical analysis 
Both SNPs were analyzed in a dominant model. In order to analyze independent effects of 
genotypes both GCLC polymorphisms were analyzed simultaneously as two dummy 
variables, with the most common combination of genotypes used as a reference, i.e. C/C 
for C(-129}T SNP and 7 /7, 7 /8 or 7 /9 for the TNR. 
FEV1 change was calculated as yearly decline (ml/year} between two surveys in the 
Doetinchem cohort. The effects of polymorphisms on lung function parameters {FEV1, VC, 
FEV1/VC at the last survey in both cohorts and annual FEV1 change in the Doetinchem 
cohort} were tested with linear regression analysis adjusted for age, height, and packyears 
smoked, and for sex and initial FEV1 level if appropriate. Linear mixed effect (LME} models 
were used to estimate longitudinal FEV1 course in the Vlagtwedde-Vlaardingen cohort (see 
online supplement for details}. 
Genotype-smoking interactions were tested by introduction of interaction terms (i.e. 
number of packyears smoked*genotype} into the regression and LME models. All 
interaction terms reported assessed whether the joint effect of packyears smoked and a 
certain genotype was larger than the sum of these factors separately. 
We studied the effect of vitamin C on lung function within the whole Doetinchem cohort 
(n=3 ,224 } (see online supplement for details}. To assess whether vitamin C intake affected 
the relations between genotypes and lung function parameters, we repeated the analyses 
stratified according to tertiles of vitamin C intake. 
Statistical analyses were performed using SPSS (version 14 .0; SPSS, Inc., Chicago, IL} and $­
PLUS (version 7.0; Insightful, Seattle, WA}. P values less than 0.05 were considered to be 
sign ifi cant. 
RESULTS 
GCLM and GCLC genotypes 
The characteristics of the Doetinchem cohort and Vlagtwedde-Vlaardingen cohort are 
shown in table 1. SNPs and the TNR were distributed according to Hardy-Weinberg 
Equilibrium in both cohorts. The C(-129}T SNP and TNR variants in GCLC formed 3 
characteristic groups of genotypes (as shown in table 2 for the Doetinchem cohort}, 
implicating that the rare TNR alleles (i.e. 8 and 9 GAG repeats} are in linkage 
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disequilibrium with the wild type SNP allele {i.e. "C"}. According to the confirmed 
functionality 15'17'19 and linkage disequilibrium, both GCLC polymorphisms were analyzed 
by defining the reference genotype combination {black shade in table 2} and 
simultaneously the two other groups of genotypes {the light and dark grey shades in table 
2, which were both entered into the statistical model as dummy variables}. The same 
groups were observed and defined in the Vlagtwedde-Vlaardingen cohort. 
Table 1: Comparison of characteristics at the last survey in the two cohorts used in the study 
Doetinchem cohort Vlagtwedde-Vlaardingen cohort 
(n=l,152) (n=l,390) 
Duration of follow up in years {year of the last visit) 
5 { 1 999-200 3 )  / 2 25(1 989-1 990 )  / 7 
/number of surveys {median) during follow up 
Males, n {%) 541 {47.0 ) 71 4 {51 .4) 
Age in years, median {range) 49.9 {3 1 .2-70 .9) 51 .7 {3 5.0 -79.0 )  
Height in cm, mean {SD) 1 72.6 {9 . 1 ) 1 70 .2 {9.2) 
Smokers/Ex-smokers, n {%) 30 8 (26.7) / 473 (41 . 1 ) 489 (3 5.2)/456 (3 2.8) 
Packyears smoked, median {range) 5.0 {0 -84) 9.0 {0 -262) 
FEV1 in liters, mean {SD) 3 .3 9  {0 .79) 2.86 {0 .77) 
VC in liters, mean {SD) 4.3 5 { 1 .0 1 )  3 .89 {0 .98) 
FEV1% of predicted, mean (SD) 10 6 . 1  ( 1 5.3 ) 92.6 ( 1 5.3 ) 
VC % of predicted, mean {SD) 1 1 2.8 { 1 4.4) 10 1 .8 ( 1 4.5) 
FEVi/VC %, mean {SD) 78.0 (7.2) 73 .9  (8.8) 
FEV1 change ml/year, mean (SD) -30 .6  {45.3 ) -20 .8 (22.9) 
Vitamin C intake mg/day, mean {SD) 10 8.4 (41 .4) NA 
Genotype frequency: 
GCLC C{-1 29)T, {%C/C, %C/T, %T/T) 86.4/1 3 . 1 /0 .5 88.7 /10 .9/0 .4 
GCLM C{-588)T, (%C/C, %C/T, %T/T) 72.3 /25. 1 /2.6 72.6/25.9/1 .5 
GCLC TNR, 
(%7/7, %7/8, %7/9, %8/8, %8/9, %9/9) 3 1 .6/1 9.7 /3 1 .0 /3 .0 /8.2/6.5 3 7. 7 /1 9.6/27.3 /2.3 /7.5/5.6 
Hardy-Weinberg Equilibrium test p value* :  
GCLC C{-1 29)T 0 .91 0 .55 
GCLM C(-588)T 0 .41 0 .3 2  
GCLC TNR 0 .65 0 .84 
*For 1 degree of freedom {df) (SNPs) or 3 df {TNR) chi-square test comparing the observed genotypes 
distribution with the expected as derived from the allele frequencies 
GCLC = glutamate cysteine ligase, catalytic subunit; GCLM = glutamate cysteine ligase, modifier subunit ; TNR = 
trinucleotide GAG repeat; NA=not applicable; SNP = Single Nucleotide Polymorphism 
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Table 2: Cross-tabulation of two GCLC promoter polymorphisms in 1 1 3 6  genotypes in the Doetinchem cohort 
Number of individuals carrying: 
Trinucleotide GAG repeat genotype 
8/8 8/9 9/9 
C/C 34 94 74 
C(-1 29)T genotype C/T 0 0 0 
T/T 0 0 0 
GCLC = glutamate cysteine ligase, catalytic subunit 
Cross-sectional and longitudinal analyses on associations between GCLM and GCLC 
genotypes and lung function 
We found no significant associations of GCLM and GCLC SNPs, or TNR in GCLC with FEV1 or 
FEVi/VC levels in both cohorts (table 3 ). C/T and T/T genotypes from the GCLC C(-129}T 
SNP were significantly associated with lower VC levels than the reference genotype in 
both cohorts (table 3}. 
None of GCLC or GCLM polymorphisms was significantly associated with the change in 
FEV1 over time in any of the populations investigated (table 3 }. 
Interaction of genotypes with smoking in the Doetinchem and the Vlagtwedde­
Vlaardingen cohorts 
GCLC: We observed a significant, negative interaction between the number of packyears 
smoked and both GCLC genotypes on FEV1 and VC levels in the Doetinchem cohort (table 
3 }, e.g. subjects carrying two copies of the mutant GCLC TNR alleles had a 9.6 ml lower 
FEV 1 for each packyear smoked compared to the reference genotype and this effect 
significantly enlarged the separate effects caused by packyears smoked and the TNR 
genotype. Such an interaction was observed in the Vlagtwedde-Vlaardingen cohort only 
for the rare TNR variants in GCLC which resulted in a significantly lower FEV1 level (table 
3 }. The effect of the interaction between GCLC C(-129}T SNP and packyears smoked on VC 
level was borderline significant in the Vlagtwedde-Vlaardingen cohort (p=0.07, table 3 }. 
There was a significant, negative effect of the interaction between packyears and rare TNR 
variants in GCLC (i.e. 8/8, 8/9 and 9/9} on the FEVi/VC ratio in both cohorts (table 3 }. 
In the longitudinal analyses, the rare TNR alleles in GCLC interacted with packyears 
smoked and contributed to accelerated FEV1 decline in the Vlagtwedde-Vlaardingen 
cohort only (table 3 ,  genotype carriers compared with the reference}. 
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GCLM: The interaction of packyears smoked and the GCLM SNP on FEV1 level had an 
opposite direction in the Doetinchem (B=-3 .9, SE=2.2) and Vlagtwedde-Vlaardingen 
cohorts { 8=2.53 , SE=l.4 3 ), the associations being of borderline significance (both p values 
p=0.08, table 3 ). This was also the case for the FEVi/VC ratio, where the positive 
association reached the significance level in the Vlagtwedde-Vlaardingen cohort 
(p=0.04 ).There was an additional and highly significant packyear-dependent excess FEV1 
decline in the Doetinchem cohort in individuals carrying at least one mutant allele of the 
GCLM C(-588)T SNP (table 3 ), but this was not observed in the Vlagtwedde-Vlaardingen 
population. 
In order to check for confounding effects, we tested the association between packyears 
smoked and GCLC and GCLM genotypes. No significant differences in packyears smoked 
were found between the three GCLC genotypes in both cohorts. Carriers of the mutant 
allele of GCLM SNP smoked significantly more (median of 7.6 packyears smoked) than the 
wild type (median of 4 .2 packyears smoked) in the Doetinchem cohort exclusively. 
GCLM-GCLC interaction in the Doetinchem and the Vlagtwedde-Vlaardingen cohorts 
No significant interaction between GCLM and GCLC polymorphisms that existed in the 
Doetinchem cohort were replicated in the Vlagtwedde-Vlaardingen cohort (table ES). 
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Table 3: Analyses of the effect of GCLC and GCLM polymorphisms on lung function parameters in both cohorts 
Doetinchem cohort Vlagtwedde-Vlaardingen cohort 
FEV1 [mlf 
B SE p B1NT SE/NT PINT B SE p BINT SEINT PINT 
GCLCC(-1 29)T C/T+T/T 
-48.4 41.6 0.24 -7 .7 3 .1 0.01 -25 .2 39.5 0.52 -2.2 1.5 0.16 
and TNR7 /7 +7 /8+7 /9 
GCLCC(-1 29)T C/C 
-58.8 37 .2 0.12 -9.6 2.7 0.0004 -24.7 34.9 0.48 -4.8 2.1 0.02 
and TNR 8/8+8/9+9/9 
GCLM 
-48.1 31.1 0.12 -3.9 2.2 0.08 8.6 27 .6 0.7 6 2.5 1 .4 0.08 
C(-588)T C/T + T /T 
VC [ml]* 
B SE p BINT SE/NT PINT B SE p BINT SEINT PINT 
GCLC C(-1 29)T C/T +T/T 
-97 . 1  47 .8 0.04 -9.3 3.6 0.01 -88.1 44.3 0.047 -3.2 1.8 0.07 
and TNR7 /7 +7 /8+7 /9 
GCLC C(-1 29)T C/C 
-55.6 42.6 0.19 -10.1 3.1 0.001 -9.3 39.0 0.81 -2.6 2.3 0.26 
and TNR 8/8+8/9+9/9 
GCLM 
-38.9 36.1 0.28 -0.6 2.6 0.83 -18.4 31.0 0.55 1.1 1.6 0.48 
C(-588)T C/T+T/T 
FEVJVC [%]' 
B SE p BINT SEINT PINT B SE p 8/NT SE/NT PINr 
GCLC C(-1 29 )T C/T + T /T 
0.22 0.58 0.41 -0.04 0.05 0.36 0.62 0.67 0.36 -0.01 0.03 0.7 8 
and TNR 7 /7 +7 /8+7 /9 
GCLC C(-1 29 )T C/C 
-0.43 0.51 0.7 0 -0.08 0.04 0.03 -0.50 0.60 0.40 -0.08 0.04 0.04 
and TNR8/8+8/9+9/9 
GCLM 
-0.55 0.44 0.21 -0.05 0.03 0.09 0.52 0.47 0.27 0.05 0.02 0.04 
C(-588)T C/T+T/T 
FEV1 change [ml/yrt 
B SE p BINT SEINT PINT B SE p B1NT SE/NT PINT 
GCLCC(-1 29)T C/T+T/T 
-4.94 3.91 0.21 -0.04 0.30 0.88 -0.27 1.65 0.87 -0.07 0.07 0.30 
and TNR7 /7 +7 /8+7 /9 
GCLC C(-1 29 )T C/C 
-4.40 3.50 0.21 -0.29 0.26 0.26 -0.03 1.40 0.98 -0.30 0.08 0.0001 
and TNR 8/8+8/9+9/9 
GCLM 
-4.37 2.93 0.14 -0.87 0.21 0.00002 -0.42 1.10 0.7 0 -0.04 0.05 0.44 
C(-588)T C/T + T /T 
Regression coefficient (B), standard error (SE) and P values are estimated from models without interaction terms. P 
values in boldface type are significant (P <0.05). I NT index indicates the coefficient for the interaction term 
(genotype x pack-years) when inserted in the latter model. 
*linear regression adjusted for age, sex, height, packyears smoked 
tlinear regression adjusted for age, height, packyears smoked 
* linear regression adjusted for age, height, packyears smoked and initial FEV1 level (Doetinchem) or LME model 
analysis on FEV1 change adjusted for packyears smoked, sex, initial FEV1 level and time (Vlagtwedde­
Vlaardingen).AII analyses with interaction terms were additionally adjusted for the effect of genotype(s). 
GCLM = glutamate cysteine ligase, modifier subunit; GCLC = glutamate cysteine ligase, catalytic subunit ; TNR = 
trinucleotide GAG repeat ; I NT = interaction 
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Effects of smoking, vitamin C intake, GCLC and GCLM genotypes and their interactions 
on lung function in the Doetinchem cohort 
Within the total Doetinchem cohort (n=3 ,224 ) the level of FEV1 and VC were both 
significantly higher in never-smokers or mild smokers (defined as packyears smoked <12.5, 
being the median value for ever-smokers) when compared to heavy smokers (packyears � 
12.5, figures 1 and 2). Similarly, the two tertiles with the highest vitamin C intake had 
significantly higher FEV1 and VC levels when compared to the tertile with the lowest intake 
(figures 1 and 2). The rate of FEV1 decline and the FEV1/VC ratio did not significantly differ 
between tertiles (data not shown). Heavy smokers with the lowest vitamin C intake had 
significantly lower FEV1 and VC levels when compared to any subgroup defined by vitamin 
C intake and number of packyears smoked (figures 1 and 2). 
None of the polymorphisms was associated with FEV1, VC or the rate of FEV1 decline in any 
tertile of vitamin C intake (see table E3 in the online supplement). The GCLM 
polymorphism was negatively associated with a lower FEVi/VC within the lowest tertile of 
vitamin C intake (MEVi/VC= -1.93%, SE=0.07, p=0.01, see table E3). The analyzed 
genotype-packyear interaction terms in the Doetinchem cohort remained significant 
predominantly in the lowest tertile of the vitamin C intake for all lung function parameters 
(table E4 in the online supplement). An interaction between rare TNR variants and 
packyears smoked additionally contributed to the accelerated FEV1 decline in this tertile 
exclusively (table E4 ). 
These results implicate that there exists a three-factor interaction between packyears 
smoked, vitamin C intake, and any of the GCLC polymorphisms, and this interaction 
negatively affects FEV1 and VC levels. In the group with the lowest vitamin C intake and 
the highest number of packyears smoked, there was particularly a significant impact of the 
GCLC variations on FEV1 and VC levels in the Doetinchem cohort (figures 3 and 4 ). 
In order to check for confounding effects we tested the association between vitamin C 
intake and GCLC and GCLM genotypes in the Doetinchem cohort but no significant 
differences were observed. 
- 30 -
Chapter 2 - GCL polymorphisms and lung function 
Figure 1: Means of FEV1 % predicted values according to smoking habits and vitamin C intake in the Doetinchem 
cohort (n=3 ,224) 
* p<0.0 5 while compared to any of the other 
groups of the vitamin C intake 
t p<0.0 5 while compared to any of the other 
groups of the smoking habits 
:j: p<0 .0 5  in the linear regression for VC adjusted 
for height, sex and age while compared with 
any of the other eight groups, represented by 
bars (except for heavy smokers with medium 
vitamin C intake where p = 0.0 6). 
C . I .  = confidence interval; py = pack-years 
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Figure 2: Means of VC % predicted according 
to smoking habits and vitamin C intake in the 
Doetinchem cohort (n=3 ,224) 
* p<0 .0 5  while compared to any of the 
other groups of the vitamin C intake 
t p<0 .0 5 while compared to any of the 
other groups of the smoking habits 
:j: p<0 .0 5 in the linear regression for VC 
adjusted for height, sex and age while 
compared with any of the other eight groups, 
represented by bars 
·····--········ 
C. I .  = confidence interval; py = pack-years smoked; 
VC = vital capacity 
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Figure 3: GCLC genotype effect on FEV1 % of predicted values according to the vitamin C intake class and smoking 
status in the Doetinchem cohort (n=l, 1 52) 
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Figure 4: GCLC genotype effect on VC % of predicted values according to the vitamin C intake class and smoking 
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DISCUSSION 
We describe a novel candidate gene for lung function loss, a risk factor for COPD. We 
show that genetic variations in GCLC, a gene that is important in the reduction of oxidative 
burden, enhance the harmful effects of smoking on lung function in two independent 
cohorts in the general Dutch population. This negative effect was mainly observed in 
individuals with a low vitamin C intake, i.e. a poor exogenous antioxidant protection. 
The genetics of the glutathione metabolism pathway has been intensively studied also in 
relation to interaction with smoking. The majority of studies has focused on GSH 
transferases {GSTs} polymorphisms 22-24• GSTs and GCL functions are likely correlated since 
the latter provides the essential substrate glutathione for GSTs activity. GCLM and GCLC 
are predominantly expressed in lung epithelium 25-29, where they belong to the first line of 
antioxidant defense and may be responsible for the uniquely high GSH content in the 
epithelial lining fluid 13• Many antioxidant genes, including GCLC and GCLM, display a 
characteristic expression pattern in airway epithelial cells - the lowest expression in never 
smokers, higher expression in healthy smokers 28'29 and an even further increase in COPD 
stage O and I as defined by the Global Initiative for Chronic Obstructive Lung Disease 
{GOLD) 3'28 • GCLC is less expressed_in more severe COPD {GOLD stage II - IV} than in stage I 
28
• The latter indicates inadequate expression of GCLC and consequently lower GSH 
production, which may contribute to the development of more severe COPD. However, 
other studies have shown the same level of GCLC and GCLM proteins in bronchial 
epithelium of COPD smokers and healthy subjects 25 or even induction of GCLC mRNA in 
COPD patients 26• 
The GCLC C{-129}T SNP has been associated with lower expression of GCLC in endothelial 
cells in vitro 15• So far, no studies have focused on the in vivo impact of this SNP on GSH 
metabolism, but our data suggests that this SNP impairs the antioxidant protection in 
conditions like oxidative stress. We have observed in two independent cohorts that this 
impaired protection is reflected by a lower VC level which is further pronounced by 
smoking. The VC measurement may reflect a slightly different lung capacity in both 
cohorts given a difference in measurement methodology, nevertheless the effects on VC 
were present in two populations. 
GCLC TNR has been studied in vitro in a panel of tumour cell lines 17• Walsh and colleagues 
found the wild type (7 GAG repeats} allele to be responsible for the lowest intracellular 
GSH level. Interestingly, the allele with 8 GAG repeats was responsible for higher cell 
sensitivity to several chemotherapeutics 17• This contrasts with results in skin fibroblasts 
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associating the 7 GAG repeat allele with the highest cellular GSH content 19• Moreover, the 
mutant alleles (8 and 9 GAG repeats) negatively affected GCL activity and GCLC expression 
for 7 /8, 8/8, 8/9, and 9/9 genotypes when compared to 7 /7 and 7 /9 19• Likewise we found 
the rarest genotypes (i.e. 8/8, 8/9, and 9/9 genotypes) to constitute a risk factor for 
smoking-induced lower FEV1 and FEVi/VC levels in both cohorts. Additionally, rare TNR 
variants were associated with excess lung function decline while interacting with smoking 
in the Vlagtwedde-Vlaardingen cohort and in individuals with the lowest vitamin C intake 
in the Doetinchem cohort. In contrast, the mutant TNR alleles had a protective effect on 
FEV1 as found in mild cystic fibrosis patients 
30
• Since previous functional studies focused 
on specific cell lines (i.e. tumour cells from different tissues and skin fibroblasts) or 
subjects with cystic fibrosis, further research is needed to determine the role of this TNR 
in normal, lung-derived cells that may differently respond to oxidant stimuli. It is 
furthermore important to study this also in the context of GSH excretion that is especially 
important in the lung 10'13 • We speculate that rare TNR alleles (i.e. 8 and 9 GAG repeats) 
may increase the sensitivity of pulmonary cells to cigarette smoke by the impairment of 
GCL function and ultimately lower GSH levels in lung epithelial fluid. This negative effect 
might be then further enhanced by insufficient vitamin C intake. 
The GCLM C(-588)T SNP has been associated with COPD in a Chinese population 18. This 
likely can be explained by the observation that GCLM induction in response to oxidative 
stress in vitro is lower in mutant 'T' allele carriers than wild type carriers 16 which may 
result in lower GSH level in vivo 18 . Our results indicate that the same allele in the GCLM 
C(-588)T SNP interacts with smoking and thus contributes to excess lung function decline 
in the Doetinchem cohort only. We did not observe a similar association in the 
Vlagtwedde-Vlaardingen cohort. We also observed opposite effects of the interaction 
between this SNP and packyears on FEV1 and FEVi/VC ratio level in two cohorts although 
they were mostly not significant. This clearly suggests that the observed contradictory 
associations for this SNP are spurious rather than caused by the "cohort effect" that 
occurs when different characteristics of two cohorts alter the genetic effect. This 
potentially spurious finding may also be due to a confounding effect of packyears smoked 
that was observed for this SNP in the Doetinchem cohort. 
A remarkable and new finding is that the significant interaction of the GCLC genotype with 
packyears smoked, as observed in both cohorts, specifically existed in individuals with the 
lowest vitamin C intake in the Doetinchem cohort. A logical rationale for these effects 
might be an in vivo interaction between vitamin C and glutathione 31 that are both crucial 
components of the tissue antioxidant defense. The latter compound serves as a reducing 
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agent for the oxidized form of vitamin C in a  spontaneous reaction or in enzymatic 
reactions catalyzed by the glutaredoxins or omega glutathione transferases 31• Moreover, 
both GSH and vitamin C are present in a high concentration in the lung 10 which 
additionally implicates their special role in this tissue. 
In summary, our studies in two independent Dutch populations show that functional 
polymorphisms in the GCLC gene, which is involved in GSH-mediated lung antioxidant 
protection, are importantly contributing to a reduced lung function level and accelerated 
lung function decline particularly in heavy smokers and in individuals with poor intake of 
vitamin C. Our study provides possible strategies for neutralizing harmful effects of 
smoking, since particularly individuals with a low vitamin C intake experience the harmful 
effects of smoking in the presence of GCLC polymorphisms. Further molecular and 
epidemiological studies are needed to determine the role of vitamin C and genetic factors 
like GCLC in lung function loss and consequently in the pathogenesis and progression of 
COPD. 
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Online Data Supplement 
Statistics 
Linear Mixed Effects (LME} models were used to investigate the effect of GCLC and GCLM 
polymorphisms on the annual decline in FEV1 in the Vlagtwedde-Vlaardingen cohort. Time 
was defined as the time in years relative to the first FEV1 measurement and corresponding 
age. FEV1 measurements were included from the age of 30 years, because an individual's 
maximal achieved lung function is assumed to have been reached before that age and 
lung function is considered to be either in the plateau or decline phase 1. Variables 
included in the model were age at entry, sex, pack-years of smoking, and the first available 
FEV1 after age 30 years and their interaction with time. 
We studied the effect of vitamin C on lung function within the whole Doetinchem cohort 
(n=3 ,224 } assessing intake as tertiles coded as dummy variables and using linear 
regression adjusted for confounders. The upper limit of the 1st tertile (i.e. 85.9 mg/day} 
corresponded approximately to the vitamin C content in one fresh orange or to the 
Recommended Dietary Allowance of vitamin C 2• 
Genotyp ing 
DNA from all subjects was isolated from blood samples using DNA Blood Mini Kit (Qiagen, 
USA}. SNPs were genotyped using TaqMan SNP Genotyping Assays (Applied Biosystems, 
USA} as described previously 3 and the TNR was genotyped using MegaBACE 1000 (GE 
Healthcare, UK} system. Sequences of primers and probes used for genotyping are shown 
in table El. 
Table El. Sequences of primers and probes 
SNP Primers Probe 1 {FAM)* Probe (VIC) 2* 
Forward: 
GCLM (C-588)T rs41 30 3 970 
GCCCTTTAAAGAGACGTGTAGGAA CTCCC§.GCGTTCAG TCTCCCAGCGTTCAG 
Reverse: 
CCGCCTGGTGAGGTAGAC 
GCLC C(-1 29)T rs1 7 883 90 1  Applied Biosystems assay ID: C 587 2453 7 10 
*Underlined bases indicate specific polymorphic site recognized by each probe 
Amplification of the region spanning Trinucleotide Repeat (TNR} in the GCLC was 
performed in the 10 µI of PCR reaction that contained: 
o 10 ng of the DNA template 
o 2 µI DMSO 
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o 1 µI MgCl2 {25 mM) 
o 1 µI dNTPs {2mM) 
o 0.1 µI AmpliTaq • {Applied Biosystems, USA) DNA polymerase and 1 µI AmpliTaq • 
buffer 
o 0.5 µI of forward {5' -ggctgagtgtccgtctcg) and reverse {5' -FAM­
cttggtttcctcccagctca) primers {10 µM each) 
o water to the final volume of 10 µI 
PCR amplification consisted of the following steps : 
o Initial denaturation for 5 min. in 95.0°C 
o 3 5  cycles according to the protocol : 
o Denaturation for 4 5  sec. in 94 .0°C 
o Annealing for 30 sec. in 64 .3 °C 
o Elongation for 30 sec. in 72.0°c 
o Final elongation for 5 min. in 72.0°C 
The PCR product comprising TNR was labeled with a fluorescent FAM dye, present in the 
reverse primer, and had three possible lengths {i.e. 123 , 126 and 129 base pair) 
corresponding to the three TNR alleles {i.e. 7, 8 and 9 GAG repeats) present in our 
populations. The PCR reaction was followed by the MegaBACE electrophoresis of the 
product in the acryl amide gel in the presence of sizer. MegaBACE Genetic Profiler 
software {version 2.2, GE Healthcare, UK) was used to assign fluorescent peaks to the 
specific TNR alleles. 
Table E2: Characteristics of the sub-samples selected vs. non-selected for the study, taken from the Doetinchem 
cohort 
Males, n (%) 
Age in years, median (range) 
Smokers/Ex-smokers, n (%) 
Packyears smoked, median (range) 
FEV1 % of predicted, mean (SD) 
FEVJFVC %, mean (SD) 
FEV1 decline ml/year, mean (SD) 
Vitamin C intake mg/day, mean (SD) 
FEV1 = Forced Expiratory Volume in 1 second 
FEV1%pred. =% of predicted FEV1 
FVC = Forced Vital Capacity 
SD = standard deviation 
Selected 
(n=1 1 52) 
541 (47 .0 )  
49.9 (3 1 .2-70 .9) 
30 8 (26.7 ) / 47 3 (41 . 1 ) 
5 (0 -84) 
10 6. 1 ( 1 5.3 ) 
7 8.0 (7.2) 
-30 .6 (45.3 ) 
10 8.4 (41 .4) 
-39 -
Non-selected 
(n=20 7 2) 
10 1 9  (49.2) 
so.a (3 1 .2-70 .S) 
551 (26.6) / 7 86(3 8.0 )  
4.3 (0 -1 54) 
10 5.9 ( 1 5.1 ) 
7 8.0 (7. 1 ) 
-30 .2 (45.2) 
10 8.3 (44.9) 
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Table E3: Linear regression analyses of the effect of GCLC and GCLM polymorphisms on lung function parameters 
according to vitamin C intake in the Doetinchem cohort. P values below 0 .0 5  are depicted in bold. 
Vitamin C intake [mg/day) 
<85.9 85.9-120 .0 
1st tertile 2nd tertile 
FEVi [ml] 
B SE p B SE p 
GCLCC(-129)T C/T+ T/T 
-67 .97 81.83 0 .41 -58.3 4 68.12 0 .3 9  
and TNR7 /7 +7 /8+7 /9 
GCLC C{-129)T C/C 
-64.83 67 .0 9  0 .3 4  -51.93 67 .7 8 0 .44 
and TNR 8/8+8/9+9/9 
GCLM C(-588)T C/T+T/T -3 9 .0 6  56.22 0 .49 2.40 56.97 0 .97 
VC [ml] 
B SE p B SE p 
GCLC C(-129)T C/T+T/T 
-126.48 95.21 0 .19 7 7 .0 5  0 .0 9  
and TNR7 /7 +7 /8+7 /9 13 2.47 
GCLC C{-129)T C/C 
-59.3 9 7 7 .65 0 .45 3 .90 7 6.63 0 .96 
and TNR 8/8+8/9+9/9 
GCLM C(-588)T C/T +T/T 19.51 66.58 0 .7 7  -67 .0 6  64.96 0 .30 
FEVi/VC [%f 
B SE p B SE p 
GCLC C(-129)T C/T+T/T 
-0 .00 2 1.11 0 .99 1.21 0 .95 0 .20 
and TNR7 /7 +7 /8+7 /9 
GCLC C{-129)T C/C 
-0 .42 0 .91 0 .65 -1.66 0 .94 0 .0 8  
and TNR 8/8+8/9+9/9 
GCLM C(-588)T C/T+T/T -1.93 0 .7 7  0.01 1.47 0 .7 9  0 .0 6  
FEV1 decline [ml/yr]* 
B SE p B 
GCLC C(-129)T C/T+T/T 
-5.0 8 7 .94 0 .52 -1.93 
and TNR7 /7 +7 /8+7 /9 
GCLC C{-129)T C/C 
-.28 6.47 0 .97 -6.81 
and TNR 8/8+8/9+9/9 
GCLM C(-588)T C/T+T/T -3 .63 5.49 0 .51 -6.14 
*adjusted for age, sex, height, packyears smoked and genotype(s) 





*adjusted for age, height, packyears smoked, initial FEV1 level and genotype(s) 
p 









-10 4.0 2  
















7 7 .70 





















0 .3 9  
p 
0 .17 
0 . 18 
0 .60 
GCLC = glutamate cysteine ligase, catalytic subunit; GCLM = glutamate cysteine ligase, modifier subunit; TNR = 
trinucleotide GAG repeat genotype; FEV1 = forced expiratory volume in 1 second; FVC == forced vital capacity 
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Table E4: Linear regression analyses of the effect of GCLC and GCLM polymorphisms on lung function parameters 
according to vitamin C intake in the Doetinchem cohort. Regression coefficients (B), standard errors {SE) and p 
values are estimated for interaction terms (genotype*packyears). P values below 0 .0 5  are depicted in bold. 
Vitamin C intake [mg/day] 
<85.9 85.9-1 20 .0 
1 st tertile 2nd tertile 
FEV1 [mlf 
BINT SE/NT PtNT BINT SEtNT PtNT 
GCLC C(-1 29 )T C/T + T /T 
-1 1 .2 6.0 0 .0 6  -4.9 5.6 0 .3 8  
and TNR7 /7 +7 /8+7 /9 
GCLC C{- 1 29)T C/C 
-1 6.2 4.2 0.0002 -4.9 5.5 0 .3 7  
and TNR 8/8+8/9+9/9 
GCLM C{-588)T C/T+T/T -4.9 3 .9 0 .20 -3 . 3  3 .8 0 .3 9  
VC [ml] * 
BINT SE/NT PtNT BINT SE/NT PINT 
GCLC C{-1 29 )T C/T + T /T 
-1 4.28 7 .0 4  0.04 -8.70 6.3 8 0 . 1 7  
and TNR7 /7 +7 /8+7 /9 
GCLC C{-1 29)T C/C 
-1 4.41 4.95 0.004 -5.47 6.25 0 .3 8  
and TNR 8/8+8/9+9/9 
GCLM C{-588)T C/T+T/T .22 4.67 0 .96 -5.99 4.65 0 .20 
FEVJVC [%r 
BINT SE/NT PINT BINT SE/NT PtNT 
GCLC C(-1 29 )T C/T + T /T 
-0 .0 1 0 .0 8  0.9 1  0 .0 2  0 .0 8  0 .7 8  
and TNR7 /7 +7 /8+7 /9 
GCLC C{-1 29)T C/C 
-0 . 1 6 0 .0 6  0.007 -0 .0 9 0 .0 8  0 .25 
and TNR 8/8+8/9+9/9 
GCLM C{-588)T C/T+T/T -0 . 1 2 0 .0 5  0.03 0 .0 8  0 .0 6  0 . 1 4  
FEV1 decline [ml/yr]* 
BINT SE/NT PINT BINT SE/NT PINT 
GCLC C{-1 29 )T C/T + T /T 
-0 .57 0 .59 0 .3 4  -0 .68 0 .51 0 . 1 9  
and TNR7 /7 +7 /8+7 /9 
GCLC C(-1 29)T C/C 
-1 .21 0 .42 0.004 -0 .83 0 .50 0 . 10 
and TNR 8/8+8/9+9/9 
GCLM C{-588)T C/T+T/T -0 .7 2 0 .3 8  0.06 - 1 .21 0 .3 7  0.001 
*adjusted for age, sex, height, packyears smoked and genotype(s) 
t adjusted for age, height, packyears smoked and genotype(s) 
*adjusted for age, height, packyears smoked, initial FEV1 level and genotype(s) 
>1 20 .0 
3 rd tertile 
BINT SEtNT PtNT 
-9.0 5.0 0 .0 8  
-6.5 5.1 0 .20 
-3 .4 3 .9 0.3 9 
BINT SE/NT PINT 
-7 .7 2 5.80 0 . 1 8  
-10 .20 5.85 0 .0 8  
1 .59 4.60 0.7 3 
BINT SE/NT PtNT 
-0 . 1 2 O.D7 0 . 10 
0 .0 1  0 .0 7  0 .92 
-0 .0 9 0 .0 6  0. 1 1 
BINT SE/NT PINT 
0 .25 0 .49 0 .6 1  
0 .43 0 .49 0 .3 8  
0 .3 8  0 .3 8  0.3 2 
GCLC = glutamate cysteine ligase, catalytic subunit; GCLM = glutamate cysteine ligase, modifier subunit; TNR = 
trinucleotide GAG repeat genotype; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity 
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Table ES: GCLM C/T+T/T genotype effect on lung function parameters in both cohorts studied within GCLC genotype-
defined groups. Regression coefficient (B), standard error (SE) and p values are estimated for models without interaction 
terms. INT index indicates the coefficient for the interaction term (genotype*packyears) when inserted in the latter model. 
N(%) of Doetinchem cohort Vlagtwedde-Vlaardingen cohort 
GCLC genotype 
GCLM C(-588)T ''T"allele FEV1 (ml] 
carriers Doetinchem/ 
Vlagtwedde-Vlaardingen 
B SE p BINT SE/NT PINT B SE p B1NT SE/NT PINT 
GCLC 
C(-129)T C/T+T/T and 60 (29. 7)/55(35. 7) -133.6 72.8 0.07 1.6 5.3 0.77 -111.2 72.5 0.13 -2.6 3.5 0.45 
TNR7 /7+ 7 /8+ 7 /9 
GCLC 
C(-129)T C/C and 40 (25.8}/68(32.7) 46.6 94.0 0.62 -7.6 6.6 0.25 67.8 · 73.5 0.36 1.3 s.o 0.79 
TNR 8/8+8/9+9/9 
VC (ml]* 
B SE p B1NT SE/NT PINT B SE p B1NT SE/NT PINT 
GCLC 
C(-129)T C/T+T/T and 60 (29.7)/55(35.7) -192.5 88.0 0.03 5.0 6.5 0.44 -86.3 76.9 0.26 1.6 5.5 0.78 
TNR7/7+7/8+7/9 
GCLC 
C(-129)T C/C and 40 (25.8)/68(32.7) -40.0 92.4 0.67 -3.7 6.4 0.56 65.0 81.0 0.42 0.4 3.7 0.92 
TNR 8/8+8/9+9/9 
GCLC .,,.,.:;,{:-� ! . • ; : ·;;,' 
C(-129)T C/C and TNtfl· 213(27.5)/248(24.9) 11.3 · ,_43 9 0.80 1.5 ' 3.2 0 65 -16.2 37.6 0.67 1.6 1.9 o·.·40·� 
7/7+7/8+7/9 - .�. · -;.  
N(%) of Doetinchem cohort 
GCLC genotype 
GCLM C(-588)T ''T"allele 
carriers Doetinchem/ 
Vlagtwedde-Vlaardingen B SE p 8/NT SE/NT 
GCLC 
C(-129)T C/T+T/T and 60 (29.7)/55(35.7) 0.15 1.14 0.90 -0.04 0.08 
TNR7 /7+ 7 /8+7 /9 
GCLC 
C(-129)T C/C and 40 (25.8)/68(32.7) 1.72 1.49 0.25 -0.11 0.10 
TNR 8/8+8/9+9/9 
B SE p BINT SE/NT 
GCLC 
C(-129)T C/T+T/T and 60 (29.7)/55(35.7) -8.49 6.34 0.18 -0.60 0.46 
TNR7 /7+ 7 /8+ 7 /9 
GCLC 




PINT B SE p 8/NT SE/NT PINT 
0.61 -1.46 1.31 0.27 0.05 0.08 0.43 
0.30 -0.22 1.25 0.86 -0.05 0.06 0.55 
PINT SE p BINT SE/NT PINT 
0.19 -3.58 3.50 0.31 -0.25 0.16 0.11 
0.09 5.69 3.23 0.08 0.07 0.21 0.75 
GCLC · · . ' · ·f. ,: . ._;. ,:. · ' -· 
C{-129)T C/C and . i13(27.5)/248(24.9) -3.52 3 .65 0.34 -0.90 0.26 0.0005 -1.18 1.23 0.34 ;�0.002 . 0.06 0.98 
TNR 7/7+7/8+7/9 . -
*linear regression adjusted for age, sex, height, packyears smoked 
tlinear regression adjusted for age, height, packyears smoked * linear regression adjusted for age, height, 
packyears smoked and initial FEV1 level (Doetinchem) or LME model analysis on FEV1 change adjusted for 
packyears smoked, sex, initial FEV1 level and time (Vlagtwedde-Vlaardingen) 
All analyses with interaction terms were additionally adjusted for the effect of genotype(s) alone. 
GCLC = glutamate cysteine ligase, catalytic subunit; GCLM = glutamate cysteine ligase, modifier subunit; TNR = 
trinucleotide GAG repeat genotype; FEV1 = forced expiratory volume in 1 second; VC = vital capacity 
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ABSTRACT 
Rationale: Resveratrol is a polyphenol present predominantly in grapes and wine that has 
anti-inflammatory properties in the lung both in vivo and in vitro. These effects are at least 
partially mediated via the induction of Sirtuin 1 (SIRTl) activity. We aimed to assess the 
impact of wine and resveratrol intake and SIRT1 Single Nucleotide Polymorphisms (SNPs) 
on lung function in the general population. 
Methods: Effects of wine and resveratrol intake on lung function were analyzed in the 
prospective, population-based Doetinchem cohort (n=3,224 ). Associations of four tagging 
SIRT1 SNPs with lung function were analyzed in a random sample of the Doetinchem 
cohort (n=l,152) and in the independent Vlagtwedde-Vlaardingen cohort (n=l,390). 
Main Results: Resveratrol intake was associated with a higher Forced Vital Capacity (FVC) 
level. White wine intake was associated with a higher level of Forced Expiratory Volume in 
1 second (FEV1) and a lower risk for the presence of airway obstruction. SIRT1 SNPs were 
not significantly associated with the level or course of lung function in both cohorts 
studied. SIRT1 SNPs did not significantly affect the association between resveratrol intake 
and lung function in a sub-sample of the Doetinchem cohort. 
Conclusions: This study for the first time shows a positive effect of resveratrol intake on 
lung function in the general population. The study confirms beneficial effects of white 
wine intake on the level of FEV1, and extends this finding to protection against airway 
obstruction. These effects on lung function do not likely run via SNPs in SIRT1 in the 
general population. 
- 46 -
Chapter 3 - Resveratrol-5/RT1 pathway and COPD 
INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a worldwide prevalent disease with 
increased mortality and morbidity 1. An increased inflammatory process with an increased 
burden of proteases and oxidative stress contribute to progressive airway obstruction and 
COPD development 2'3 • The known contributors to lung function loss are both of 
environmental (e.g. smoking) and genetic origin 4-6. 
Apart from smoking, other environmental factors are related to the level of lung function, 
including the consumption of several food compounds e.g. vitamin C 7 and whole grain 
products 8• It has also been shown that out of several alcohol sources, only wine intake is 
positively associated with the level of Forced Expiratory Volume in 1 second (FEV1) and 
Forced Vital Capacity (FVC) in the general population 9, but the molecule responsible for 
this effect remains unknown so far. A putative candidate that may account for the 
observed beneficial effect of wine is resveratrol, a polyphenol present in the skin of 
grapes. Resveratrol possesses anti-inflammatory properties in airway epithelial cells 10 and 
in alveolar macrophages derived from COPD patients 11• The mechanism of this action may 
be explained by the resveratrol-mediated induction of Sirtuin 1 (SIRTl) activity 12'13. SIRTl 
belongs to the class I l l  histone/protein deacetylases. 
The resveratrol-SIRTl pathway contributes to the lifespan prolongation of several 
organisms 12'14 and to the improvement of mitochondrial function in mice 15' 16• It has 
recently been shown that cigarette smoke impairs SIRTl function in human macrophages 
in vitro and in rat lungs in vivo, which resulted in an increase of NFKB-dependent 
inflammatory burden 13• Interestingly, this effect was inhibited by resveratrol. 
Furthermore, the observed posttranslational modifications of SIRTl protein by cigarette 
smoke explained the lower SIRTl expression in lung tissue of healthy smokers and COPD 
patients as compared to never smokers 17• 
In the current study, performed in the large (n=3 ,224 ), prospective population-based 
Doetinchem cohort, we tried to replicate the previously reported beneficial effect of wine 
intake on the level of lung function 9• Furthermore, we calculated the total resveratrol 
intake and assessed its effects on the level and longitudinal decline of lung function that, if 
abnormally accelerated, can result in the development of COPD 18. Additionally we studied 
the role of SIRT1 genetic variations and their interaction with smoking in relation to lung 
function in two distinct, prospective cohorts i.e. random samples of the Doetinchem and 
Vlagtwedde-Vlaardingen cohorts. 
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METHODS 
Subjects 
The effects of food compounds and resveratrol intake on lung function were assessed in 
the Doetinchem cohort study 19, a prospective part of the larger MORGEN study 7• The 
cohort consists of 3 ,224 subjects with DNA and spirometry tests available {table 1). We 
selected a random sub-sample {n=l,152; see table El in the online supplement) for DNA 
analysis as described previously 20• Between 1994 and 2007 subjects were tested for 
prebronchodilator lung function {FEV1 and FVC) three times with 5-year intervals 
according to the European Respiratory Society {ERS) guidelines 21• Similarly to the entire 
Doetinchem cohort, in the random sub-sample 100%, 100% and 70.4% subjects 
participated in the first, second and third survey respectively. 
Table 1: Characteristics of the total Doetinchem cohort (n=3 ,224) at the second survey 
Time of the visit 1 999-200 2 
Males, n (%) 1 560 {48.4%) 
Age in years, median (range) 50.0 (3 1.2-70 .9) 
Height in cm, mean (SD) 1 7 2.8 {9.2) 
Smokers/Ex-smokers, n {%) 859 {26.7 ) / 1 259 {3 9. 1 ) 
Packyears smoked, median (range): 
Total cohort 4.6 (0.0 -1 54.0 ) 
Ever-smokers 1 3.0 {0.00 4-1 54.0 ) 
FEV1 in liters, mean (SD) 3.41 (0.80 ) 
FVC in liters, mean (SD) 4.38 (1.0 2) 
FEV1 change in ml/year*, mean (SD) -26.0 3 (3 4.0 7 )  
*calculated with the last and the first available FEV1 measurement 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; SD = Standard Deviation 
The Vlagtwedde-Vlaardingen cohort {n=l,390, described previously in detail 22) was 
included as a genetic replication sample {see table El in the online supplement). This 
cohort was prospectively followed for 25 years with lung function measurements every 3 
years {see on line supplement for details). 
There was no overlap in subjects whatsoever between the two cohorts, due to a different 
sampling time frame and sampling from different cities under responsibility of different 
institutes. The study protocols were approved by local medical ethics committees and all 
participants gave their written informed consent. 
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Assessment of the dietary intake in the Doetinchem cohort 
Dietary intake of 178 food items was assessed using a semi-quantitative food frequency 
questionnaire filled out by all participants prior to the first and prior to the second survey 
in the Doetinchem cohort (n=3 ,224 ) 19• In order to better estimate the lifetime 
consumption of these products, the average intake from both surveys was calculated and 
used in all analyses. Resveratrol intake was calculated using previously reported content 
of resveratrol in 11 food items (table 2) 23-27• 
Statistics 
Associations of wine and resveratrol intake with lung function 
Linear regression was performed to assess associations of the continuously defined 
average intake of total resveratrol, of wine, grapes, and of resveratrol from non-grape 
products with the level of FEV1 and FVC at the second survey in the Doetinchem cohort 
(n=3 ,224 , table 1). The average intake of all investigated dietary compounds was loglO 
transformed (loglO{intake+l) for the intake of wine and grapes). Identified significant 
associations were further analyzed as tertiles and presented in plots. 
Logistic regression was used to analyze the associations between the continuously defined 
average intake of wine and total resveratrol intake and the prevalence of airway 
obstruction as defined by the Lower Limit of Normal (LLN) FEV1/FVC ratio, LLN FEV1 level, 
and respiratory symptoms (breathlessness, chronic coughing and chronic phlegm 
production) at the second survey (see online data supplement for a definition of 
symptoms and LLN). 
See online data supplement for details on the selection of 5/RTl SNPs, their cross-sectional 
and longitudinal analysis, and the calculation and analysis of the dietary intake data, and 
potential confounders considered in the analyses. 
Analyses were performed either using SPSS, version 14 .0 (regression analyses) or S-PLUS, 
version 7.0 (LME models). P values<0.05 were considered to be statistically significant 
(tested 2-sided). 
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RESULTS 
Lung function level in relation to wine, grapes and resveratrol intake in the Doetinchem 
cohort (n=3,224) 
All subjects consumed resveratrol in some form and red wine was the predominant 
contributor to the overall resveratrol intake {table 2). The intake of white wine was 
associated with higher FEV1 level {figure 1 and table E2 in the online supplement), 
whereas the intake of resveratrol was associated with higher FVC level {figure 1 and table 
E2 in the online supplement). 
Table 2: Dietary characteristics of the Doetinchem cohort (n=3 ,224) 
The average intake of: 
% of consumers in the 
median { IQR) in consumers 
population 
Wine [g/day] 7 6.2 23.3 (7.1-67.6) 
White wine[g/day] 65.1 7.4 (2.5-21.4) 
Red wine [g/day] 65.4 15.4 {3.3 -50.0 ) 
Grapes [g/day] 99.4 8.1 {4.3 -13.9) 
Resveratrol [µg/day] 100.0 122.9 (3 6.0 -50 6.2) 
Resveratrol from non-grape products [µg/dayf 100.0 8.0 (5.6-11.6) 
Food item,% contribution to the resveratrol intake 
(resveratrol concentration in mg/l00 g) 
Red wine 84.1 { 1.43 ) 
White wine 9.5 {0.3 3 )  
Grapes 4.3 (0.20 ) 
Raw tomatoes 0.6 (0.0 6) 
Peanut butter 0.4 (0.0 7 )  
Chocolate 0 .3 (0.0 5) 
Strawberries 0.2 (0.0 2) 
Chocolate bars 0.2 (0.0 2) 
Peanuts 0.1 (0.0 1) 
Peanut sauce 0.1 (0.0 4) 
Chocolate milk 0.1 (0.00 2) 
*includes the resveratrol intake derived from tomatoes, strawberries, cocoa-containing and peanut-containing 
food items 
IQR = Interquartile Range 
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Figure 1: Mean adjusted level of FEV1 and FVC for the subjects according to the average intake of white wine and 
total resveratrol in the Doetinchem cohort (n=3 ,224) 
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Squares represent the adjusted mean and the bars represent 95% confidence interval. White wine intake is 
depicted according to the intake status and a median intake of 7 .4 g/day in white wine consumers. Total 
resveratrol intake is depicted in tertiles. 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity, Cl=Confidence Interval 
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White wine and resveratrol intake were further analyzed for their interaction with 
packyears smoked. There was a significant interaction between packyears smoked and 
white wine intake with the level of FEV1 (p=0.03) but not with the level of FVC (p=0.07). 
The interaction reflected that white wine consumption was associated with a higher FEV1 
level in heavy smokers only (defined using median of packyears smoked in ever-smokers, 
figure 2). The interaction term between total resveratrol intake and packyears smoked 
was not significant with respect to the level of FEV1 (p=0.17) and level of FVC (p=0.27). 
Figure 2: Mean adjusted Forced Expiratory Volume in 1 second {FEV1) level according to the average intake of 
white wine and packyears smoked in the Doetinchem cohort {n=3 ,224) 
FEV1 in liters, 





White wine intake: 
1 p�0.50 1 
1)=0.9S 
No 0.1-7.4 >7.4 
i nta ke g/day g/day 
n=379 n=398 n=330 
Never Smokers 
packyears=0 
1 p=0.43 I 
p=0.21 
No 0.1-7.4 >7.4 
i nta ke g/da y g/da y 
n=287 n=367 n=377 
Mild smokers 
O<packyears::.1 3.0 
No 0.1·7.4 >7.4 
i n ta ke g/day g/day  
n=441 n=265 n=318 
Heavy smokers 
packyears> 1 3.0 
Squares represent the adjusted mean and the bars represent 95% Confidence Interval {Cl) .  White wine intake is 
depicted according to the intake status and a median intake of 7 .4 g/day in white wine consumers. Mild/heavy 
smokers are depicted according to the median of packyears smoked in ever-smokers {n=1 3 .0 ). 
Respiratory symptoms, airway obstruction and low FEV1 level in relation to wine and 
resveratrol intake in the Doetinchem cohort (n=3,224} 
Red wine, but not white wine intake was associated with an increased risk for chronic 
coughing (table E3 in the online supplement). White wine, but not red wine intake was 
significantly associated with a decreased risk for an FEVi/FVC ratio < LLN level, FEV1 < LLN 
level and borderline significantly (p=0.06) with a decreased risk for breathlessness (table 
E3 in the online supplement). 
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Lack of white wine consumption significantly (p=0.017) increased the risk for the 
combination of FEV1< LLN and FEVJFVC < LLN (figure 3). The association was even more 
significant (p=0.007) when adjusted for the presence of self-reported doctor diagnosed 
asthma, which, similarly to COPD, might be reflected in a low prebronchodilator FEVJFVC 
ratio. 
FEV1 decline in relation to wine and resveratrol intake in the Doetinchem cohort 
(n=3,224) 
There was no significant association between the intake of white wine and the change in 
FEV1 across the three surveys in the Doetinchem cohort (p=0.67). Furthermore, no 
significant difference in FEV1 decline was observed between non-consumers of white wine 
and subjects who reported white wine intake at the first and second survey (B= -1.15 
ml/year difference, SE=l.36, p=0.4 0) and subjects who changed (started or stopped} their 
white wine drinking habits (data not shown). 
Figure 3: Adjusted relative risks for a low FEVJFVC ratio and normal FEV1 level, and for a low FEVJFVC ratio and 










n=78 n=73 n=74 
FEV 1 2: LLN & FEV ifFVC< LLN 
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n=lOO n=52 n=49 
FEV 1 < LLN & FEV ifFVC < LLN 
*p=0 .0 89 
** p=0.0 17 
*** p=0 .0 51 
Squares represent the relative risks and the bars represent 95% confidence intervals. The reference group 
(n=2,290 )  has no respiratory symptoms (breathlessness, chronic cough and chronic phlegm production), 
FEV1�LLN and FEVJFVC�LLN. Numbers correspond to subjects identified within each group in the Doetinchem 
cohort. 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; LLN = Lower Limit of Normal 
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Genetic variations in SIRTl and lung function level in the random sample of the 
Doetinchem cohort (n=l,152) and Vlagtwedde-Vlaardingen cohort (n=l,390) 
Since SNPs rs10823108 and rs2273 773 were in complete linkage disequilibrium (r2=1.0) in 
both cohorts, only data on rs2273 773 are presented. All SNPs were in the Hardy-Weinberg 
Equilibrium (table 3 ). No strong correlation (r2<0.3) existed for any other SNP pair in both 
cohorts. Four haplotypes in SIRTl were identified (table E4 in the online supplement) and 
only one (containing the mutant allele of rs7069102 and wild type alleles of all the other 
SNPs) was unique i.e. was not tagged by a single allele of any investigated SIRTl SNP. 
Table 3: SIRT1 genotype characteristics in the two cohorts studied 
Doetinchem cohort (n=l, 1 52) 
Total SIRT1 SNP call rate, (%) 98.4 
SIRT1 variation: Heterozygotes n (%) 
Homozygotes mutant n MAF HWE te:t p 
(%) (%) value 
rs1 27 7 83 66' 264 (23 .2) 27 (2.4) 1 3 .9 0 .23 
rs70 6910 i' 529 (46.9)  1 45 (1 2.8) 3 6.3 0 .65 
rs227 3 7 7 3 9 1 7 3  ( 1 5.3 } 8 (0 .7 } 8.3 0 .96 
Unique haplotype 27 6 (24.4} 15 (1.3 ) 13 .5 0 .15 
Vlagtwedde-Vlaardingen cohort (n=l,3 90 )  
Total SIRT1 SNP call rate, {%) 96.4 
S/RT1 variation: Heterozygotes n (%} 
Homozygotes mutant n MAF HWE te:t p 
(%) (%) value 
rs127 7 83 66
t 
290 {21 .5) 14 (1.0 )  11.8 0 .21 
rs70 6910 2' 57 6 (43 .8)  1 53 { 1 1 .6} 3 3 .5 0 .52 
rs227 3 7 7 3 9 20 9 (1 5.0 )  9 {0 .6) 8.4 0 .86 
Unique haplotype 27 6 (21 .9) 28 (2.2) 1 3 .2 0 . 1 3  
for 1 df chi-square test comparing the observed genotypes distribution with the expected as derived from the 
allele frequencies 
t located in the SIRT1 promoter; tagged SNP located in the intron 3 
* located in the SIRT1 intron 4; tagged SNPs located in the promoter, intrans 1 - 8 and 3 '  near region 
§ synonymous SNP {Leu3 3 2Leu) in the exon 5; tagged SNPs located in the promoter and intrans 3 - 5 
SIRT1 = Sirtuin 1; SNP = Single Nucleotide Polymorphism 
SIRTl variations and the level of FEV 1 and VC 
None of the 5/RTl genetic variations was significantly associated with FEV1 or VC level in 
an additive model in the Doetinchem cohort, Vlagtwedde-Vlaardingen cohort, and in the 
pooled cohort analysis (table 4 ). Additionally, in the pooled cohort none of the 5/RTl 
variations was associated with FEV1 or VC level analyzed with the recessive or dominant 
model (data not shown). 
Three significant interactions between SIRTl genetic variations (additive model) and 
packyears smoked were observed in the Doetinchem cohort and one other in the 
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Vlagtwedde-Vlaardingen cohort in relation to the level of FEV1 and VC, but none of these 
was observed in the pooled cohort analysis (table ES in the online supplement). No 
additional significant interactions were observed in the pooled analysis for the dominant 
or recessive effect. We found no significant interaction between SIRT1 variations and 
resveratrol intake with respect to the FEV1 or FVC level at the second survey in the 
random sample of the Doetinchem cohort in any genetic model (see table EG in the on line 
supplement for the additive model). 
SIRT1 variations and FEV1 decline 
No significant associations were observed between SIRT1 variations and FEV1 decline in 
either of the cohorts or in the pooled cohort analysis for additive (table 3 ), recessive and 
dominant genetic models (data not shown). 
Table 4: Estimated effects of the SIRT1 genetic variation (additive model) on lung function parameters in the 
random sample of the Doetinchem cohort and Vlagtwedde-Vlaardingen cohort 
Pooled 
Doetinchem (n=l,152} Vlagtwedde-Vlaardingen (n=l,390) cohorts 
SIRT1 genetic variation: (n=2,542) 
FEV1 level [ml]* 
B SE p B SE p p 
rs1 27 7 83 66 23.7 27 .8 0 .3 9  -29.5 28.0 0 .29 0.98 
rs70 6910 2 1 7 .8 1 8.6 0.3 4 -28.6 20 .6 0.1 7 0 .86 
rs227 3 7 7 3  - 1 .5 3 2. 1  0 .96 -3 3.7 3 5.5 0.3 4 0.54 
Unique haplotype -4.2 29.6 0 .89 8.6 25.9 0.7 4 0 .84 
VC level [ml]* 
rs1 27 7 83 66 49.8 30 .9 0 . 11 1 9.5 3 2.5 0 .55 0 . 10 
rs70 6910 2 3 6.3 20.7 0 .0 8  -10 .8 24.1 0 .66 0.3 5 
rs227 3 7 7 3  -1 7.9 3 5.7 0.62 -42.7 41 .4 0 .30 0.30 
Unique haplotype -9.4 3 4.5 0.7 9 29.6 28.8 0 .3 1  0.62 
FEV1 change [ml/year] 
rs1 27 7 83 66 0.1 2.0 0.96 1.7 1 .5 0 .28 0.63 
rs70 6910 2 1.7 1 .5 0 .25 0 .5 1 .0 0 .65 0.99 
rs227 3 7 7 3  5.0 2.6 0 .0 53 0 .2 1 .7 0 .93 0.49 
Unique haplotype 0.9 2.2 0.69 2.0 1.4 0.1 8 0.53 
*linear regression analysis adjusted for sex, age, packyears smoked and height and the cohort binary variable for 
pooled analysis 
\inear Mixed Effect model analysis adjusted for the age at entry, sex, initial FEV1 level (cohort binary variable for 
pooled analysis) and their interaction with time 
SNP = Single Nucleotide Polymorphism; df = degree of freedom; HWE = Hardy-Weinberg Equilibrium; MAF = 
Minor Allele Frequency; FEV1 = Forced Expiratory Volume in 1 second; VC = Vital Capacity measured as Forced VC 
in the Doetinchem cohort and lnspiratory VC in the Vlagtwedde-Vlaardingen cohort; SIRTl = Sirtuin 1 
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DISCUSSION 
This is the first study investigating resveratrol intake in relation to lung function and 
development of COPD. We found a beneficial effect of resveratrol intake on FVC level in 
the general population. Furthermore, we replicate the previously observed beneficial 
effect of white wine intake on the level of FEV1 in the general population 
9
, and extend this 
observation by showing that white wine intake is positively associated with a lower risk 
for airway obstruction as present in COPD. Our results do not implicate that heavy wine or 
alcohol consumption are protective in any respect. Finally, we conclude that 
polymorphisms in 5/RTl do not appear to affect lung function neither via an independent 
effect, nor via interaction with packyears smoked or the intake of resveratrol. 
The beneficial effects of wine consumption are postulated to account for the "French 
paradox", the observation of lower mortality due to coronary heart disease in the French 
population despite this population's relatively high consumption of a cholesterol-rich and 
saturated fat-rich diet 28'29 • The proposed mechanism includes the inhibition of platelet 
reactivity by wine 28, and resveratrol is a prominent candidate responsible for the vascular 
protection provided by wine 30. However, our study shows that white wine intake and not 
red wine intake, which is the major dietary resveratrol source, is associated with a lower 
risk for airway obstruction and higher FEV1 levels, both indices of COPD. This is of great 
importance given the fact that reduced lung function is a marker for cardiovascular related 
mortality 31• 
We found that resveratrol intake contributes to a higher FVC level. However, its beneficial 
effect on FEV1 level was not significant. Similarly we did not observe significant effects of 
resveratrol intake on any of the respiratory symptoms or on the presence of airway 
obstruction. Therefore, the relevance of the observed association in relation to respiratory 
disorders other than COPD needs to be further addressed. Interestingly none of the grape 
sources of resveratrol was associated with FVC level, and neither was the resveratrol from 
non-grape sources, which suggests that the effect of resveratrol intake is specific to FVC 
and independent of the source. 
The analysis of individual sources of resveratrol revealed that particularly white wine 
intake is associated with a higher FEV1 level. Accordingly, Schunemann and colleagues 
found white wine to display a stronger effect on FEV1 level compared with red wine in the 
cohort of 1,555 New York residents 9• They suggested that health-promoting lifestyle 
factors associated with white wine drinking might be responsible for this effect. We like to 
put forward that other polyphenolic compounds present in white wine may exert 
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beneficial effects on lung function as well. Plausible candidates in this respect are tyrosol 
and hydroxytyrosol, polyphenolic white wine molecules with, similar to resveratrol, 
antioxidant and cardioprotective effects in vivo 32• Other candidates are flavonoids that 
were associated with a higher level of FEV1 in the MORGEN study 
33
• However since 
flavonoids like quercetin and myricetin are present in red wine predominantly 34, they are 
likely not responsible for the beneficial effects of white wine we found. 
We additionally showed that the intake of white wine interacts with the amount of 
cigarettes smoked. Smokers particularly benefitted from a higher white wine intake. This 
observation suggests that white wine might be efficient in the detoxification of molecules 
derived from cigarette smoke that elevate oxidative or inflammatory burden in the lung, 
and thus the effects of white wine intake become more easily apparent in smokers as 
compared to never-smokers. Eventually, as shown in our study non-drinkers of white wine 
are at increased risk for abnormally low FEV1 and low FEV1/FVC levels, both indices of 
COPD in a moderate stage. Since we did not observe a significant effect of white wine 
intake on FEV1 change in time we speculate that white wine drinking might contribute to a 
higher maximal attained FEV1 before 30 years of age 
35
. 
We could not include all known sources of resveratrol i.e. grape juice and fortified wine or 
other sources suggested to contain resveratrol like hop, present in beer 36 or cherries 37 • 
Nevertheless, our estimation of resveratrol intake might be acknowledged as sensitive on 
a population level, since the sources that were not used contain a low concentration of 
resveratrol 27'36'37 and/or are not widely consumed in the total population. Sensitivity of 
the current estimation of the resveratrol intake is certainly lower on an individual level. 
This is due to the fact that the resveratrol content of grapes and wines is affected by many 
factors that could not be taken into account in the current study. In particular it has been 
shown that the resveratrol content of wine depends on the type of wine and the region 
where the grapes were harvested, due to the climate/species dependent resveratrol 
synthesis by grapes 23'38'39 • 
Since resveratrol induces deacetylase 5/RTl activity in vitro 12•14 and SIRTl expression is 
decreased in lung tissue of COPD patients 17, we were interested in analyzing genetic 
variations in this gene in the context of lung function. Although we found some significant 
interaction of 5/RTl SNPs with smoking with respect to the lung function level, none of 
these associations was replicated in the two cohorts investigated. The current study also 
does not identify any significant interaction between SIRTl SNPs and resveratrol intake 
with respect to the level of lung function. 
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In summary, we demonstrate a beneficial effect of white wine intake on the level of FEV1 
in the general population that is pronounced in smokers. Consequently white wine 
consumption lowers the risk for moderate airway obstruction. We show for the first time 
that resveratrol intake is associated with higher FVC levels on a general population level. 
Moreover, genetic variants in SIRT1, a deacetylase gene that can be induced by resveratrol 
in vivo, are unlikely to play a role in the positive association between resveratrol and lung 
function. 
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Online Data Supplement 
METHODS 
Lung function measurements in Doetinchem and Vlagtwedde-Vlaardingen cohorts 
Subjects from the Doetinchem cohort study were tested for FEV1 and FVC (performed with 
forced expiratory maneuver} with a heated pneumotachometer (Jaeger, WOrzburg, 
Germany}. 
Subjects from the Vlagtwedde-Vlaardingen cohort study were tested for FEV1 and VC (slow 
inspiratory maneuver} with a water-sealed spirometer (Lode Instruments, Groningen, the 
Netherlands}. 
Genotyping 
Four SNPs, that tag all 22 SNPs in SIRTl and its 5kb up-/downstream region with r2>0.8 
and Minor Allele Frequency>5% (based on the HapMap release 23a/March 2008}, i.e. 
rs127783 66, rs10823108, rs7069102, and rs2273 773 were genotyped in both cohorts by 
K-Bioscience Ltd {UK} using the patent-protected competitive allele specific PCR system 
(KASPar}. Since SNPs rs10823 108 and rs2273773 were found to be correlated {r2=1.0} in 
both cohorts the information they provided was the same and therefore presented only 
for the latter SNP. We identified 4 haplotypes in the SIRTl using PHASE software (table 
E2} i,2 _ 
Assessment of the dietary intake in the Doetinchem cohort 
The resveratrol intake included the intake of both isomers {cis- and trans-} of resveratrol 
and its glycoside, i.e. piceid. The latter is known to be deglycosylated in the intestinal 
tract 3, thus the piceid intake was transformed to resveratrol equivalents. Since we had no 
specific data on the intake of grape juice and fortified wine these two resveratrol sources 
were not taken into account, but their overall contribution to the resveratrol intake is low, 
as reported previously 4• 
Statistics 
Odds ratios for LLN FEVJFVC ratio and/or LLN FEV1 were calculated for each of the groups 
of white wine drinkers separately {defined according to intake status and a median of 
intake in consumers} as compared to remainders and were converted into relative risks as 
previously described 5• 
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All analyses were adjusted for the following potential confounders :  sex, age, height (FEV1 
and FVC only), packyears smoked, smoking status (categorized to never-, ex- and current 
smokers), average energy intake, educational level (categorized into 5 groups), physical 
activity (categorized into 4 groups), environmental tobacco exposure at home, waist to hip 
ratio, presence of obesity (BMl>30kg/m2 ) and the average, continuously defined, intake of 
dietary items previously associated with lung function, i.e. vitamin C, whole grain products 
and non-wine alcohol (calculated from non-wine sources and loglO transformed) 6'7• 
Both red wine and white wine intake were analyzed as separate variables in one model. 
When analyzing the intake of grapes and resveratrol from non-wine sources adjustments 
were made for the intake of red and white wine. 
Cross-sectional analyses of SIRT1 SNPs and lung function level 
The additive (genotype code:O=homozygotes wild type, l=heterozygotes, 2=homozygotes 
mutant) effects of the SIRT1 SNPs and a unique SIRT1 haplotype on lung function level 
were assessed with linear regression adjusted for sex, height, age and packyears smoked 
in the random sample of the Doetinchem cohort (second survey, n=l,152) and 
Vlagtwedde Vlaardingen cohort (last survey). In this way, the median age was similar for 
the two cohorts and the number of participating subjects was the highest. In order to 
check the consistency of the results we performed additional analyses when both cohorts 
were pooled, with additional adjustment for a cohort variable. The pooled cohort analysis 
was further used to test two other genetic models, i.e. dominant (genotype coded : 
O=homozygotes wild type, l=heterozygotes, l=homozygotes mutant) and recessive 
(genotype coded : O=homozygotes wild type, O=heterozygotes, l=homozygotes mutant). 
The effect of the white wine intake on lung function change in the Doetinchem cohort 
(n=3,224} 
In order to disentangle the cross-sectional and longitudinal effects of white wine intake on 
FEV1 we performed Linear Mixed Effect model analysis on the FEV1 change across the 
three surveys. We defined time in relation to the first FEV1 measurement and adjusted the 
analysis for the same confounders as the cross-sectional FEV1 analysis and additionally for 
their interaction with time. Random effect was assigned to the intercept and time. 
The effect of SIRT1 SNPs on FEV1 change in both cohorts 
In both cohorts LME models were used to estimate the effect of SNPs on longitudinal FEV1 
course across all available surveys. Time was defined as the time in years relative to the 
first FEV1 measurement. Variables included in the model were genotypes, age at entry, 
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sex, packyears smoked, first available FEV1 and their interaction with time (random effect 
additionally assigned to the intercept and time). In the Vlagtwedde-Vlaardingen cohort, 
FEV1 measurements were included from the age of 30 years, because an individual's 
maximal attained lung function is assumed to have been reached before that age, and 
lung function is considered to be either in the plateau or decline phase 8• In the 
Doetinchem cohort, all subjects had passed the age of 30 years at the second survey and 
were thus included in the analysis. 
Genotype by smoking, respectively resveratrol intake interactions were tested in relation 
to the level of FEV1 and FVC by introduction of interaction terms (i.e. number of packyears 
smoked/resveratrol intake x genotype) into the regression models. All interaction terms 
assessed whether there was an additional effect of packyears smoked respectively 
resveratrol intake in combination with a certain genotype over the sum of the separate 
effects of these factors. 
Definition of dichotomous outcome variables in the Doetinchem cohort: 
Lower Limit of Normal FEV1 and FEVJFVC ratio level - linear regression equations for 
FEV1 level and FEVi/FVC ratio level were obtained separately for 3 70 males and 4 4 4  
females (reference subjects} who at the second survey described themselves as never­
smokers without respiratory symptoms (i.e. breathlessness, chronic cough, chronic 
phlegm production, nocturnal wheezing, wheezing without a cold}, self-reported doctor 
diagnosed asthma, and BMI within 18.5  - 30.0 range, similarly to a previously published 
study 9• Assuming the lowest fifth percentile of FEV1 level and FEVi/FVC ratio level within 
reference subjects as a "case" group and using residual standard deviation (RSD) from 
reference regression equations we identified cases within the whole cohort (n=3 ,224 } 
whose lung function was below 1.64 5 standardized residuals from a predicted value. 
The reference equations were as follow: 
Males 
FEV1 [ml] = height (cm) * 4 0.4 1 - age (years) * 23 .3 2 -1978.72 
FEVi/FVC [%] = height (cm} * (-0.17) - age (years) * 0.15 +117.39 
Females 
FEV1 [ml] = height (cm) * 27.86 - age (years} * 21.61 - 531.77 
FEV1/FVC [%] = height (cm) * (-0.21} - age (years) * 0.17 + 125.29 
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Breathlessness - positive answer to both statements: 'breathlessness during normal 
walking' and 'breathlessness in hurry and/or climbing stairs' 
Chronic coughing - positive answer to statements: 
'cough after waking up during winter' and 'coughing for 3 months each day during winter' 
or 'coughing during winter, day and night' and 'coughing during winter, day and night, 
each day for 3 months' 
Chronic phlegm production - positive answer to statements: 
'sputum production after waking up during winter' and 'sputum production for 3 months 
each day during winter' or 'sputum production during winter, day and night' and 'sputum 
production during winter, day and night, each day for 3 months' 
Doctor diagnosed asthma - positive answer to both statements: 'do you have asthma' 
and if yes 'was this confirmed by a doctor?' 
Table El: Comparison of characteristics at the second (Doetinchem cohort) and the last (Vlagtwedde­
Vlaardingen) survey in the random samples of two cohorts studied 
Doetinchem cohort 
Vlagtwedde-Vlaardingen 
(n=l, 1 52) 
cohort 
(n=l,3 90 )  
Time of the visit, years 1 999-200 2 1 989-1 990 
Total duration of follow-up (years)/number of visits (median) 10 /3 * 25/7 
Males, n (%) 541 (47 .0 )  7 1 4 (51 .4) 
Age in years, 
49.9 (3 1 .2-70 .9) 51.7 (3 5.0 -7 9.0 )  
median (range) 
Height in cm, mean (SD) 1 7 2.6 {9. 1 ) 1 70 .2 (9.2) 
Smokers/Ex-smokers, n(%) 
30 8 (26.7 ) / 47 3 
489 (3 5.2)/456 {3 2.8) 
(41 . 1 ) 
Packyears smoked, median (range): 
Total cohort 5.0 (0 .0 -84.0 ) 9.0 (0 .0 -262.2) 
Ever-smokers 1 2.5 (0 .00 4-84.0 ) 1 8.9 (0 . 1- 262.2) 
FEV1 in liters, mean (SD) 3 .3 9  (0 .7 9 )  2.86 (0 .7 7 )  
VC in liters, mean (SD) 4.3 5 ( 1 .0 1 )  3 .89 (0 .98) 
FEVJVC in %, mean (SD) 7 8.0 {7 .2) 7 3 .9 {8.8) 
FEV1 change in ml/year, mean (SD) -26.2 (3 3 .4) -20 .8 (22.9) 
Average resveratrol intake in µg/day, median ( IQR) 1 29.7 (3 7 .8-487 .0 )  n.a. 
* applicable to the 70 .4% of subjects who additionally participated in the third survey (200 3 -200 7 ); the 
remainder of the cohort participated in the first { 1 993 -1 997 ) and the second (1 999-200 3 )  survey only 
FEV 1 = Forced Expiratory Volume in 1 second; VC = Vital Capacity 
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Table E2: The impact of average intake of resveratrol and particular sources of resveratrol (loglO transformed) 
on the level of FEV1 and FVC in the Doetinchem cohort (n=3 ,224) 
Log10 transformed intake of: 
FEV1 [ml] FVC [ml] 
B 95% CI p B 95% CI p 
Total resveratrol [µg/day] 1 5.0 -10.0 - 40.1 0 .23 9 3 2.2 2.8 - 61 .6  0.032 
Wine [g/day] 1 8. 1  -3.8 - 40 .6 0.10 5 23.7 -2.4 - 49.8 0 .0 75 
Red wine [g/day] -2.0 -26.3 - 22.4 0 .875 1 2.0 - 1 6.5 - 40 .6 0.40 9 
White wine [g/day] 30 .5 2.5 - 58.4 0.033 1 9.4 -1 3.5 - 52.3 0 .247 
Grapes [g/day] 3 .5 -60 .2 - 67.1 0 .9 1 5 49.9 -23 .8 -1 25.6 0 .1 82 
Resveratrol from non-grape sources [µg/day] -20 .0 -93 .5 - 53 .6 0 .595 29.8 -56.7 - 1 1 6.2 0 .499 
Significant associations are depicted in bold. 
All analyses were adjusted for sex, age, packyears smoked, height, smoking habits, presence of cigarette smoke 
at home, education level, physical activity, waist to hip ratio, presence of obesity, environmental tobacco 
exposure at home, average energy intake, average intake of whole grain products, vitamin C, alcohol from non­
wine sources, red wine and white wine (except for the analysis concerning total resveratrol intake). 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; Cl = Confidence Interval 
Table E3: The impact of average resveratrol and wine intake (loglO transformed) on the presence of respiratory 
symptoms, and low lung function level in the Doetinchem cohort (n=3 ,224) 
Total resveratrol Wine Red wine White wine 
N [%] [µg/day] [g/day] [g/day] [g/day] 
OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Breathlessness 1 89 0 .953 0 .745 0 .9 1 4 0.73 4 - 1 . 1 3 4  0 .893 - 0 .757 0 .569 -
(5.9) 1 .21 8 1 . 1 3 7  1.440 1 .00 7 
Chronic coughing 240 1. 1 3 7  0.920 - 1.1 58 0 .958 - 1.233 1.003 - 0.966 0.760 -
(7.5) 1 .40 5 1.40 1 1.515 1.227 
Chronic phlegm 20 4 0 .970 0 .773 0.945 0 .772 - 1.0 30 0.824 - 0.941 0.725 -
(6.3 ) 1.21 7 1. 1 56 1 .288 1 .220 
Any of the three 475 1 .0 29 0 .875 - 0 .996 0 .862 - 1 . 1 25 0.961 - 0 .883 0.73 5 -
above symptoms (1 4.8) 1 .210 1 .1 51 1.3 1 8  1.0 62 
FEVJFVC<LLN 41 6 0 .994 0 .843 - 0 .9 1 9 0 .792 - 1.0 46 0.891 - 0.816 0.674 -
( 1 2.9) 1 . 1 73 1 .0 67 1.229 0.987 
FEV1<LLN 3 86 0 .889 0 .746 - 0.847 0.724 - 0.988 0 .830 - 0.754 0.612 -
{ 1 2.0 )  1 .0 60 0.991 1 . 1 77 0.930 
FEVJFVC<LLN & 20 1 0 .920 0.73 1 - 0.83 3 0 .677 - 0 .944 0.750 - 0 .790 0.60 1 -
FEV1<LLN (6.2) 1 . 1 58 1 .0 25 1 .1 89 1 .0 3 8  
Significant associations are depicted in bold. 
All analyses were adjusted for sex, age, packyears smoked, height, smoking habits, presence of cigarette smoke 
at home, education level, physical activity, waist to hip ratio, presence of obesity, environmental tobacco 
exposure at home, average energy intake, average intake of whole grain products, vitamin C, alcohol from non­
wine sources, red wine and white wine (except for the analysis concerning total resveratrol intake). 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; LLN = Lower Limit of Normal; OR = 
Odds Ratio; Cl = Confidence Interval 
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Table E4: Four 5/RTl haplotypes identified in the Doetinchem cohort (n=l,152) 
Haplotype Frequency (%) rs12778366 rs7069102 rs2273773 
A 63 .8 0 0 0 
B 13 .9 0 1 0 
C 8.4 0 1 1 
D 13 .9 1 1 0 
Haplotype B is unique 
0 /1- wild type/mutant allele of the corresponding Single Nucleotide Polymorphism 
Table ES: Estimated effects of the interaction between 5/RTl genetic variations (additive model) and packyears 
smoked on lung function level in the random sample of the Doetinchem cohort and Vlagtwedde-Vlaardingen 
cohort 
Doetinchem (n=l,152) Vlagtwedde-Vlaardingen (n=l,390) Pooled cohorts(n=2,542) 
FEV1 [ml] * 
B1NT SE1NT PINT B1NT SEtNT PINT PINT 
rs127 7 83 66 -2.90 2.24 0 .20 -0 .0 8 1 .42 0 .96 a.so 
rs70 6910 2  -3 . 16 1.44 0.03 0 .13 1.0 3 0 .90 0 .23 
rs227 3 7 7 3  -8.0 5  2.44 0.001 -0 .61 1.42 0 .67 0 . 12 
Unique haplotype 0 .55 1.87 0 . 7 7  1.0 5  1.40 0 .45 0 . 7 4  
VC [ml] * 
rs127 7 83 66 -3 .0 2  2.60 0 .25 -0 .61 1 .58 0 .70 0 .3 6  
rs70 6910 2  -2.86 1.69 0 .0 9  0 .89 1.15 0 .44 0 .68 
rs227 3 7 7 3  -7 .55 2.85 0.01 -1.68 1.58 0 .29 0 .0 7  
Unique haplotype 0 .91  2.19 0 .68 3 .96 1.55 0.01 0 .0 7  
*linear regression analysis adjusted for sex, age, packyears smoked, genotype and height and the cohort binary 
variable for pooled analysis 
Table E6: Estimated effects of the of the interaction between 5/RTl genetic variations (additive model) and log10 
transformed resveratrol intake on lung function level in the random sample of the Doetinchem cohort (n=l,152) 
SIRT1 genetic variation: 
FEV1 [ml]* 
B1NT SE1NT PINT 
rs127 7 83 66 -0 .6 40 .4 0 .99 
rs70 6910 2  -2.5 29.9 0 .93 
rs227 3 7 7 3  10 . 3  49 .6  0 .84 
Unique haplotype 13 . 7  40 .8  0 .7 4  
FVC [ml]* 
B1NT SE1NT PtNT 
rs127 7 83 66 -17 . 1  46.8 0 .7 2  
rs70 6910 2  -3 9.0 3 4.8 0 .26 
rs227 3 7 7 3  -50 .2  57 .7 0 .3 8  
Unique haplotype -3 8.7 47 .5 0 .42 
*linear regression analysis adjusted for sex, age, packyears smoked, log10 transformed resveratrol intake, 
genotype and height 
FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital Capacity; S/RTl = Sirtuin 1 
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ABSTRACT 
Objective: The ATP-binding cassette transporter ABCC1, (i.e. Multidrug Resistance­
associated Protein 1 (MRP1)) is a membrane pump excreting a variety of xenobiotics from 
the cell and thus ABCC1 may play an important role in smoking related lung function loss 
and development of Chronic Obstructive Pulmonary Disease (COPD). We previously 
showed that bronchial epithelium of COPD patients have lower ABCC1 expression than 
that of healthy controls, with even further decrements in more severe COPD stages. In line 
of these results, we now aimed to assess effects of ABCC1 single nucleotide 
polymorphisms (SNPs) on both the level and the longitudinal course of lung function in the 
general population. 
Methods: All 51 prevalent (Minor Allele Frequency>5%) and non-correlated (r2<0.8) 
ABCC1 SNPs were analyzed in two independent, prospective, population-based cohorts, 
i.e. Doetinchem (n=l,152) and Vlagtwedde-Vlaardingen (n=l,390) studies (respectively 
three and seven median lung function measurements per subject), using linear regression 
and linear mixed effect models. 
Results: SNPs rs4 14 83 82 and rs212093 in the 3 '  ABCC1 region were significantly 
associated with a higher and respectively lower forced expiratory volume in one second 
(FEV1) in both cohorts. Another rs3 5621 SNP (intron 14 ) was significantly associated with a 
highly excessive FEV1 decline in both cohorts. All replicated associations were additionally 
confirmed by permutation testing. 
Conclusion: This is the first study showing a significant relation between ABCC1 SNPs and 
lung function in two independent cohorts. These SNPs are therefore putative candidates 
for studies aiming to prevent COPD and investigating pharmacogenetics in established 
COPD. 
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INTRODUCTION 
The ATP-binding cassette, sub-family C (CFTR/MRP), member 1 (ABCCl, i.e. Multidrug 
Resistance-associated Protein 1 (MRPl)) is a membrane-bound pump that is responsible 
for the glutathione-dependent organic anion excretion (e.g. leukotriene C4 or NNAL-0-
glucuronide, a cigarette smoke metabolite) from the cell in vivo 1. Therefore ABCCl has 
been widely studied in the context of pharmacogenetics and cancer, where it was 
primarily identified to be responsible for doxorubicin-resistance 2-5• Since lungs are 
particularly exposed to the noxious particles and xenobiotics, and especially to those 
derived from cigarette smoke, ABCCl likely possesses important functions in this tissue. 
The role of ABCCl in lung tissue derangement is emphasized by the observations that 
ABCCl activity is negatively affected by cigarette smoke in bronchial epithelial cells in 
vitro, whereas cell survival is synergistically impaired by ABCCl inhibition and cigarette 
smoke extract 6• 
We have recently shown that ABCCl is lower expressed in bronchial epithelium of patients 
with Chronic Obstructive Pulmonary Disease (COPD) than in that of healthy controls, with 
a further expression decrement in more severe COPD stages 7• COPD is a highly prevalent 
chronic respiratory disease and leading cause of smoking-related mortality worldwide, and 
its death rates are still increasing 8• The disease is characterized by slowly progressive 
airflow limitation that is predominantly caused by inhalation of airway irritants and 
particularly cigarette smoke. Since previous studies imply that a genetic predisposition is 
involved in the pathogenesis of COPD, only a subset of smokers develops clinically 
relevant COPD, and that lung function is genetically determined 9·11, the metabolism of 
xenobiotics is widely studied as a mechanism that can contribute to COPD in case of 
malfunctioning. Variations within genes that are involved in xenobiotic metabolism have 
been intensively studied 12-15• Additionally, it has been shown that genes involved in 
cellular detoxification processes display different expression patterns in COPD patients 
and never-smokers or healthy controls 16-18• 
Single nucleotide polymorphisms (SNPs) in ABCCl spanning 196.7 kb on chromosome 16, 
have been comprehensively analyzed in the Caucasian population which resulted in the 
identification of a tagging SNP set 19• So far no studies have focused on the ABCCl genetics 
and lung function decline in humans. 
We aimed to investigate the impact of all tagging SNPs in ABCCl on the level of Forced 
Expiratory Volume in one second (FEV1), an important lung function characteristic in the 
general population. We had also the unique opportunity to assess the impact of these 
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SNPs on the longitudinal course of FEV1 that, if abnormally accelerated, can result in the 
development of COPD 20• We performed our study in two distinct and independent 
prospective Dutch population-based cohorts since the need for replication of genetic 
findings is widely acknowledged. 
METHODS 
Subjects 
Subjects from the prospective Doetinchem cohort study 21 were included. 
A sub-sample (n=l,152) was randomly selected from the total cohort with spirometry 
tests and DNA available (n=3 ,224 Caucasians) as described previously 22• Subjects were 
tested for FEV1 three times with a 5-year interval according to the European Respiratory 
Society (ERS) guidelines 23• Characteristics of participant in the first {100% subjects 
included), second {100%), and third {70.4%) survey are presented in table Sl {online 
supplement). 
The Vlagtwedde-Vlaardingen cohort {n=l,390 Caucasians, described previously in detail 24) 
was included as a replication sample {table 1). This cohort was prospectively followed for 
25 years with FEV1 measurements every 3 years {following ERS guidelines). 
There was no overlap in subjects whatsoever between the two cohorts, due to different 
sampling time frame and sampling from different cities. The study protocols were 
approved by the local university medical hospital ethics committees and all participants 
gave their written informed consent. 
Selection and genotyping of the ABCC1 tagging SNPs 
ABCC1 was tagged using all 51 SNPs {minor allele frequency {MAF)>5%, r2<0.8) as 
described previously for the 24 3 Caucasians 19• 3 5  SNPs were genotyped, remaining 16 
SNPs were tagged and 2 nonsynonymous SNPs (MAF<5%) were additionally included {see 
on line supplement for description of the genotyping protocol). 
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Table 1: Comparison of characteristics at the second (Doetinchem cohort) and the last (Vlagtwedde-Vlaardingen 
cohort) survey in the two cohorts studied 
Doetinchem cohort 
Vlagtwedde-
(n=l, 1 52) 
Vlaardingen cohort 
(n=l,3 90 )  
Time of the visit, years 1 999-200 3 1 989-1 990 
Total duration of follow-up (years)/ 10 · / 3 (2-3 ) 25 I 7 ( 1 -8) 
/number of visits (median (range)) 
Available lung function measurements 
3 , 1 1 5 8, 1 59 
across all surveys (n) 
Males, n (%) 541 (47 .0 )  7 1 4 (5 1 .4) 
Age in years, median (range) 49.9 (3 1 .2-70 .9) 51 .7 ( 3 5.0 -7 9.0 )  
Height in cm, mean (SD) 1 7 2.6 (9.1 ) 1 70 .2 (9.2) 
Smokers/Ex-smokers, n (%) 30 8 (26.7 ) / 47 3 (41 . 1 ) 489 (3 5.2) / 456 (3 2.8) 
Packyearsb smoked, median (range): 
Total cohort 5.0 (0 .0 -84.0 ) 9.0 (0 .0 -262.2) 
Ever-smokers 1 2.5 (0 .00 4-84.0 ) 1 8.9 (0 . 1- 262.2) 
FEV1 in liters, mean (SD) 3 .3 9  (0 .7 9) 2.86 (0 . 7 7 )  
FEV1 / VC ' in %, mean (SD) 7 8.0 (7 .2) 7 3 .9 (8.8) 
COPD GOLD stage I I / stage Ill or higher, n (%) 3 6  (3 . 1 ) / 1 (0 . 1 ) 1 64 ( 10 .9) / 21 ( 1 .5) 
FEV1 change in ml/year, mean (SD) -26.2 (3 3 .4) -20 .8 (22.9) 
ABCCl SNPs genotyped/tagged/analyzed (n) 3 7  I 1 6  / 53 1 5  / 4 / 1 9  
The total ABCCl SNPs call rate (%) 98.4 9 7 .3  
• applicable for the 70 .4% of subjects; the remainder of the cohort participated in the first ( 1 993 - 1 997 ) and the 
second (1 999-200 3 ) survey 
b 1 packyear corresponds to 1 pack of cigarettes smoked per day in 1 year 
c VC measured as Forced VC in the Doetinchem cohort and lnspiratory VC in the Vlagtwedde-Vlaardingen cohort 
FEV1 = Forced Expiratory Volume in 1 second; SD = standard deviation; ABCC1 = ATP-binding cassette, sub-family 
C {CFTR/MRP), member 1 ;  VC = Vital Capacity; COPD = Chronic Obstructive Pulmonary Disease; GOLD = Global 
Initiative for Chronic Obstructive Lung Disease 
Genetic analysis and inclusion criteria for replication 
SNPs were processed for a replication in the Vlagtwedde-Vlaardingen cohort when there 
was significant association between SNPs (additive, recessive, dominant or general 
(heterozygotes/homozygotes mutant vs. wild type} model} and FEV1 level or course of 
FEV1 in the Doetinchem cohort. 
Statistics 
SNPs analyses: 
Linear regression model adjusted for age, sex, packyears smoked (1 packyear corresponds 
to 1 pack of cigarettes smoked per day in 1 year}, and height was used to assess effects of 
SNPs on FEV1 level at the second survey in the Doetinchem cohort and at the last survey in 
the Vlagtwedde-Vlaardingen cohort. In this way, the median age was similar for the two 
cohorts and the number of subjects analyzed was the highest. 
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The online data supplement describes the linear mixed effect (LME} models used to assess 
the effect of ABCCl SNPs on the level of lung function across all surveys, as well as the 
lung function course (both analyses adjusted for a correlation of lung function 
measurements within subjects}. 
SNPs x smoking interaction analyses 
SNPs by smoking interactions were tested in ever-smokers in relation to the level and 
course of FEV1 by introduction of interaction terms (i.e. number of packyears smoked x 
genotype} into the models concerning three SNPs that were successfully replicated 
between the two cohorts. Thus interaction terms assess whether there is an additional 
effect of packyears smoked and a certain genotype over the sum of the separate effects of 
these factors. 
Most statistical analyses were performed using SPSS (version 14.0}. LME models and 
permutation tests, performed on 3000 datasets reshuffled by genotypes, were assessed 
by S-PLUS (version 7.0}. Effects of haplotype(s} (tagging a minor allele of non-genotyped 
SNPs} were assessed using the haplo.stats package (version 1.3 .1} 25 implemented in the R 
environment (version 2.6.0} 26• Linkage disequilibrium pattern was plotted with Haploview 




All genotyped SNPs, i.e. 3 7  in the Doetinchem cohort and 15 SNPs processed for 
replication in the Vlagtwedde-Vlaardingen cohort, were found to be in Hardy Weinberg 
Equilibrium (HWE, p>0.05} and were not correlated (r2<0.8) with each other in both 
cohorts (see figure 1 for the Doetinchem cohort}. 
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Figure 1: Linkage disequilibrium plot and correlation coefficients (100·r2) for 37 ABCCl polymorphisms genotyped in 
the Doetinchem cohort (n=l,152) 
• 
..... ., ,� 111� .,. J  X I I I 
The location of single nucleotide polymorphisms is given for the Hap Map Data Release 23a/March 2008. 
Presentation 
ABCCl 5NPs data concerning genetic association results in a general model (tables S2 and 
S3 ), SNPs that failed replication (tables 54 - S7) and haplotype-tagged SNPs (table 58) are 
presented in the supplementary materials. 
Associations of genotyped SNPs with lung function 
Doetinchem cohort 
Nine SNPs showed significant associations in any model with the level of FEV1 in the 
Doetinchem cohort (see table 2 for additive effects and supplementary table S2 for a 
general model), while five SNPs were associated in any model with the annual change in 
FEV1 (see table 2 for additive effects and supplementary table S3 for a general model). 
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Replication in the Vlagtwedde-Vlaardingen cohort 
The associations of rs212093 and rs4 14 8382 SN Ps with FEV1 level were directly replicated 
in the Vlagtwedde Vlaardingen cohort, i.e. the significant effects were of the same 
direction as in the Doetinchem cohort (figure 2, table 2 and supplementary table S4 ). Since 
both SNPs form 3 prevalent haplotypes (D'=0.98 in both cohorts; haplotype with mutant 
alleles of both SNPs virtually does not occur) these were tested for an effect on the level 
of FEV1, with a significant difference between haplotype containing mutant allele of 
rs4 14 8382 SNP and two other haplotypes in both populations (supplementary figure S1). 
The effect of SNP  rs35621 on annual FEV1 change was directly replicated (figure 3, table 3 
and supplementary table S5) in the Vlagtwedde-Vlaardingen cohort. 
Smoking status and effects of rs212093, rs4148382 and rs35621 SNPs 
The significant effects estimates observed in the total cohorts of the rs212093 and 
rs4 14 8382 SNP on the level of FEV1 and of the rs35621 SNP on the change of FEV1 were 
similar in both ever- and never-smoking sub-groups of both cohorts (table 3). In the 
Doetinchem cohort these effects reached the significance level in ever-smokers only, 
while in the Vlagtwedde-Vlaardingen cohort effects of rs4 14 8382 SNP on the level of FEV1 
and rs35621 on the change of FEV1 were significant in never-smokers, whereas the effect 
of rs212093 SNP on the level of FEV1 was significant in both subgroups (table 3). Within 
the ever-smokers in the Vlagtwedde-Vlaardingen cohort we observed a significant 
negative interaction between the packyears smoked and the rs212093 SNP in relation to 
the level of FEV1 (table 3). 
Permutation tests of the effects of rs212093, rs4148382 and rs35621 SNPs 
The additive effect estimates of the rs212093 and rs4 14 8382 SN Ps on the level of FEV1 
were observed in respectively 1.5% and 0.2% of reshuffled datasets in the Doetinchem 
cohort and respectively in 1.4% and 0.3% of reshuffled datasets in the Vlagtwedde­
Vlaardingen cohort. The recessive effect estimates of the rs35621 SN P on FEV1 decline 
were observed in 0.5% and 1.3% of reshuffled datasets in the Doetinchem and 
Vlagtwedde-Vlaardingen cohort respectively. 
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Figure 2: Mean adjusted FEV1 level according to rs21 20 93 (top) and rs41 483 82 (bottom) genotype in the 
Doetinchem (second survey) and the Vlagtwedde-Vlaardingen (last survey) cohort. 
ABCC1 rs212093 
Doetlnchem Vlagtwedde-Vlaardingen 
3 .0 3.5 cohort cohort 
f I I • 3.4 - 1 T · 2.9 I I FEV 1 in liters, l mean [95% C.I.J I 3.3 · 2.8 
p=0.02 
3.2 p,O 03 for •r,add,i....� �lied p=0.02 · 2.7 
p=O.UJ for a11 add11111� �Hf'<;t 
3.1 2 .6 
Genotype: A/A A/G G/G A/A A/G G/G 
Number of individuals: 352 532 245 444 655 245 
ABCC1 rs4148382 
3 9 Doetinchem Vlagtwedde-Vlaardingen - 3.3 cohort cohort 
3 .8 l 3.2 3.7 · 3.1 3 6  
f 
3 .0 






p=0.003 - 2.6 
p=0.005 for an additive effect 




2 .9 2.4 
Genotype: G/G G/A A/A G/G G/A A/A 
Number of individuals: 929 198 11 1104 242 15 
FEV1 = Forced Expiratory Volume in 1 second; C. I. = Confidence Interval; ABCC1 = ATP-binding cassette, sub­
family C (CFTR/MRP), member 1 
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Table 2: Additive effects of 53 ABCCl SNPs on the level and change of FEV1 in the Doetinchem cohort (n=l, 1 52) 
SNP 
rs41 483 30 
rs504348 28 
rs1 520 22 
rs21 50 49 
rs21 50 68 
rs21 50 7 9  
rs21 5100 
rs246220 
rs47 81 699 
rs80 60 7 50 
rs80 45000 
rs7 1 90 484 
rs7 1 96970 
rs21 510 1 
rs47 81 7 1 1  
rs21 50 59 
rs41 483 3 7  
rs47 81 7 1 8 
rs24621 3  
rs246240 
rs7 1 8893 7 
rs24623 3 
rs246230 









rs41 483 53 
rs45511401 
(Gly671 Val) 29'31 
rs20 7 40 86 
rs20 7 40 87 
rs41 483 58 
rs2283 51 5 
rs1 244923 9 
rs1 1 8643 7 4  
rs993 3 51 1  
rs3 81 9552 
rs223 847 5 
rs223 847 6 
rs1 2599429 





























lntron 1 2  
lntron 1 2  
lntron 1 3  
lntron 1 4  
lntron 1 5  
Exon 1 6  
lntron 1 8  
lntron 1 8  
lntron 1 9  
lntron 1 9  








MAF [%] HWE p value 
3 4.2 0 .96  
1 9.3 0 .6 1  
20 .3 0 . 1 2  
3 1 .9 0 .7 2  
30 .9 0 .2 1  
2 1 .0 0 .24 
3 2. 1  0 .7 7  
1 2.6 0 .3 4  
3 1 .4 0 .63 
1 2. 7  0 .52 
3 2.8 -





3 1 .9 0 .7 2  
1 4.3 0 .3 9  
8.8 0 .97 
1 8.0 0 .28 
46.4 -
9.0 -
1 4.6 0 .42 
29.5 -
2.2 1 .00 
27 .8 0 .57 
1 5.7 -
23 . 1  0 .44 
46.7 0 . 3 3  
1 5.8 0 . 30 
10 .7 0 .6 1  
1 4.8 0 .46 
4.9 1 .00 
3 1 .9 0 .43 
1 4.2 -
23 .5 0 .94 
46.6 -
1 4.9 -
22.6 0 .62 
27 . 1  0 .0 9  
49.0 0 .57 
4.6 0 . 1 6  
5.9 0 .7 4  
3 1 .8 0 .85 
4. 1 0 .85 
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Additive effect on the Additive effect on the 
level of FEV1 [ml] a change of FEV1 [ml/yr] b 
B SE p p SE p 
-63 .2 20 .4 0.002 - 1 .8 1 .4 0 .20 
-54.9 24.7 0.03 -2.4 1 .7 0 . 1 5  
9.0 24.0 0 .7 1  0 .4 1 .6 0 .83 
-3 2.5 21 . 1  0. 1 2  - 1 .5 1 .5 0 .3 1  
22.7 2 1 .5 0 .29 -0 .7 1 .5 0 .64 
3 .2 23 .9 0 .89 -1 .5 1 .7 0 .3 7  
-48.8 20 .9 0.02 -1.0 1 .4 0 .50 
-1 9.0 30 . 1  0 .53 1 .2 2. 1 0 .55 
-56.6 20 .9 0.01 -2.2 1 .4 0 . 1 3  
24.4 29.2 0 .40 -1.1 2.0 0 .59 
-51 .2 20 .8 0.0 1 - 1 .8 1 .4 0 .20 
-48.8 20 . 1  0 .0 2  - 1 .8 1 .4 0. 1 9 
-28.6 20 . 1  0 . 1 5  -1 .0 1 .4 0 .49 
3 6.2 3 3 . 1  0 .27 -0 .9 2.2 0 .70 
-22.0 41 .5 0 .60 0 . 3 2.9 0 .9 1  
1 5.6 28.8 0 .59 0 .8 2.0 0 .69 
-25.4 21 .0 0 .23 -1 .0 1 .4 0 .51 
-0 . 1  27 .8 0 .99 -2. 1  1 .9 0 .28 
-46.9 3 4.9 0 . 1 8  -2.9 2.4 0 .24 
3 . 1 25.3 0 .90 -0 .7 1 .7 0 .7 1  
-22.0 1 9.2 0 .25 -1 .9 1 .3 0 . 1 4  
-8.8 3 7 .7 0 .82 1 .8 2.6 0 .49 
-5.2 27 .5 0 .85 -0 . 1  1 .9 0 .97 
-1 4.0 22.3 0 .53 -0 .2 1 .5 0 .89 
-25.2 68.0 0 .7 1  3 .3 4.7 0 .48 
-22.8 22.0 0 .30 -0 .5 1 .5 0 .7 4  
1 2.5 28.4 0 .66 0 .5 1 .9 0 .80 
-1 1 .0 23 .7 0.64 0 .9 1 .6 0 .57 
3 2.9 20 . 1  0.10 3 . 1 1 .4 0.02 
-3 8.0 27 .5 0. 1 7  - 1 .6  1 .9 0 .41 
-7 .8 3 1 .4 0.80 -3 .0 2 . 1  0 . 1 7  
-4.5 28.3 0 .87 0 .4 2.0 0 .84 
22.5 45.4 0 .62 -0 .7 3 . 1 0 .8 1  
1 1 .7 2 1 .0 0 .58 -1 .0 1 .4 0 .49 
42. 1 30 .6 0 . 1 7  -3 .6 2. 1 0 .0 8  
1 1 . 1 23 .2 0 .63 -0 .1 1 .6 0 .93 
-1 7 .5 1 9 .8 0 .3 8  -2.8 1 .3 0.04 
-20 .4 29.8 0 .49 -0 .7 2.0 0 .7 4  
-27 .4 24.2 0 .26 -2.9 1 .6 0 .0 8  
9.5 22.7 0 .68 -0 .5 1 .5 0 .7 5  
6.6 1 9.9 0.7 4 2.7 1 .4 0.04 
-10 .8 46.0 0 .82 1 .2 3 .2 0 .7 1  
28.0 41 .5 a.so -1 .5 2.8 0 .59 
1 7 . 7 2 1 .5 0 .41 2.0 1 .5 0 . 1 7  
-20 .3 so.a 0 .69 -5.9 3 .4 0 .0 9  
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Table 2 (continued): Additive effects of 53 ABCC1 SNPs on the level and change of FEV1 in the Doetinchem cohort 
(n=l,1 52) 
HWE p 
Additive effect on the Additive effect on the 
SNP Position MAF [%] 
value 
level of FEV1 [ml] a change of FEV1 [ml/yr] b 
B SE p p SE p 
rs21 20 83 lntron 27 1 9.5 0.46 -10.6 24.6 0.67 -3.9 1.7 0.02 
rs2230 67 1  
Exon 28 0 .98 5.7 21 .6 0 .7 9  1.9 1 .5 0 . 1 9  
(Ser1 334Ser) 29.8 
rs37 43527 3' UTR 22.5 0 .0 9  -58.6 23.5 0.01 -1.3 1 .6 0.44 
rs21 20 90 3' UTR 45.5 - -1 1.2 1 9.4 0 .56 4.3 1.3 0.001 
rs2 1 20 93 3' region 45.3 0 . 10 -42.5 1 9.3 0.03 -2.9 1.3 0.03 
rs41 48382 3' region 9.7 1.00 94.2 33.4 0.005 -3.6 2.3 0 . 1 1  
rs21 20 94 3' region 1 8.0 - 1 5.9 25.8 0 .54 -5.3 1 .8 0.003 
rsl24487 60 3' region 29.1 - -7 .5 21 .6 0 .7 3  2.7 1 .5 0 .0 7  
The lack of HWE p values indicates haplotype-tagged SNPs. Significant p values are depicted in bold. SNPs that 
were previously identified as functional are depicted in italics and marked with appropriate references. 
• Regression coefficient (B), its standard error (SE) and p value were obtained with linear regression analysis 
adjusted for age, sex, height and packyears smoked 
b Parameter estimate {P), its standard error {SE) and p value were obtained with LME model adjusted for sex, 
initial FEV1 level, packyears smoked, and their interaction with time 
Table 3: Effects of rs21 20 93, rs41 48382 and rs35621 SNPs according to smoking status and their interaction with 
packyears smoked in ever-smokers 
Doetinchem (n=l,152) Vlagtwedde-Vlaardingen (n=l,390) 

















rs2 1 20 93 Additive 
FEV1 
-33.3 32.4 0.30 4 -47.1 24.0 0.050a -56.6 27.5 0.040 -32.5 22.8 0.1 54d 
levelg 
rs41 48382 Additive 
FEV1 




















-29.6 1 7.5 0 .0 92 -21 .4 9.3 0.021' -1 9.7 8.3 0.017 -1 3.7 8.6 o.10i 
declineh 
Significant p values are depicted in bold. 
Results of the SNP x packyears interaction analysis within ever-smokers additionally adjusted for genotypes: 
Doetinchem cohort: 
• B1Nr = -1 .0 SE1NT =1.6 PINT =0 .52 b B1Nr = -0 .2 SE1NT =3.1  PINT =0.96 ' P1Nr = -0.2 SE1NT =0.7 p=0.7 3 
Vlagtwedde-Vlaardingen cohort: 
d B1Nr = -2. 1  SE1NT =1 .0 P1NT =0.04 eB1Nr = 2.7 SE1NT =2.2 PINT = 0 .20 fplNT = -0 .2 SE1NT = 0.4 p=0 .60 
g Regression coefficient (B), its standard error (SE) and p value were obtained with linear regression analysis 
adjusted for age, sex, height and packyears smoked 
h Parameter estimate (P), its standard error (SE) and p value were obtained with LME model adjusted for sex, 
initial FEV1 level, packyears smoked, and their interaction with time 
FEV1 = Forced Expiratory Volume in 1 second; SNP=Single Nucleotide Polymorphism, MAF=Minor Allele 
Frequency; HWE=Hardy-Weinberg Equilibrium; ABCC1 = ATP-binding cassette, sub-family C (CFTR/MRP}, member 
1; LME=Linear Mixed Effect; UTR = Untranslated Region 
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Linear mixed effect model analysis of the rs212093� rs4148382 and rs35621 SNPs across all 
available surveys 
Both rs212093 ,  rs4 14 8382 SNPs were significantly associated with a lower and 
respectively higher FEV1 level across all surveys in both cohorts using an additive model, 
but not in the sub-sample of the Vlagtwedde-Vlaardingen cohort aged below 30 years 
(4 87 subjects, 1193 lung function measurements, table 4 }. 
Table 4: Linear Mixed Effect model analysis on the level or change of FEV1 across all surveys in relation to the 
successfully replicated SNPs 
Doetinchem cohort Vlagtwedde-Vlaardingen 
The additive SNP effect 
on the level of FEV1 [ml] : 
(n=3,115 lung function measurements) cohort (n=B,159 lung function measurements) 
p SE p p SE p 
rs21 2093 • -40.1 1 8.6 0.031 -3 7 .3 1 6.3  0.022c 
rs41 483 82 • 93.9 3 1 .7 0.003 66.0 26.5 0.013d 
The recessive SNP effect Doetinchem cohort Vlagtwedde-Vlaardingen 
on the change of (n=3,115 lung function measurements) cohort (n=6,966 lung function measurements) 
FEV1 [ml/yr] : p SE p p SE p 
rs3 5621 ° -22.2 8.1 0.006 -1 5.3 6.3 0.015 
Parameter estimate (P), its standard error (SE) and p values are estimated for and additive (0=homozygotes wild 
type, l=heterozygotes, 2=homozygotes mutant) or recessive (0=homozygotes wild type + heterozygotes, 
l=homozygotes mutant) effect model of the SNP. Significant p values are depicted in bold. 
• Linear Mixed Effect model analysis on FEV1 level across all surveys adjusted for age, height, sex, packyears 
smoked, and correlation of lung function measurements within subjects (random factor assigned to the 
intercept) 
b Linear Mixed Effect model analysis on FEV1 change across all surveys adjusted for age at entry, sex, packyears 
smoked, lung function level at baseline (and their interaction with time) and correlation of lung function 
measurements within subjects (random factor assigned to the intercept and time) 
c P = - 1 6.0, SE=27 . 1 , p=0.56 for 487 subjects aged below 3 0  years ( 1 1 93 FEV1 measurements) 
d P = 62.5, SE=43 .5, p=0. 1 5  for 487 subjects aged below 3 0  years ( 1 1 93 FEV 1 measurements) 
SNP = Single Nucleotide Polymorphism; FEV1 = Forced Expiratory Volume in 1 second 
Cross-phenotype analysis on FEV1 level and decline 
Seven SNPs that failed replication in the analysis concerning FEV1 level were further 
investigated with respect to the longitudinal FEV1 course in the Vlagtwedde-Vlaardingen 
cohort. SNPs rs504 3 4 8  and rs4 781699 were not associated with FEV1 level (supplementary 
table S4 }, but were associated with accelerated FEV1 decline. Homozygotes mutant had 
6.6 ml/yr (SE=3 .4 , p=0.05} and 3.7 ml/yr (SE=2.2, p=0.08} respectively additional FEV1 
decline as compared to the wild type (p>0.80 for the heterozygotes as compared to the 
wild type for both SNPs}. The same SNPs were significantly associated with lower FEV1 
level In the Doetinchem cohort (supplementary table S4 ), with a negative trend with 
respect to the change in FEV1, being 3 .8 ml/yr (SE=2.l, p=0.07} and 1.2 ml/yr (SE=4 .7, 
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p=0.80} additional FEV1 decline for the rs504 34 8 heterozygotes and homozygotes mutant 
genotypes respectively as compared to the wild type, and 0.7 ml/yr (SE=2.0, p=0.75} and 
6.1 ml/yr (SE=3.3, p=0.06} additional FEV1 decline for the rs4 781699 heterozygotes and 
homozygotes mutant genotypes respectively as compared to the wild type. 
SNPs that failed replication in the analysis of FEV1 change were further analyzed with 
respect to the FEV1 level in the Vlagtwedde-Vlaardingen cohort but no significant 
associations were observed. 
Figure 3: Mean adjusted FEV1 change according to rs3 5621 genotype in the Doetinchem (across 3 surveys) and 
the Vlagtwedde-Vlaardingen (across 8 surveys) cohort 
Doetinchem Vlagtwedde--Vlaardingen 
0 cohort cohort 
-10 ' 
-20 




-30 1 f • •  30 FEV 1 change in ml/yr, mean [95% C.1,1 -40 I • -40 












Genotype: C/C C/T T/T C/C C/T T/T 
Number of Individuals: 902 212 15 1153 203 9 
FEV1 = Forced Expiratory Volume in 1 second; C . I .  = Confidence Interval; ABCC1 = ATP-binding cassette, sub­
family C (CFTR/MRP}, member 1 
Associations of haplotype-tagged SNPs with lung function 
Doetinchem cohort 
Three tagged SNPs showed a significant association with the FEV1 level using additive, 
dominant, or recessive models (see supplementary table S6 and table 2 for additive 
effects}. Five SNPs were associated with annual change in FEV1 (supplementary table S7 
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Replication in the V/agtwedde-Vlaardingen cohort 
None of the associations concerning haplotype-tagged SNPs as observed in the 
Doetinchem cohort was replicated in the Vlagtwedde-Vlaardingen cohort (supplementary 
tables 56 and 57}. 
Cross-phenotype analysis on FEV1 level and decline 
Haplotype-tagged 5NPs that failed replication in the analysis of FEVl level were further 
analyzed with respect to the FEV1 decline, and conversely haplotype-tagged SNPs that 
failed replication in the analysis of FEV1 decline were further analyzed with respect to the 
FEV1 level, but no significant associations were found in both cases. 
DISCUSSION 
This study is the first showing associations of genetic polymorphism in ABCC1, a gene 
involved in xenobiotic transport, with longitudinal lung function decline in two 
independent cohorts of the general population. Furthermore, it identified a set of ABCC1 
polymorphisms that most likely affects the level of lung function. Our observations are 
further strengthened by the fact that effect estimates concerning the 5NPs that replicated 
the association with lung function level or decline were observed in a very small subset of 
randomly generated datasets in both cohorts after permutation testing. 
Although genetic predisposition explains approximately 4 0% of the variability in the level 
of lung function 11'32 only the minority of genetic associations has been successfully 
replicated with respect to their effect on COPD development or the level of lung function 
so far. The relatively rare (frequency 1%-3% in Caucasians} Glu3 4 2Lys substitution in 
SERPINA1,  that leads to al-antitrypsin deficiency, is the only established genetic risk 
factor for both COPD development 20'33 and lung function decline 34• A growing body of 
evidence suggests that a rare (frequency 1%-2% in Caucasians} and functional Arg213Gly 
substitution in Superoxide Dismutase 3 may protect against COPD development 35'36 • 
Likewise low prevalent long GT repeats variant in the Heme Oxygenase 1 promoter have 
been linked to the accelerated FEV1 decline in smokers by two independent studies 
14'15• 
These findings suggest that rare genetic variations may have significant contributions to 
the loss of lung function in humans. 
Decline in FEV1 is a normal, physiological phenomenon that starts at about 30 years of age 
and varies between 20-30 ml per year 37. Accelerated FEV1 decline is a risk factor for COPD 
development 20, yet only a few studies have focused on this lung function parameter when 
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analyzing genes relevant for COPD so far. The current study identifies the rs3 5621 SNP  
(located in intron 14 } as a risk factor for an excessive, almost twice the normal FEV1 
decline. Moreover, a detrimental, recessive effect of this SNP on FEV1 decline might be 
considered as clinically relevant, given the fact that it is approximately 4 times higher than 
the effect observed in lifetime ever-smokers, which provides 5.3 ml/yr and 4 .0 ml/yr 
additional FEV1 decline as compared to never-smokers in the Doetinchem and 
Vlagtwedde-Vlaardingen cohort respectively. The affected group, i.e. homozygous 
mutants for the rs3 5621 SNP, accounts only for 0.6%-1.3% of the total population which 
further supports the observations that low-prevalent genotypes significantly contribute to 
the course of lung function. As the SNPs analyzed in the current study were tagging SNPs, 
the functional polymorphism that constitutes the risk factor may be in linkage 
disequilibrium with the rs3 5621 SNP. 
The two other SNPs that we successfully replicated for the effect on FEV1 level, i.e. 
rs4 14 83 82 and rs212093 ,  that is in complete linkage disequilibrium with rs129081 located 
in the 3 '  ABCC1 untranslated region 19, are located in the 3 '  near region and may be 
therefore involved in the regulation of ABCCl mRNA stability. We showed that the results 
concerning these SNPs are also observed after inclusion of all other surveys to the 
analysis, which may suggest their possible role in lung development. However, we did not 
observe these associations in subjects below 30 years in the Vlagtwedde-Vlaardingen 
cohort, that is, those who still show growth in their lung function or have reached their 
plateau phase of lung growth. This could be explained by the low number of subjects in 
this group and consequently low power for detecting such associations. Interestingly, the 
detrimental effect of the rs212093 SNP may be mediated via the interaction with 
packyears smoked in ever-smokers, an effect being significant in Vlagtwedde-Vlaardingen 
cohort, but not in the Doetinchem cohort. This might be explained by the higher number 
of subjects and higher amount of packyears smoked in the Vlagtwedde-Vlaardingen 
cohort, which could make the effect of rs212093 more apparent. Both rs212093 and 
rs4 14 83 82 SNPs are located closely to the 5' end of the ABCC6 on chromosome 1 6. 
However ABCCl, but not ABCC6, is abundantly present in human lung tissue 1'38, thus the 
effect of the mentioned SNPs is likely ABCC1-specific. 
We identified also 2 other SNPs that showed a trend for an associations in both cohorts, 
yet with different lung function outcomes. SNPs rs504 3 4 8 (promoter} and rs4 781699 
(intron l} were associated with a lower FEV1 level at the second survey in the Doetinchem 
cohort and with an accelerated FEV1 decline in the Vlagtwedde-Vlaardingen cohort. These 
two outcomes often provide a similar information since the first might be a consequence 
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of the latter. These two SNPs are also moderately correlated (r2=0.4 2, figure 1) thus the 
effect we found is driven in vivo by only one of them. It has been reported that the 
rs504 3 4 8  SNP enhances ABCC1 promoter activity 28, thus our finding may implicate the 
detrimental effect of the higher ABCC1 expression. This can support a previous 
observation of the lower inflammation level in response to cigarette smoke in the 
ABCCl/ABCBla/ABCBlb deficient mice 39• 
The distinct location of the SNPs that were successfully replicated for the effect on lung 
function in the current study makes the debate about their functionality difficult and 
suggests many mechanisms that can be modified by those SNPs (e.g. transcription 
regulation or splicing variant formation). So far, mostly SNPs located in ABCC1 exons have 
been studied in a functional context with no significant effect of the synonymous SNPs on 
ABCC1 expression 40 and indications for a deleterious effect of nonsynonymous SNPs on 
ABCCl function 29-31• Although these nonsynonymous SNPs were not associated with lung 
function in the current study, it is of future interest whether these SNPs and the SNPs we 
successfully replicated can affect COPD development and severity. We have previously 
shown suggestive evidence that both the presence and severity of COPD are correlated 
with a lower ABCCl expression in lung tissue 7, although the underlying causal mechanism 
is not known and may include epigenetic or cis-acting factors as well. 
Using publicly available data from the 100K Framingham Heart Study 11 on the level and 
change in FEV1 and data from the British 1958 Birth Cohort 
41 on the level of FEV1, we 
checked whether observed associations of the rs3 5621 SNP with decline in FEV1, and 
rs212093 and rs4 14 8382 SNPs with the level of FEV1 replicate in these two non-Dutch 
cohorts. The 100K Framingham Heart Study has no genotyping data on any of these 3 
SNPs. The online data from the British 1958 Birth Cohort does not contain information on 
the rs4 14 8382 SNP, while the rs212093 SNP is not associated with the level of FEV1 in this 
cohort (8=20.4 ml, SE=17.1, p=0.23 5 for an additive model adjusted for potential 
confounders in 1,372 subjects aged 4 4  - 4 5). The discrepancy between results on the 
rs212093 SNP from the current study and those from the British 1958 Birth Cohort may 
be explained by the different countries from which the cohorts have been obtained. In 
this way, country-specific environmental and behavioral factors (e.g. air pollution, smoking 
habits or dietary patterns) potentially influence the effect of the SNP differentially in the 
two areas of residence. Therefore, subsequent replication of our findings is warranted to 
confirm a role of these specific ABCC1 variations in the level and decline of lung function in 
the general population. 
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In summary, we obtained evidence that three ABCC1 SNPs affect lung function in the 
Dutch population by using two independent population-based cohorts. The important 
biological role of ABCCl in xenobiotic transport and our previous observation regarding a 
lower ABCCl expression in lung tissue of COPD patients 7 make these findings of great 
importance for future research concerning smoking-related lung diseases and COPD in 
particular. Eventually, our findings may contribute to pharmacogenetics of COPD 
management, which will result in more accurate and targeted therapy. 
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The Doetinchem cohort study 
FEV1 measurements were performed with a heated pneumotachograph (Jaeger, Germany) 
according to the European Respiratory Society (ERS) guidelines 1. 
The Vlagtwedde-Vlaardingen cohort 
FEV1 measurements were performed using a water-sealed spirometer (Lode Instruments, 
the Netherlands) according to the ERS guidelines 1. 
Selection and genotyping of the MRP1 tagging SNPs 
ABCC1 (196.7kb) was tagged using all 51 prevalent (minor allele frequency (MAF)>5%) and 
non-correlated (r2<0.8) SNPs as described previously for the 24 3 Caucasians by Leschziner 
and colleagues 2• The initial SNP set they used included HapMap data, dbSNP database 
data and novel SNPs in exons, untranslated regions, intron-exon boundaries and 3kb of 
the 5' and 3' flanking regions, all identified by sequencing the ABCC1. 35 SNPs were 
genotyped and the remaining 16 SNPs were tagged (table SB) and analyzed for the effect 
of the minor allele in the Doetinchem cohort. We additionally genotyped two low­
prevalent (MAF<5%) nonsynonymous SNPs (nsSNPs) in ABCC1 i.e. Arg4 33Ser (rs60782127) 
and Gly671Val (rs4 55114 01) that were suggested to have a functional role 3-5• 
Three SNPs, i.e. rs215068, rs4 14 8330 and rs4 14 8337, were genotyped in-house using 
Taqman SNP genotyping assays designed by Applied Biosystems (USA). All other SNPs 
were genotyped by K-Bioscience Ltd (UK) using their patent-protected competitive allele 
specific PCR system (KASPar). 
All tagged SNPs that showed a significant association in the Doetinchem cohort were 
tagged (in case the tagging SNPs were processed for replication) or genotyped in the 
Vlagtwedde-Vlaardingen cohort as well. 
Statistics 
Cross-sectional analysis 
Linear mixed effect models were used in both cohorts to estimate the effect of the 
rs212093 and rs4 14 8382 SNPs on the level of FEV1 across all available surveys. This 
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analysis was adjusted for age, height, sex, packyears smoked and correlation of lung 
function measurements within subjects (random factor additionally assigned to the 
intercept). 
Longitudinal analysis 
LME models were used in both cohorts to estimate the effect of genotyped MRP1  SNPs on 
longitudinal course of lung function across all available surveys. Time was defined as the 
time in years relative to the first measurement. Variables included in the model were age 
at entry, sex, packyears smoked, the first available measurement, genotypes and their 
interaction with time (random factor additionally assigned to the intercept and time). In 
the Vlagtwedde-Vlaardingen cohort subjects aged above or equal 30 years were included, 
because an individual's maximal achieved lung function is assumed to have been reached 
before that age and lung function is considered to be either in the plateau or decline 
phase 6• In the Doetinchem cohort all subjects crossed the 30 years of age at the second 
survey and were thus included to the analysis. 
Haplotype tagged SNPs were analyzed using haplo.stats package 7• FEV1 change was 
defined using the first and the last available FEV1 measurement. The analysis was adjusted 
for age, sex, packyears smoked and first available FEV1 measurement. 
All significant associations were confirmed by the analysis without adjustment for the 
baseline lung function level, which could possible lead to the "regression to the mean" 
effect. 
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Figure Sl: The effect of 2 haplotypes containing mutant alleles of rs212093 (G) or rs4148382 (A) SNPs on FEVl 
level as compared to haplotype with both wild type alleles 
Additive effect 
on FEV1 in ml 
as compared to 
AG haplotype, 










second survey, n =1,152 
AA 9.4% 
GG 45.1% ··· 1 
p=0.002 
Vlagwedde-Vlaardingen cohort 
last survey, n=l,390 




Percentage values represent frequency of haplotypes in the population. First letter corresponds to the rs212093 
allele (G-mutant, A-wild type) and the second letter corresponds to the rs4148382 allele (A-mutant, G-wild type). 
Both mutant haplotypes were compared to the wild type i.e. AG centered to 0 ml of FEV1 . 
FEV1=Forced Expiratory Volume in 1 second; SNP=Single Nucleotide Polymorphism; C. I .  = Confidence Interval 
Table Sl: Characteristics of the random subsample of the Doetinchem cohort across the three su rveys 
First survey Second survey Third survey 
(n=l,152) (n=l,152) (n=811) 
Time of the visit, years 1993-1997 1999-2003 2004-2007 
Males, n (%) 541 (47.0) 541 (47.0) 390 (48.1) 
Age in years, median (range) 44.9 (26.2-65.8) 49.9 (31.2-70.9) 53.8 (36.2-75.9) 
Smokers/Ex-smokers, n (%) 351 (30.5) / 446 (38.7) 308 (26.7) / 473 (41.1) 180 (21.7) / 377 (45.4) 
Packyears smoked, median (range) 5.5 (0-93) 5 (0-84) 5 (0-82) 
FEV1 in liters, mean (SD) 3.54 (0.79) 3.39 (7.9) 3.33 (7.9) 
FEV1=Forced Expiratory Volume in 1 second 
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Table S2: Cross-sectional analyses on FEV1 (general model} at the last second in the Doetinchem cohort - results 
for all 3 7  genotyped SNPs in ABCC1 
FEV1 [ml] 
SNP HWE p value a MAF Heterozygotes Homozygotes mutant 
B SE p B SE p 
rs1 1 8643 7 4  0 .62 22.6 -30 .7 29.3 0 .29 -44.5 70 .3 0 .53 
rsl2445600 0 .57 27 .8 -1 3 .2 29.7 0 .66 -59.8 52.9 0 .26 
rsl2599429 0 .85 3 1 .8 52.3 29.6 0 .0 8  -6.7 49.6 0 .89 
rs1 520 22 0 . 1 2  20 .3 3 .5 30 .6 0 .91 -46.9 65.1 0 .47 
rs20 7 40 86 0 .43 3 1 .9 20 .4 29.7 0 .49 1 4.4 47 .5 0 .7 6  
rs21 20 7 9  0 .85 4.1 -23 . 7  51 . 1  0 .64 10 5. 1 465.8 0 .82 
rs21 20 83 0 .46 1 9.5 -2.7 30 .7 0 .93 -43 . 1  70 .2 0 .54 
rs21 20 93 0 . 10 45.3 -24. 1 3 2.2 0 .45 -88.5 3 8.9 0 .0 2  
rs21 50 49 0 .7 2  3 1 .9 -21 .3 29.6 0 .47 -7 7 .0 47 .7 0 . 1 1  
rs21 50 68 0 .21 30 .9 3 2.9 30 .5 0 .28 3 4. 7  48.8 0 .48 
rs21 50 7 9  0 .24 21 .0 3 5.0 30 .4 0 .25 -66.6 64.5 0 .30 
rs21 5100 0 .7 7  3 2. 1  -55.1 29.5 0 .0 6  -91 . 1  47 .3 0 .0 5  
rs223 847 5 0 . 1 6  4.6 -1 5.1 50 .8 0 .7 7  1 6.0 20 8.9 0 .94 
rs223 847 6 0 .7 4  5.9 47 . 1  44.7 0 .29 -1 61 .9 20 8.8 0 .44 
rs223 93 30 0 .98 29.8 1 9.0 29.3 0 .52 -6.6 50 .8 0 .90 
rs24621 3  0 .97 8.8 -41 . 1  3 7 .9 0 .28 -1 52.3 1 63 .9 0 .3 5  
rs246220 0 .3 4  1 2.6 -3 2.8 3 3 .3 0 .3 2  68.6 1 25.3 0 .58 
rs246230 0 .42 1 4.6 6.7 3 2. 7  0 .84 -57 .5 89.5 0 .52 
rs246240 0 .28 1 8.0 -5.7 3 1 .3 0 .86 3 1 .9 7 3 .8 0 .67 
rs3 5596 0 .44 23 . 1  -0 .3 29.5 0 .99 -49.6 65.4 0 .45 
rs3 5597 0 .3 3  46.7 62.5 3 2.8 0 .0 6  61 .2  40 .4 0 . 1 3  
rs3 5610 0 .30 1 5.8 -10 .3 3 1 .3 0 .7 4  -226.1 98.5 0 .0 2  
rs3 5621 0 .61 10 .7 1 9.6 3 5.6 0 .58 -1 84.3 1 20 .6 0 . 1 3  
rs3 7 43 527 0 .0 9  22.5 -48.5 29.9 0 . 1 1  -1 40 .5 63 .4 0 .0 3  
rs3 81 9552 0 .57 49.0 4. 1  3 3 .8 0 .90 1 3 .3 3 9.8 0 .7 4  
rs41 483 30 0 .96 3 4.2 -70 .7 29.4 0 .0 2  -1 1 9.8 45.0 0 .0 1  
rs41 483 3 7  0 .7 2  3 1 .9 -3 3 .5 29.3 0 .25 -42.1  47 .6 0 .3 8  
rs41 483 53 0 .46 1 4.8 25.3 3 2.0 0 .43 -1 86.6 10 5.4 0 .0 8  
rs41 483 58 0 .94 23 .5 3 3 .9 29.7 0 .25 -27 .6 6 1 .6 0 .65 
rs41 483 82 1 .00 9.7 94.2 3 6.7 0 .0 1  1 88.5 1 47 . 1 0 .20 
rs4551 1 40 1  1 .00 4.9 1 2.8 48.0 0 .7 9  20 3 .6 268. 1  0 .45 
rs47 81 699 0 .63 3 1 .4 -54.4 29.4 0 .0 6  -1 1 5.7 47 .6 0 .0 2  
rs47 81 7 1 8  0 .3 9  1 4.3 1 4.3 3 3 .0 0 .66 058.6  9 1 .0 0 .52 
rs50 43 48 0 .61 1 9.3 -54.9 30 .5 0 .0 7  -10 9.7 7 1 .2 0 . 1 2  
rs60 7 821 27 1 .00 2.2 -25.2 68.0 0 .7 1  - - -
rs80 60 7 50 0 .52 1 2.7 49 .6  3 3 .8 0 . 1 4  -7 6.2 10 2.8 0 .46 
rs993 3 51 1  0 .0 9  27 . 1  -5.4 29.0 0 .85 49.3 58.3 0 .40 
Regression coefficient (B), its standard error (SE} and p values are estimated for heterozygous and homozygous 
mutant genotypes as compared to wild type using linear regression adjusted for age, sex, height and packyears 
smoked. 
a for 1 df chi-square test comparing the observed genotypes distribution with the expected as derived from the 
allele frequencies 
MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; FEV1=Forced Expiratory Volume in one 
second; ABCC1 = ATP-binding cassette, sub-family C (CFTR/MRP), member 1; HWE=Hardy Weinberg Equilibrium 
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Table 53: Longitudinal analyses on FEV1 change (general model) in the Doetinchem cohort - results for all 3 7  
genotyped SNPs in ABCCl 
FEV1 change [ml/year] 
SNP MAF Heterozygotes Homozygotes mutant 
p SE p p SE p 
rs1 1 8643 7 4  22.6 -2.3 2.0 0 .25 -7 .5 4.7 0 . 1 1  
rsl2445600 27 .8 -2.0 2.0 0 .3 2  1 .3 3 .6 0 .7 3  
rs1 2599429 3 1 .8 2.4 2.0 0 .24 3 . 6 3 .3 0 .28 
rs1 520 22 20 .3 2.4 2.1 0 .25 -4.1 4.5 0 .3 6  
rs20 7 40 86 3 1 .9 1 .2 2.0 0 .56 -4.2 3 .2 0 . 1 9  
rs21 20 7 9  4.1 -6.1 3 .5 0 .0 8  1 .8 3 8.6 0 .96 
rs21 20 83 1 9.5 -3 .5 2.1 0 .0 9  -9.1 4.8 0 .0 6  
rs21 20 93 45.3 -2.0 2.2 0 . 3 7  -6.0 2.7 0 .0 2  
rs21 50 49 3 1 .9 -2.1 2.0 0 .3 1  -2.3 3 .3 0 .48 
rs21 50 68 30 .9 1.3 2.1  0 .52 -3 .6 3 .4 0 .29 
rs21 50 7 9  21 .0 -1 .9 2.1 0 .3 8  -2.2 4.6 0 .64 
rs21 5100 3 2. 1  -0 .5 2.0 0 .7 9  -2.4 3 .3 0 .46 
rs223 847 5 4.6 2.8 3 .5 0 .42 -1 1 .9 1 4.2 0 .40 
rs223 847 6 5.9 -0 .8 3 . 1 0 .81  -1 1 .9 1 4.0 0 .3 9  
rs223 93 30 29.8 2.7 2.0 0 . 1 8  2.9 3 .4 0 .40 
rs24621 3  8.8 -1 .9 2.6 0 .48 -1 5.4 1 1 .2 0 . 1 7  
rs246220 1 2.6 0 .8 2.3 0 .7 2  5.7 8.8 0 .52 
rs246230 1 4.6 0 .2 2.2 0 .93 -1 .5 6.5 0 .82 
rs246240 1 8.0 -0 . 1  2 .2 0 .97 -3 .0 5.2 0 .56 
rs3 5596 23 . 1  0 .2 2.0 0 .93 3 .8 4.5 0 .40 
rs3 5597 46.7 3 .9 2.2 0 .0 9  6.1 2.8 0 .0 3  
rs3 5610 1 5.8 -2.0 2.2 0 .3 6  -1 .0 6.7 0 .88 
rs3 5621 10 .7 -0 .2 2.4 0 .93 -22.3 8 . 1  0 .0 1  
rs3 7 43 527 22.5 -2.3 2.0 0 .25 0 .0 4.4 0 .99 
rs3 81 9552 49.0 2.7 2.3 0 .25 5.4 2.7 0 .0 5  
rs41 483 30 3 4.2 -0 .5 2.0 0 .81  -4.7 3 . 1 0 . 1 3  
rs41 483 3 7  3 1 .9 -0 .S 2.0 0 .81  -2.5 3 .3 0 .45 
rs41 483 53 1 4.8 -0 . 1  2 .2 0 .96 3 .7 7 .2 0 .61 
rs41 483 58 23 .5 -0 .4 2.0 0 .86 0 .2 4.2 0 .96 
rs41 483 82 9.7 -2.7 2.5 0 .28 -1 5.3 10 . 1  0 . 1 3  
rs4551 1 40 1  4.9 -0 .3 3 .3 0 .92 -8.2 1 8.6 0 .66 
rs47 81 699 3 1 .4 -0 .7 2.0 0 .7 5  -6.1 3 .3 0 .0 6  
rs47 81 7 1 8  1 4.3 -1 .0 2.3 0 .65 -8.5 6.3 0 . 1 8  
rs50 43 48 1 9.3  -3 .8 2. 1  0 .0 7  -1 .2 4.7 0 .80 
rs60 7 821 27 2.2 3 .3 4.7 0 .48 - - -
rs80 60 7 50 1 2.7 0 .4 2.3 0 .85 -10 . 1  7 .2 0 . 1 6  
rs993 3 51 1  27 . 1  -1 .2 2.0 0 .55 0 .3 3 .9 0 .94 
Parameter estimate (P), its standard error (SE) and p values are estimated for heterozygous and homozygous 
mutant genotypes as compared to wild type, using Linear Mixed Effect model adjusted for age, sex, initial FEV1 
level, packyears smoked and their interaction with time. 
MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; FEV1=Forced Expiratory Volume in one 
second; ABCCl = ATP-binding cassette, sub-family C (CFTR/MRP), member 1 
- 92 
Chapter 4 - ABCC1/MRP1 SNPs and lung function in humans - supplementary materials 
Table S4: Significant associations between genotyped SNPs in ABCC1 and FEV1 level at the second survey in the 
Doetinchem cohort and their subsequent replication in the Vlagtwedde-Vlaardingen cohort (last survey) 
HWE p 
FEV1 level [ml] 
Cohort SNP MAF 
value a 
Heterozygotes Homozygotes mutant 
B SE p B SE p 
rs4148330 3 4.2 0 .96 -70 .7 29.4 0.016 -1 1 9.8 45.0 0.008 
rs212093 45.3 0 . 10 -24.1 3 2.2 0 .454 -88.5 3 8.9 0.02 
rs4781699 3 1 .4 0 .63 -54.4 29.4 0 .0 64 -1 1 5.7 47 .6  0.02 
Doetinchem 
rs215100 3 2. 1  0 .7 7  -55.1 29.5 0 .0 6  -91 . 1  47 .3 0.05 
(n=l, 1 52) 
rs35597 46.7 0 .3 3  62.5 3 2.8 0 .0 6° 61 .2 40 .4 0 . 1 3 D 
rs35610 1 5.8 0 .30 -10 .3 3 1 .3 0 .7 4  -226.1 98.5 0.02 
rs3743527 22.5 0 .0 9  -48.5 29.9 0 .1 1  -1 40 .5 63 .4 0.03 
rs4148382 9.7 1 .00 94.2 3 6. 7  0.01< 1 88.5 1 47 . 1 0 .20 < 
rs504348 1 9.3  0 .6 1  -54.9 30 .5 0 .0 7 c -10 9.7 7 1 . 1 0 . 1 2< 
rs41 483 30 3 1 .2 0 . 10 -5.2 26.4 0 .84 -10 .8 41 .8 0 .80 
rs212093 42.6 0 .93 -1 5.4 28. 1 0 .58 -88.6 3 6.6 0.02 
rs47 81 699 29.0 0 .41 29.2 26.3 0 .27 -25.3 45.3 0 .58 
Vlagtwedde- rs21 5100 3 1 . 1 0 .67 27 .6 26.5 0 .30 6.4 43 .9 0 .88 
Vlaardingen rs3 5597 49.8 0 .92 -1 .7 30 .6 0 .96 -28.8 3 5.3 0 .42 
(n=l,3 90 )  rs3 5610 1 6. 1  0 .0 7  1 1 .8 28.7 0 .68 3 6.6 70 .5 0 .60 
rs3 7 43 527 1 7 .7 0 .24 -42.0 27 . 9  0 . 1 3  -7 .0 66.0 0 .92 
rs4148382 10 .0 0 .7 5  97 .2  3 2.4 0.003< 10 7 .5 1 1 7 .4 0 .3 6c 
rs50 43 48 1 7 .0 0 .61 23 .9 28.0 0 .40 -90 .6 7 3 .1 0 .22 
Regression coefficient (B), its standard error (SE) and p values are estimated for heterozygous and homozygous 
mutant genotypes as compared to wild type, using linear regression adjusted for age, sex, height and packyears 
smoked. SNPs showing a significant effect are depicted in bold. 
a for 1 df chi-square test comparing the observed genotypes distribution with the expected as derived from the 
allele frequencies 
b p<0 .0 5 for a dominant effect 
c p<0 .0 5 for an additive effect 
MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; F EV1=Forced Expiratory Volume in one 
second; HWE=Hardy Weinberg Equilibrium; ABCC1 = ATP-binding cassette, sub-family C {CFTR/MRP}, member 1 
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Table S5: Significant associations between genotyped SNPs in ABCCl and annual FEV1 change in the Doetinchem 
cohort and their subsequent replication in the Vlagtwedde-Vlaardingen cohort 
FEV1 change [ml/year] 
Cohort SNP MAF HWE p value a 
Heterozygotes Homozygotes mutant 
p SE p p SE p 
rs212093 45.3 0 .10 -2.0 2 .2 0 .3 7  -6.0 2.7 0.02 
Doetinchem 
rs35597 46. 7  0 .3 3  3 .9 2 .2 0 .0 9  6.1 2.8 0.03 
(n=l, 1 52) 
rs35621 10 .7 0 .61 -0 .2 2.4 0 .93 -22.3 8. 1  0.006 
rs212083 1 9.5 0 .46 -3 .5 2.1 0 .0 9° -9. 1  4.8 0 .0 6° 
rs3819552 49.0 0 .57 2.7 2.3 0 .25 5.4 2.7 0.05 
rs21 20 93 42.6 0 .93 1.1 1 .3 0 .3 9  -0 .9 1 .7 0 .65 
Vlagtwedde-Vlaardingen 
rs3 5597 49.8 0 .92 -0 .2 1 .5 0 .9 1  -0 .5 1 .7 0 .7 6  
rs35621 8.1 1 .00 1 .2 1 .6 0 .3 3  -1 5.0 6.3 0.02 
(n=l,3 90 )  
rs21 20 83 21 .2 0 .69 -0 .7 1 .3 0 .57 -0 .9 3 .0 0 .7 5  
rs3 8 1 9552 47 .5 0 .42 0 . 7 1 .4 0 .63 1 .0 1 .8 0 .57 
Parameter estimate (P), its standard error (SE) and p values are estimated for heterozygous and homozygous 
mutant genotypes as compared to wild type, using LME model adjusted for sex, initial FEV 1 level, packyears 
smoked, and their interaction with time. SNPs showing a significant effect are depicted in bold. 
• for 1 df chi-square test comparing the observed genotypes distribution with the expected as derived from the 
allele frequencies 
b p<0 .0 5 for an additive and dominant effect 
MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; FEV1=Forced Expiratory Volume in one 
second; LME=Linear Mixed Effect; HWE= Hardy Weinberg Equilibrium; ABCCl = ATP-binding cassette, sub-family C 
{CFTR/MRP},member 1 
Table S6: Tagged ABCCl SNPs significantly associated with FEV1 level in the Doetinchem cohort and their 
subsequent replication in the Vlagtwedde-Vlaardingen cohort 
Cohort SNP Tagging SNPs 
Haplotypes tagging 
MAF Model 
FEV1 level [ml] 
minor allele B SE 
Doetinchem 
rs8045000 rs50 43 48, rs47 81 699 0 1 , 1 1  3 2.8 additive -51 .2  20 .8 
(n=l, 1 52) 
rs7190484 rs47 81 699, rs21 5100 1 1 ,0 1 , 10 3 8. 1  additive -48.8 20 . 1  
rs2074087 �41 483 5� �1 1 8643 7 4  0 1  1 4.2 recessive -230 .0 99.4 
Vlagtwedde- rs80 45000 tagged as in the Doetinchem cohort 29.5 additive 3 . 1 1 9. 1  
Vlaardingen rs7 1 90 484 tagged as in the Doetinchem cohort 3 5.6  additive -2.0 1 8.3  
(n=l,3 90 )  
rs20 7 40 87 genotyped (HWE p value=0 .96)" 1 3 .9 recessive -24.5 89.7 
Regression coefficient (B), its standard error (SE) and p values are estimated for the mutant allele as compared to 
wild type using haplo.stats regression analysis adjusted for age, sex, height and packyears smoked. 
SNPs showing a significant effect are depicted in bold. 
• linear regression analysis adjusted for age, sex, height and packyears smoked; HWE tested with a 1 df chi-square 
test comparing the observed genotypes distribution with the expected as derived from the allele frequencies 
0 /1 = major/minor allele of the tagging SNP; MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; 
FEV1=Forced Expiratory Volume in one second; ABCCl = ATP-binding cassette, sub-family C {CFTR/MRP}, member 
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Table S7: Tagged ABCCl SNPs significantly associated with FEV1 change in the Doetinchem cohort and their 
subsequent replication in the Vlagtwedde-Vlaardingen cohort 
Haplotypes FEV1 change 
Cohort SNP Tagging SNPs tagging MAF Model [ml/year] 
minor allele B SE p 
rs8045000 rs50 43 48, rs47 81 699 0 1 , 1 1 ,  10 3 2.8 recessive -6.5 3 . 1 0.03 
rs212990 rs21 20 93 ,  rs41 483 82 00 45.5 additive 4.3 1 .3 0.001 
Doetinchem rs212094 
rs21 20 83 ,  rs21 20 93 1 1  1 8.0 additive -5.3 1 .8 0.003 
(n=l, 1 52) rs2283515 
rs41 483 53 , rs20 7 40 86, 1 10 ,0 1 1 , 
46.6 additive -2.8 1 .3 0.04 
rs1 1 8643 7 4  0 10 ,00 1 
rsl2448760 
rs223 93 30 ,  rs21 20 83 ,  
100 29.0 recessive 4.0 1 .9 0.04 
rs3 7 43 527 
rs80 45000 tagged as in the Doetinchem cohort 29.5 recessive -2.7 2.1 0 .20 
Vlagtwedde- rs21 20 90 tagged as in the Doetinchem cohort 47 .5 additive 0 . 3 0.8 0 .7 1  
Vlaardingen rs21 20 94 tagged as in the Doetinchem cohort 1 8.9 additive 0 .9 1. 1 0 .43 
(n=l,3 90 )  rs2283 51 5 genotyped (HWE p value=0 .82)a 41 .4 additive 1.0 0 .9 0 .26 
rs1 24487 60 genotyped (HWE p value=0 .83 t 3 1. 7  recessive -1 . 1  1.9 0 .59 
Regression coefficient (B), its standard error (SE) and p values are estimated for the mutant allele as compared to 
wild type, using haplo.stats regression analysis adjusted for age, sex, initial FEV 1 level, and packyears smoked. 
SNPs showing a significant effect are depicted in bold. 
a annual FEV1 change analyzed by LME model adjusted for sex, initial FEV1 level, packyears smoked, and time; 
HWE tested with a 1 df chi-square test comparing the observed genotypes distribution with the expected as 
derived from the allele frequencies 
Table S8: Haplotype-tagged SNPs in ABCCl and their corresponding tagging SNPs and haplotypes 
SNP Tagging SNPs Haplotypes tagging minor allele 
rs80 45000 rs50 43 48, rs47 81 699 0 1 ,  1 1  
rs7 1 8893 7 rs47 81 7 1 8, rs41 483 3 7 ,  rs246240 100 ,0 1 1 ,0 10 
rs7 1 90 484 rs47 81 699, rs21 5100 1 1 , 0 1 , 10 
rs20 7 40 87 rs41 483 58, rs1 1 8643 7 4  0 1  
rs2283 51 5 rs41 483 53 , rs20 7 40 86, rs1 1 8643 7 4  1 10 ,0 1 1 ,0 10 ,00 1  
rs7 1 96970 rs41 483 3 7 ,rs1 2445600 1 1 0 1 10 
rs24623 3 rs246240 ,  rs3 5596 1 1  
rs1 93 53 7 rs246230 , rs3 5596 10 , 0 1 , 1 1 
rs21 510 1 rs21 5100 , rs246220 1 1  
rs47 81 7 1 1  rs21 50 49, rs47 81 7 1 8, rs41 483 3 7  0 10 
rs21 50 59 rs21 50 49, rs1 520 22 1 1  
rs21 20 90 rs21 20 93 ,  rs41 483 82 00 
rs21 20 94 rs21 20 83 ,  rs21 20 93 1 1  
rs41 483 44 rs246230 , rs1 2445600 0 1  
rs1 24487 60 rs223 93 30 ,  rs21 20 83 ,  rs3 7 43 527 100 
rs1 244923 9 rs41 483 58, rs1 1 8643 7 4  10 
0 /1 = major/minor allele of the tagging SNP; MAF=Minor Allele Frequency; SNP=Single Nucleotide Polymorphism; 
FEV1=Forced Expiratory Volume in one second; ABCCl = ATP-binding cassette, sub-family C (CFTR/MRP}, 
member; HWE = Hardy Weinberg Equilibrium 
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ABSTRACT 
Background 
The metabolism of xenobiotics plays an essential role in smoking related lung function loss 
and development of Chronic Obstructive Pulmonary Disease. Nuclear Factor Erythroid 2-
Like 2 (NFE2L2 or NRF2) and its cytosolic repressor Kelch-like ECH-associated protein-1 
(KEAPl) regulate transcription of enzymes involved in cellular detoxification processes and 
N/e2/2-deficient mice develop tobacco-induced emphysema. We assessed the impact of 
Single Nucleotide Polymorphisms (SNPs) in both genes on the level and longitudinal 
course of Forced Expiratory Volume in 1 second (FEV1) in the general population. 
Methods 
Five NFE2L2 and three KEAPl tagging SNPs were genotyped in the population-based 
Doetinchem cohort (n=l,152) and the independent Vlagtwedde-Vlaardingen cohort 
(n=l,390). On average 3 FEV1 measurements during 3 surveys, respectively 7 FEV1 
measurements during 8 surveys were present. Linear Mixed Effect models were used to 
test cross-sectional and longitudinal genetic effects on repeated FEV1 measurements. 
Results 
In the Vlagtwedde-Vlaardingen cohort SNP rs1108573 5 in KEAPl was associated with a 
higher FEV1 level (p=0.02 for an additive effect), and SNP rs2364 723 in NFE2L2 was 
associated with a lower FEV1 level (p=0.06). The associations were even more significant in 
the pooled cohort analysis. No significant association of KEAPl or NFE2L2 SNPs with FEV1 
decline was observed. 
Conclusions 
This is the first genetic study on variations in key antioxidant transcriptional regulators 
KEAPl and NFE2L2 and lung function in a general population. It identified 2 SNPs in 
NFE2L2 and KEAPl which affect the level of FEV1 in the general population. It additionally 
shows that NFE2L2 and KEAPl variations are unlikely to play a role in the longitudinal 
course of FEV1 in the general population. 
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BACKGROUND 
The mortality and morbidity of Chronic Obstructive Pulmonary Disease (COPD} has been 
increasing over the past decades and the disease is a fundamental medical and 
economical problem in Western societies 1. A genetic predisposition is thought to play a 
crucial role in the onset of COPD and the heritability of lung function loss that precedes 
COPD development has been clearly established 2'3• Several polymorphisms have been 
identified in association with level of lung function, but subsequent studies have failed to 
replicate these reported associations 4'5• So far, only a small subset of polymorphisms has 
been consistently replicated in their association with COPD development or lung function 
decline across independent studies or populations 6-11• 
Nuclear Factor (Erythroid-derived 2)-Like 2 (NFE2L2 or NRF2} regulates the transcription of 
numerous antioxidant enzymes in response to oxidant injury, via direct binding to the 
antioxidant responsive element in the target gene 12•15• It therefore is a potent candidate 
gene for excess lung function loss and COPD development. 
Kelch-like ECH-associated protein-1 (KEAPl} is a cytosolic repressor of NFE2L2. Oxidative 
stress causes disruption of the KEAP1-NFE2L2 complex, translocation of NFE2L2 to the 
nucleus and subsequent induction of the expression of antioxidant genes 16• It has been 
shown that Nfe212 protects mice against elastase-induced 17 and tobacco-induced 18 
emphysema. Additionally, the expression pattern of both KEAPl and NFE2L2 is different in 
COPD patients as compared to healthy never- or former- smokers 19'20 and the expression 
of NFE2L2-regulated antioxidant genes is lower in COPD subjects than in non-diseased 
controls 21• 
Three new polymorphisms have been discovered in the promoter region of NFE2L2, but 
these were not associated with COPD in a Japanese population 22• One study showed that 
one of these polymorphisms decreases NFE2L2 expression in vitro and is associated with 
development of acute lung injury in a Caucasian population 23• So far no studies have 
investigated the role of NFE2L2 or KEAPl polymorphisms in relation to the longitudinal 
course of lung function in the general population. 
Therefore, in the current study we investigated whether NFE2L2 or KEAPl polymorphisms 
affect the level and longitudinal course of FEV1 (Forced Expiratory Volume in 1 second}, 
both being important risks for COPD 24• In order to assure consistency of results, we 
performed this study in two prospective and independent population-based cohorts. 
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METHODS 
Subjects 
Subjects from the Doetinchem cohort study 25, a prospective part of the MORGEN study 26, 
were included. A sub-sample (n=l,152 subjects with 3 ,115 FEV1 measurements during 3 
surveys: surveys 1993 -1997 (n=l,152), 1998-2002 (n=l,152), and 2003 -2007 (n=811)), 
table 1) was randomly selected from the total cohort with spirometry tests and DNA 
available as described previously 27• FEV1 was measured three times (maneuver 
performed with a heated pneumotachograph (Jaeger, Germany)) with 5-year intervals 
according to the European Respiratory Society (ERS) guidelines 28• 
An independent cohort (Vlagtwedde-Vlaardingen; n=l,3 90 subjects with 8,159 FEV1 
measurements during 8 surveys, table 1) was additionally studied. This cohort was 
prospectively followed for 25 years with FEV1 measurements (maneuver performed with a 
water-sealed spirometer (Lode Instruments, the Netherlands)) every 3 years (following 
ERS guidelines) 29• 
The study protocols were approved by local medical ethics committees and all participants 
gave their written informed consent. 
Selection/genotyping of Single Nucleotide Polymorphisms {SNPs) 
We pairwise tagged NFE2L2 and KEAP1 with respectively five and three SNPs according to 
the HapMap CEU genotype data {23a) with an r2 threshold of 0 .8 and Minor Allele 
Frequency (MAF)>5%. We additionally included three novel NFE2L2 polymorphisms 22 with 
MAF>5%: G(-686)A (rs3 5652124 ), C(-6S0)A (rs6721961} and Trinucleotide CCG Repeat 
(TNR}. SNPs were genotyped by K-Bioscience Ltd (UK} using their patent-protected 
competitive allele specific PCR system (KASPar}. The additional file 1 contains details on 
SNP-selection and NFE2L2 TNR genotyping. 
- 100 -
Chapter 5 - Genetics of NFE2l2/KEAP1 and FEV1 
Table 1: Characteristics of Doetinchem cohort and Vlagtwedde-Vlaardingen cohort 
Doetinchem Vlagtwedde-Vlaardingen 
cohort cohort 
(n=l, 1 52) (n=l,3 90 )  
Total duration of follow-up (years) 10 25 
Number of visits (median) 3 7 
The total number of FEV1 measurements across all visits 3 , 1 1 5 8, 1 59 
Follow-up time frame, years 1 997 -200 7 1 965 -1 990 
Males, n (%) 541 (47.0 ) 7 1 4 (51 .4) 
FEV1 change in ml/year, mean (SD) -26.2 (3 3.4) -20 .8 (22.9) 
Last available: 
FEV1 level in liters, mean (SD) 3.3 1 (0 .80 ) 2.86 (0. 7 7 )  
Age in years, median (range) 53 . 7 (3 2-7 6) 52.0 (3 5-7 9)  
Never smokers, n (%) 3 7 2  (3 2.3 ) 445 (3 2.0 )  
Packyears smoked in ever smokers, median (range) 1 3 .2 (0 .00 4-84.0 ) 1 8.9 (0 . 1 -262.2) 
FEV1 = Forced Expiratory Volume in 1 second; SD = Standard Deviation 
Statistics 
SNPs in NFE2L2 and KEAP1 and level of FEV1 
We used Linear Mixed Effect {LME) to study the effects of SNPs and haplotypes {additive 
genetic model; coded: O=homozygote wild type, l=heterozygote, 2=homozygote mutant) 
on the level of FEV1 in both cohorts separately, using all available FEV1 measurements 
across all surveys. This analysis was adjusted for age {defined with natural cubic spline 
with 4 degrees of freedom in order to take into account varying effects of age on the level 
of FEV1 throughout lifetime), sex, packyears smoked, height and the correlation of FEV1 
measurements within each subject {random effect assigned to the intercept). 
SNPs in NFE2L2 and KEAP1 and course of FEV1 
We studied the effect of SNPs on course of FEV1 by introducing the interaction term of SNP 
x time {defined in relation to the first FEV1 measurement and with random effect 
assigned) into the primary analysis model described above {see additional file 1 for 
details). 
Analysis on the pooled cohorts 
Finally, we pooled both cohorts, and performed analysis on level and course of FEV1 with 
additional adjustment for cohort. We studied also two other models {recessive/dominant 
= mutant/wild type homozygotes compared to the rest genotypes) which were reported in 
case they showed significant effects in the pooled cohort analysis. Similarly we 
investigated whether there was a significant interaction between KEAP1 and NFE2L2 
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genotypes in relation to the level of FEV1, using two-way combinations of genetic effects 
with the highest statistical power i.e. dominant and additive. 
Interaction with smoking 
Gene by smoking interaction analysis in relation to the level of FEV1 was performed on the 
pooled cohorts using data from single surveys (i.e. second in the Doetinchem cohort and 
last in the Vlagtwedde-Vlaardingen cohort) in order to ensure the highest cumulative 
exposure to tobacco smoke and the highest number of subjects analyzed. The following 
interaction terms in two following regression models were analyzed :  
1 .  'SNP by ever/never smoking status i n  the total population with adjustment for ever­
smoking status and genotypes and no adjustment for packyears smoked 
2. SNP by packyears smoked within ever smokers with adjustment for packyears smoked 
and genotypes 
P values<0.05 were considered to be statistically significant (tested 2-sided). 
Software 
LME models were run using S-PLUS (version 7.0). Linkage Disequilibrium (LO) plots and 
Hardy-Weinberg Equilibrium (HWE) tests were performed with Haploview (version 4 .1) 30• 
We identified, with a probability>95%, subjects carrying no, one or two copies of a specific 
haplotype, using the * .out_pairs output file from PHASE software (version 2.1) 31'32 • We 
used MIX software (version 1. 7) 33'34 to meta-analyze results from the Doetinchem, 
Vlagtwedde-Vlaardingen and British 1958 Birth cohort 35• 
RESULTS 
Genetic structure of NFE2L2 and KEAP1 
There was an excess of KEAPl rs104 8290 SNP heterozygotes in the Vlagtwedde­
Vlaardingen cohort, which caused a significant deviation (p=0.01) from HWE (table 2). To 
eliminate potential genotyping errors as underlying cause of this, we additionally 
genotyped KEAPl rs9676881 SNP, that is in complete LO with rs104 8290 (based on 
HapMap; distance between the two SNPs=3.7 kb). This SNP also showed a significant 
deviation from HWE (p= 0.01; frequency of 50.6% and 12.4% for heterozygotes and 
homozygote mutants respectively) in the Vlagtwedde-Vlaardingen cohort. 
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Table 2: Characteristics of NFE2L2 and KEAP1 genotypes in the Doetinchem cohort and Vlagtwedde-Vlaardingen 
cohort 
Doetinchem cohort Vlagtwedde-Vlaardingen cohort 
(n=l, 1 52) (n=l,3 90 )  
The total SNP call rate, % 97 .5 96.4 
The total unique 
93 .7 90 .6 haplotype call rate, % 
Genotypes distribution, Heterozy- Homozygotes 
HWE 
Heterozy- Homozygotes 
MAF p MAF 
n(%): gates mutant 
value 
gates mutant 
NFE2l2 rs67 263 95 561 (49.6) 256 (22.7 ) 47 .5 0 .9 1  670 (49.6) 27 7 (20 .5) 45.3 
rs4243 3 87 210 ( 1 8.8) 10 (0.9) 10.3 0 .69 1 91 ( 1 4.1 ) 1 4 ( 1 .0 )  8.1 
rs1 80 6649 454 (40 .5) 7 2  (6.4) 26.7 0 .27 510 (3 9 . 1 ) 83 (6.4) 25.9 
rs1 300 1 694 530 (47.3 ) 1 7 8  ( 1 5.9) 3 9.6 0 .7 4  647 (48. 1 ) 223 ( 1 6.6) 40 .6 
rs23 647 23 499 (44.6) 10 5 (9.4) 3 1 .7 0.38 57 4 (42.8) 1 56 ( 1 1.6) 3 3 .0 
Haplotype C 3 26 (30 .4) 41 3 .8) 1 8.9 0 .7 2  40 2 (3 2.6) 44 (3 .6) 1 9. 1  
Haplotype D 23 7 (22.1 ) 1 3 1.2) 1 2.4 0 .47 283 (22.9) 1 4  ( 1 . 1 ) 1 3 .0 
KEAP1 rs10 48290 50 7 (45.5) 1 47 ( 1 3 .2) 3 6.0 0.7 7 67 1 (50 .6) 1 64 ( 1 2.4) 3 7.6  
rs1 10 857 3 5  1 1 7  ( 10 .4) 5 (0 .4) 5.6 0 .56 1 29 (9.6) 2 (0 . 1 ) 4.9 
rs10 48287 20 3 ( 1 8.0 )  1 8  ( 1 .6) 10 .6 0. 1 4  248 (1 8.4) 1 1  (0 .8) 10.0 
Haplotype A 520 (47 .9) 1 97 ( 1 8 . 1 ) 57 .7 0.64 659 (51.2) 222 ( 1 7 .3 )  57 .0 
Haplotype B 40 1 (3 6.9) 80 (7.4) 26. 1  0.27 541 (42. 1 ) 88 (6.8) 28.0 
SNP = Single Nucleotide Polymorphism; HWE = Hardy Weinberg Equilibrium; MAF = Minor Allele Frequency 
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Five NFE2L2 TNR alleles, including three alleles not observed previously 22 i.e. 2, 6 and 7 
CCG repeats, were identified in the Doetinchem cohort. These three novel alleles occurred 
with a total cumulative frequency of 0.4% (see additional file 1 for details). 
The NFE2L2 G(-686)A (rs3 5652124 ) SNP, CCG TNR and rs23 64 723 SNP were in high LD as 
well as NFE2L2 C(-6SO)A (rs6721961) and rs4 24 3 387 SNPs (r2�0.96, figure 1). We observed 
5 prevalent (>5% frequency) haplotypes in NFE2L2, and 4 prevalent haplotypes in KEAP1 in 
both cohorts (table 3 ). Two haplotypes in NFE2L2 (haplotypes C and D) were unique, i.e. 
they were not tagged by a single allele of any SNP (table 3 ). Similarly, 2 haplotypes in 
KEAP1 (haplotypes A and B) were unique (table 3 ). 
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Figure 1: NFE2L2 and KEAPl linkage disequilibrium plots { 100 ·r2) in the Doetinchem cohort (n=l, 1 52) 
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*given for the  wild type {5  CCG repeats) and the mutant (4  CCG repeats) allele 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2; KEAPl = Kelch-like ECH-associated protein-1 
NFE2L2 and KEAP1 variations and level of FEV1 
SNP rs23 64 723 in NFE2L2 was associated (p=0.06) with a lower FEV1 level, and SNP 
rs1108573 5 in KEAPl was significantly associated with a higher FEV1 level in the 
Vlagtwedde-Vlaardingen cohort (table 4 ). Similar, but non-significant trends for an 
additive effect were observed in the Doetinchem cohort, resulting in significant effects in 
the pooled cohort analysis (table 4 ). 
Heterozygote subjects for rs23 64 723 SNP had a significantly lower FEV1 level as compared 
to homozygote wild type subjects (figure 2), while for the rs1108573 5 SNP all between­
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Table 3: Characteristics of NFE2L2 and KEAP1 haplotypes occurring with >5% frequency in the two cohorts 
studied 
SNP* Frequency [%] 
1.1'1 ,.._ m c:r. m  Gene Haplotype � � � � �  Doetinchem cohort Vlagtwedde-Vlaardingen cohort ):!l ;  l!l 8 l 
ro � � z: � 
:C � � f IC 
A 0 -0 -0 -0 -1 3 1 .0 3 2.5 
B 1 -0 -1 -1 -0 25.0 24.5 
NFE2L2 
C 0 -0 -0 -0 -0 1 8.9 1 9. 1  
D 1 -0 -0 -1 -0 1 2.4 1 3 .0 
E 1 -1 -0 -0 -0 9.3 7 .0 
- Rare pooled 3 .6 3 .9 
0 "'  .... 
a, r- oo  
N "1 N 
00 � 00 
� � �  
KEAP1 A 0 -0 -0 57 .7 57 .0 
B 1 -0 -0 26. 1 28.0 
C 1 -0 -1 9.8 9.7 
D 0 -1 -0 5.5 4.9 
- Rare pooled 0 .9 0 .4 
*0 /1 corresponds to the major/minor allele of SNPs 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2; KEAP1 = Kelch-like £CH-associated protein-1 
Figure 2: Mean adjusted FEV 1 level for heterozygote and homozygote mutant genotypes of the NFE2L2 
rs23 647 23 SNP as compared to wild type 
FEV1 level In ml 
as compared to wild 








rs2364723 genotype: G/C C/C 











Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. 
*p<0.0 5 as compared to wild type 
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Figure 3: Mean adjusted FEV 1 level for heterozygote and homozygote mutant genotypes of the KEAPl rs11085735 




FEV1 level in ml 
as compared to wild 400 
























Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are presented. 
* p<0.05 for homozygote mutant genotype as compared to wild type or heterozygotes 
t p<0.05 for heterozygote genotype as compared to homozygote wild type 
t p<0.05 for all between-genotype comparisons 
KEAPl = Kelch-like £CH-associated protein-1; FEV1 = Forced Expiratory Volume in 1 second 
Haplotype C in NFE2L2 was associated with higher FEV1 levels using an additive model in 
the pooled cohort analysis exclusively (table 4 ). Haplotype A in KEAP1 was associated with 
higher FEV1 level in a recessive model in the pooled cohort analysis (table 4 ). No additional 
consistent associations were observed for other SNPs or other genetic models (data not 
shown). 
Interaction between SNPs in NFE2L2 and KEAP1 
There was no significant interaction between SNPs in KEAP1 and NFE2L2 (using 
combinations of dominant and/or additive effects) in relation to the level of FEV1 in the 
pooled cohort analysis (data not shown). 
Interaction between smoking and NFE2L2 and KEAP1 variations and level of FEV1 
We observed no significant interaction between ever/never smoking status and variations 
in NFE2L2 or KEAPl in relation to the level of FEV1. Yet the effect of rs1108573 5 in KEAPl 
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was significant only in never smokers, while the effect of rs23 64 723 and haplotype C in 
NFE2L2 was significant only in ever smokers (table 5). In the pooled cohort analysis we 
observed significant interactions between packyears smoked with two linked variations in 
KEAP1 i.e. rs104 8290 (B 1Nr=l.9 ml/(packyear*allele number) SE,Nr=0.9 p=0.03) and 
haplotype B (B,Nr=l.9 ml/(packyear*allele number) SE,Nr=0.9 p=0.04 ). In the single cohort 
analysis these interaction terms were not significant (p>0.10 for both cohorts). 
Table 4: Additive effects of genetic variations in NFE2L2 and KEAPl on the level of FEV1 
Gene Variation 
Doetinchem cohort Vlagtwedde-Vlaardingen cohort Pooled cohorts 
B [ml] 95% CI p B [ml] 95% CI p p 
rs67 263 95 -1 3 .8 -51 .0 - 23 .4 0 .47 1 4. 1  -1 7 .9 - 46.1 0 .3 9  0 .827 
rs4243 3 87 0 .2 -61 .9 - 62.3 0 .99 20 .6 -3 6.5 - 7 7 .7 0 .48 0 .620 
rs1 80 6649 -44.5 -87 .3 - -1 .7 0.04 0 .2 -3 6.7 - 3 7 .1 0 .99 0 . 1 50 
NFE2L2 rs1 300 1 694 -20 .9 -58.7 - 1 6.9 0 .28 1 3 .0 -1 9.5 - 45.5 0 .43 0 .948 
rs23 647 23 -22.9 -63 .6 - 1 7 .8 0 .27 -3 2.1 -65.4 - 1 .2 0 .0 6  0.026 
Haplotype C 44.8 -3 .4 - 93 .0 0 .0 7  24.3 -1 7 .8 - 66.4 0 .26 0.040 
Haplotype D 47 .0 -1 2. 1 - 10 6.1 0 . 1 1  2 1 .2 -29.7 - 7 2.1 0 .41 0 .0 64 
rs10 48290 1 2.4 -26.3 - 51 .1 0 .53 -6.5 -40 .8 - 27 .8 0 .7 1  0 .7 84 
rsl10 857 3 5  69.9 -9.3 - 1 49.1 0 .0 8  97 . 1  22.4 - 1 7 1 .8 0.01 0.003 
KEAPl rs10 48287 -1 1 .9 -70 .8 - 47 .0 0 .69 -3 3 .2 -86.3 - 1 9.9 0 .22 0 .287 
Haplotype A* 23 .9 -1 3 .8 - 61 .6 0 .21 7 .0 -26.5 - 40 .5 0 .68 0 .20 6 
Haplotype B 8.9 -3 3 .2 - 51 .0 0 .68 4.6 -3 2.5 - 41 .7 0 .81 0 .60 1  
Significant p values are depicted in bold 
* for the recessive effect: 8=7 6.8 ml (95% Cl: 8.0 -1 45.6), p=0 .0 3  (Doetinchem cohort) and B=45.l ml (95% Cl: -
1 5.5-10 5.7 ) p=0 . 1 4  (Vlagtwedde-Vlaardingen cohort); p=0 .0 1  in the pooled cohort analysis 
Parameter estimate B (corresponding to the "per-allele" effect on the level of FEV1 in ml), its 95% Confidence 
Interval and p value are estimated for genetic variations in NFE2L2 and KEAPl using Linear Mixed Effect model 
analysis on FEV1 level adjusted for genotypes (coded: 0 =homozygotes wild type, l=heterozygotes, 
2=homozygotes mutant) packyears smoked, sex, age, height and correlation of FEV1 measurements within 
subjects and cohort binary variable for the pooled cohorts analysis. 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2 ;  KEAPl = Kelch-like £CH-associated protein-1; FEV1 = Forced 
Expiratory Volume in 1 second; Cl = Confidence Interval 
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Table 5: Additive effects of NFE2L2 and KEAPl SNPs on the level of FEV1 in never- and ever-smokers 
Doetinchem cohort (n=l,152) Vlagtwedde-Vlaardingen cohort (n=l,390) 
second survey last survey 
Gene Variation 
Never smokers Ever smokers Never smokers Ever smokers 
B SE p B SE p B SE p B SE 
rs67 263 95 -3 3 . 1 3 4. 1  0 .3 3  -3 .4 24.2 0.89 9.7 28.3 0 .7 3  6.4 22.7 
rs4243 3 87 1 5.5 55.5 0 .7 8  -1 .2  41 . 1  0 .98 3 .9 56.0 0 .94 1 2 .8 3 8.6 
rs1 80 6649 -97 . 1  3 7 .7 0 .0 1  -1 9.0 28.4 a.so 40 .6 3 1 .S 0 .20 -1 3 . 1 26.6 
NFE2L2 rs1 300 1 694 -54.S 3 4.7 0 . 1 2  -1 6.0 24.5 0 .52 1 3 .5 28.2 0 .63 5.6 23.3 
rs23 647 23 21 .5 3 7 .3 0 .56 -3 6 .6 26.8 0.17 -3 .2 28.4 0 .91 -3 6.2 24.0 
Haplotype C 3.5 44.6 0 .94 54.2  3 1 .3 0.08 -22.9 3 5.2 0.52 47 .5 30.5 
Haplotype D 86.7 59. 1  0 . 1 4  1 9.5 3 7 .0 0 .60 -40 .3 42.5 0.3 4 3 8.7 3 7. 1  
rs10 48290 -0 .8 3 5.3 0 .98 1 7 .0 25.5 0 .51 -21 .8 29.2 0 .46 44.6 24.6 
rs 1 10 857 3 5  1 1 6.2 7 5.8 0.13 64.6 50 .4 0 .20 1 1 2.2 60 .8 0.07 23 .5 54.5 
KEAPl rs10 48287 -25.0 53.8 0.64 -10.4 3 8.7 0 .7 9  -56.8 44.0 0 .20 5.1 3 8.6 
Haplotype A* 25.8 3 4.0 0 .45 22. 1 24.9 0 .3 8  4.8 28.8 0 .87 3 6.7 23 .8 
Haglotyge B 1 2.3 3 8.3 0 .7 5  2.3 27 .8 0 .93 3 .6 30 . 7  0 .91 46.3 26.7 
P values depicted in bold indicate associations significant (p<0 .0 5) in the pooled cohort analysis within never- or 
ever-smokers. 
*p<0.0 5 for a positive recessive effect in ever and never smokers in the pooled cohort analysis (p>0 .0 5  for the 
analysis concerning separate cohorts) 
None of the SNP in any model showed significantly different effect between never and ever smokers as tested 
with the pooled cohort linear regression analysis containing interaction term (binary variable reflecting smoking 
status) adjusted for height, sex, age, cohort and ever/never smoking status.Two underlined KEAPl variations 
showed a significant interaction with packyears smoked in an additive model within ever-smokers in the pooled 
cohort analysis: 
rs10 48290 :  B,Nr=l.9 ml/(packyear*number of alleles) SE,Nr=0.9 p=0 .0 3 
Haplotype B: B,Nr=l.9 ml/(packyear*number of alleles) SE,Nr=0 .9 p=0 .0 4 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2 ;  KEAPl = Kelch-like £CH-associated protein-1; FEV1 = Forced 
Expiratory Volume in 1 second; SE = Standard Error 
SNPs in NFEZLZ and KEAP1 and course of FEV1 
We did not observe any significant effect of SNPs in NFE2L2 and/or KEAP1 on the course 
of FEV 1 in either of the cohorts nor in the pooled cohort analysis for any genetic model 
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[ml/yr] [ml/yr) p 
rs67 26395 0 .2 -2.5- 2.9 0 .88 0.1 -1 .5 - 1 .7 0 .90 0.87 3 
rs4243387 - 1 .2  -5.6- 3.2 0 .60 -1 .9 -4.8- 1 . 1 0 .21 0 .10 6 
rs1 80 6649 1 .5 -1 .6- 4.5 0 .35 1 .0 -1 .0- 3.0 0 .3 1  0 . 1 51 
NFE2l2 rs1 300 1 694 0 .0 -2.7 - 2.7 1 .00 0.7 -1 .0- 2.4 0 .40 0 .337 
rs23647 23 -0 .3 -3.2- 2.6  0 .84 -0.6 -2.3- 1 .1 a.so 0.368 
Haplotype C -0 .3 -3.8- 3. 1  0 .85 0.9 -1 .3- 3.1  0.40 0 .40 1 
Haplotype D -2.3 -6.6- 2.0 0.29 0 .0 -2.6- 2.5 0 .98 0.627 
rs10 48290 -2.0 -4.7-0 .8 0 .1 6  1.0 -0.8- 2.8 0 .28 0.90 7 
rs1 10 857 35 3.6 -2. 1- 9.4 0 .22 -0 . 7  -4.7 - 3.3 0.7 2 0.7 7 4  
KEAP1 rs10 48287 -1 .8 -5.9- 2.4 0 .41 -0.4 -3. 1- 2.4 0 .80 0.61 4 
Haplotype A - 1 .3 -4.0- 1 .4 0 .35 0 .8 -1 .0- 2.5 0 .38 0 .81 7 
Haplotype B -1 .6 -4.6- 1 .4 0 .30 1 .5 -0 .5 - 3.4 0 . 1 4  0.57 3 
Parameter estimate B (corresponding to the "per-allele" effect on the change in FEV1 in ml/yr), its 95% 
Confidence Interval and p value are estimated for genetic variations in NFE2l2 and KEAP1 using Linear Mixed 
Effect model analysis on FEV1 level adjusted for genotypes (coded: 0 =homozygotes wild type, l=heterozygotes, 
2=homozygotes mutant), age at entry, sex, packyears smoked, FEV1 level at baseline (and their interaction with 
time) and correlation of lung function measurements within subjects (random factor assigned to the intercept 
and time) and cohort binary variable for the pooled cohorts analysis. 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2; KEAP1 = Kelch-like ECH-associated protein-1; FEV1 = Forced 
Expiratory Volume in 1 second; Cl = Confidence Interval 
DISCUSSION 
The current study shows that polymorphisms in antioxidant transcription factor NFE2L2 
and its repressor KEAP1 affect the level of FEV1 in the general population. 
NFE2L2 is required for the transcription initiation of many antioxidant-related genes 
including candidate genes for lung excess function loss and COPD development such as 
Heme Oxygenase 1 and Glutamate Cysteine Ligase 11'27'36• Moreover, murine models have 
shown that the Nfe2/2 depletion in vivo results in elastase- 17 and cigarette smoke-induced 
18 emphysema development. Thus a functional genetic impairment concerning NFE2L2 
and/or its cytosolic repressor KEAP1 would likely result in detrimental consequences in 
vivo. 
It has been shown that lung function is genetically determined 2'3, however so far only 
low-prevalent polymorphisms have been consistently associated with COPD development 
across independent studies, i.e. the Glu3 4 2Lys substitution in SERPINA1 (frequency 1%-3% 
in Caucasians) that leads to al-antitrypsin deficiency G-s and the Arg213Gly substitution in 
Superoxide Dismutase 3 (frequency 1%-2% in Caucasians) 9'10, suggesting that low-
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prevalent SNPs are important contributors to COPD development. Detection of the effect 
provided by such low prevalent SNPs often requires large sample sizes, even when the 
effect size is substantial. Similarly, small genetic effects for highly prevalent variations, 
such as those genotyped in the current study, need to be assessed in large sample sizes. 
Therefore, we used all available FEV1 measurements in both cohorts, in order to achieve 
the highest possible statistical power. Moreover, we additionally performed analyses on 
the pooled cohorts including over 2,500 subjects with over 11,000 FEV1 measurements. 
In our opinion the most convincing association shown in the current study was that the 
rs11085735 SNP in KEAP1 significantly associated with higher FEV1 levels in the pooled 
cohort as well as in both cohorts analyzed separately, yet using different genetic models. 
This SNP is located in the intron 3 of KEAP1, relatively close {73 bp) to the exon 3 of this 
gene, and thus it might have functional consequences e.g. via affecting KEAP1 mRNA 
splicing. Haplotype A in KEAP1 was associated with higher FEV1 level in the Doetinchem 
cohort and in the pooled cohort analysis using a recessive model only. Since this haplotype 
does not tag any SNP that was investigated in the current study, it may be in linkage 
disequilibrium with another functional SNP that is either not known yet or is located 
outside the region that was selected for tagging. 
SNP rs2364 723 and haplotype C in NFE2L2 were associated with the level of FEV1 in the 
pooled cohort analysis, as caused by a similar though not significant trends present in both 
cohorts. SNP rs2364 723 is in almost complete LD with the recently described promoter 
polymorphisms i.e. G{-686)A {rs35652124 ) and CCG Trinucleotide repeat {figure 1) 22, 
implicating a role in the regulation of NFE2L2 transcription. We found no evidence for an 
association of another previously identified functional NFE2L2 SNP {i.e. C{-6S0)A 
{rs6721961) tagged by us with rs424 3387 SNP) 23• 
None of the analyzed genetic variations showed a significantly different effect on the level 
of FEV1 between never and ever smokers, yet the effects provided by NFE2L2 rs2364 723 
SNP and haplotype C were more prominent in ever smokers while the effect of KEAP1 
rs11085735 SNP was significant in never smokers exclusively. Interestingly another 
variation in KEAP1 {i.e. rs104 8290 linked with haplotype B) showed a protective effect on 
the level on FEV1 in interaction with packyears smoked within ever smokers. The observed 
association of the level of FEV1 and the interaction between rs104 8290 SNP and smoking 
can be somewhat weakened by a deviation from HWE observed for this SNP in one of the 
cohorts studied. Since the common cause of such deviation is a genotyping error, we have 
genotyped another, completely correlated, rs9676881 SNP, which also showed significant 
deviation from HWE. This suggests that genotyping error was not a cause of the observed 
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deviation from HWE. Significant results obtained in the analysis stratified by smoking 
status (ever and never smokers), or in the gene by packyears interaction analysis did not 
reach significance in either of the cohorts analyzed separately. Since this could be due to 
insufficient power provided by single cohorts, subsequent studies are warranted. 
Using publicly available data on the British 1958 Birth cohort 35, we checked whether our 
results on the significant association of SNPs with the level of FEV1 could be replicated in 
this independent population. The additive effects provided by. rs1108573 5 in KEAPl and 
rs23 64 723 in NFE2L2 were not significant, p values being 0.11 and 0.59-0.70 (depending 
on the genotyping method) respectively. However, both associations were in the same 
direction as found in our two Dutch cohorts, i.e. positive for rs1108573 5 in KEAPl (B=52.7 
ml/allele, 95% Confidence Interval (Cl) = -12.6 - 118.0} and negative for rs23 64 723 in 
NFE2L2 (B=-7.3 ml/allele, 95% Cl = -4 4 .3 - 29.6, representing higher p value). A 
subsequent meta-analysis of the Doetinchem, Vlagtwedde-Vlaardingen and British 1958 
Birth cohorts showed a higher significant protective effect of the KEAPl SNP on the level 
of FEV1 (p=0.0008) as compared to the pooled analysis in the two Dutch cohorts (p=0.003 , 
table 4 ). The p value of the additive and detrimental effect of the rs23 64 723 SNP was 
significant as well (0.03 6-0.04 6, depending on the genotyping technology in the British 
1958 Birth Cohort), yet higher than the p value provided by the pooled analysis in the two 
Dutch cohorts (i.e. p=0.026, table 4 ). 
CONCLUSIONS 
Our study performed in two independent Dutch cohorts shows that genetic variations in 
KEAPl and NFE2L2 affect the level, but not the longitudinal course of FEV1 in the general 
population. Therefore, it remains for future considerations whether these SNPs play a role 
in the development or growth of the lung. Given the importance of both genes in the 
regulation of oxidative stress in the lung, further studies focusing on the NFE2L2-KEAP1 
pathway are warranted. 
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Additional file 1 
Genotyping 
The three NFE2L2 novel polymorphisms were genotyped in the Doetinchem cohort only 
since they were highly correlated (r2>0.96) with certain SNPs derived from HapMap, and 
consequently did not provide different information than the HapMap-derived SNPs. Since 
rs104 8290 SNP in KEAP1 showed a significant deviation from Hardy Weinberg Equilibrium 
in Vlagtwedde-Vlaardingen cohort we additionally genotyped rs9676881 SNP, which is in 
complete linkage disequilibrium with rs104 8290 SNP (r2=1.0 according to HapMap CEU 
genotype data (release 23a/phase I I , March 2008)). Since both SNPs are located relatively 
far from each other (3 .7kb) this allowed us to check whether the observed HWE deviation 
could occur due to genotyping errors. 
Amplification of the region spanning Trinucleotide CCG Repeat (TNR) in the NFE2L2 was 
performed by 10 µI of PCR reaction containing: 
o 10 ng of the DNA 
o 2 µI DMSO 
o 1 µI MgCl2 (25 mM) 
o 1 µI dNTPs (2mM) 
o 0.1 µI AmpliTaq • (Applied Biosystems, USA) DNA polymerase and 1 µI AmpliTaq"' 
buffer 
o 0.5 µI of forward (5' -FAM-atgagctgtggaccgtgtgt) and reverse (5'­
gcgtgtagccgattaccgagt) primers (10 µM each) 
o water to the final volume of 10 µI 
PCR amplification consisted of the following steps: 
o Initial denaturation for 5 min. at 95.o0c 
o 3 5  cycles according to the protocol: 
o Denaturation for 4 5  sec. at 94 .0°C 
o Annealing for 30 sec. at 57.9°C 
o Elongation for 30 sec. at 72.0°C 
o Final elongation for 5 min. at 72.0
°C 
The PCR product comprising the TNR was labeled with a fluorescent FAM dye, present in 
the forward primer. It basically had two possible lengths (i.e. 156 and 159 base pair) 
corresponding to the two most frequent TNR alleles (i.e. 4 and 5 CCG repeats) present in 
our populations. The PCR reaction was followed by MegaBACE electrophoresis of the 
product in an acryl amide gel in the presence of sizer. MegaBACE Genetic Profiler software 
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(version 2.2, GE Hea lthcare, U K) was used to assign the specific TNR a l leles to the 
fluorescent peaks (figure l}. To check for the qua l ity of genotyping we repeated the 
genotyping process in 100 samples taken from stock vials, with no genotyping errors 
detected . 
SNP x time interaction analysis with Linear Mixed Effect models 
The i ntroduction of SNP x time (defined in relation to the first FEV1 measurement and  with 
a random effect assigned) interaction term to the model and add itiona l  adjustment for 
age at entry and FEV1 level at entry (and excl usion of height) a l lowed us to test how SNPs 
associate with FEV1 course over time. In this ana lysis FEV1 measurements (n=G,966} were 
inc luded from the age of 30 years in the Vlagtwedde-Vlaard ingen cohort, because a n  
ind ividua l's maximal ach ieved l ung function i s  assumed t o  have been reached before that 
age and the leve l of lung function is considered to be either in the plateau or dec l ine 
phase 1. I n  the Doetinchem cohort a l l  subjects crossed the 30 years of age at the second 
survey and were thus inc luded to the ana lysis. 
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Figure 1: Genetic profiler output plots for all NFE2L2 TNR genotypes found in the Doetinchem cohort (n=l, 1 52) 
5/5 (homozygotes wild type), n=527 (45.9%) 
5/4 (heterozygotes ), n=507 (44. 1 %) 
4/4 (homozygotes mutant), n=l06 (9.2%) 
4/7, n=3 (0.3%} 
4/6, n=2 (0.2%} 
2/5, n=2 (0.2%} 
5/7, n=1 (0.1%) 
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Numbers of individuals and frequencies are given for all common and rare (italics) genotypes represented by 
number of TNR alleles. 
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2; TNR=Trinucleotide CCG Repeat in NFE2L2 
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ABSTRACT 
Oxidative stress is an important causative factor in the onset and progression of smoking­
related lung diseases like chronic obstructive pulmonary disease (COPD}. Superoxide 
Dismutases (SODs} can prevent an increase in oxidative burden. 
1,390 subjects from the prospective Vlagtwedde-Vlaardingen cohort were genotyped for 
2 Single Nucleotide Polymorphisms (SNPs} in 50D2 and 4 SNPs in 50D3, that were further 
analyzed for associations with the presence of bronchial hyperresponsiveness (BHR; 
PC10S8 mg/ml of histamine}, COPD (defined as GOLD stage � I I}, lung function level and the 
longitudinal course of FEV1. 
The intronic C5774 T SNP of 50D2 was significantly associated with the presence of COPD 
and BHR in the total population. The T/T genotype for this polymorphism and the Val/Val 
genotype for the 50D2 Ala16Val substitution were risk factors for BHR in individuals 
without COPD. The 50D3 Arg213Gly substitution was associated with slower FEV1 decline 
in never smokers exclusively, and the 50D3 G{-4 4 66}T SNP was associated with a lower 
Vital Capacity level. 
Both 50D2 polymorphisms are associated with BHR, a risk factor for COPD, while 50D2 
C5774 T additionally confers a risk for COPD in the total population. We furthermore 
confirm previously reported associations of 50D3 SNPs with lung function in the general 
population. 
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INTRODUCTION 
An imbalance between oxidants and antioxidants is considered to be an important 
causative factor in the onset and progression of chronic obstructive pulmonary disease 
(COPD) 1'2 • A key molecule in the regulatory process of oxidative stress is superoxide 
anion, which is inhaled with cigarette smoke and additionally generated during numerous 
cellular reactions 3• Free superoxide anion is a substrate for the synthesis of highly reactive 
oxygen species which can damage epithelial cells, impair epithelial ciliary function, alter 
expression of cellular adhesion molecules, and increase airway smooth muscle contraction 
in response to histamine and other stimuli in in vitro and in in vivo models 4• Therefore, 
impaired superoxide metabolism may contribute to the development of bronchial 
hyperresponsiveness (BHR} and the subsequent onset of COPD 5'6• Indeed, we have 
previously shown that patients with COPD have increased production of superoxide anion 
by blood leukocytes, which was associated with more severe hyperresponsiveness 7• 
However, this cross-sectional study did not elucidate whether the increased production of 
superoxide anion was the cause or consequence of BHR and COPD. So far, studies on the 
relation between superoxide anion and both the development of COPD and BHR in the 
general population are lacking. 
The family of superoxide dismutases (SOD} is the sole unique enzymatic system able to 
degrade a superoxide anion 8• Impairment of the mitochondrial superoxide dismutase 
(SOD2} activity was related to asthma pathophysiology 9, and extracellular superoxide 
dismutase (SOD3} was shown to protect lungs against oxidant-mediated injury 10•11• 
Therefore, it is of interest to study whether Single Nucleotide Polymorphisms (SNPs} in 
these SOD genes contribute to the development of BHR and/or COPD. 5002 contains one 
prevalent nonsynonymous SNP (nsSNP), i.e. Ala16Val, which is localized in a protein signal 
sequence, thus possessing a possible functional role 12•14• This substitution has been 
associated with a higher lung cancer risk in Caucasians 15•17 but not with the presence of 
COPD in Caucasian and Chinese smokers 18'19• 5003 contains three nonsynonymous SNPs 
i.e. Ala40Thr, Phe13 1Cys and Arg213 Gly. The Arg213Gly substitution has been associated 
with elevated SOD3 levels in human plasma 20 and with protection against COPD 
development in Caucasians 18'21, whereas Ala4 0Thr and Phe13 1Cys have not yet been 
studied in this context. 
Recently it has been shown that the rs8192288 SNP in the 5003 5' untranslated region is 
associated with lower Forced Vital Capacity in two large Danish cohorts and constitutes a 
risk for more frequent COPD hospitalization in the Copenhagen City Heart Study 22• 
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This study links the well-known risk factors for COPD development, i.e. BHR and smoking, 
with polymorphisms located in genes involved in response to oxidative stress, a key 
manifestation in COPD pathogenesis. Furthermore it aims to broaden the knowledge on 
candidate 5003 SNPs with respect to (the course of) lung function and it puts a new 
insight into the 5002 role in this context. 
METHODS 
Subjects 
A total of 1,390 subjects of the Vlagtwedde-Vlaardingen cohort who participated in the 
last survey (1989-1990) were included in the study. This general population-based cohort 
of Caucasian individuals of Dutch descent started in 1965 and has been followed-up for 25 
years 23-25 • Standardized Forced Expiratory Volume in 1 second (FEV1) and Vital Capacity 
(VC) measurements were performed every 3 years (see online supplement for details) 26• 
The study protocol was approved by the local university hospital medical ethics committee 
and all participants gave their written informed consent. 
DNA extraction and genotyping 
See the online supplement for a description of DNA extraction and the genotyping 
protocol. Six SNPs in two SOD genes were genotyped, i.e. : Ala16Val (rs4 880) and C5774 T 
(rs284 2958) in 5002, and Ala40Thr (rs253 6512), Arg213Gly (rs1799895), 
G(-4 4 66)T (rs8192288), and Phe131Cys 27 in 5003. 
The C5774 T SNP was included to be able to tag 5002 haplotypes, as described 
previously 28• 
Presence of COPD and bronchial hyperresponsiveness (BHR) phenotype 
We identified subjects with COPD according to the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) criteria, i.e. an FEVi/VC<70% and an FEV1<80% predicted (GOLD 
stage II or higher) 29 at the last survey. Bronchial responsiveness to histamine {30 seconds 
method) was assessed in a random subsample of the total cohort as described 
previously 25• BHR at the last survey was expressed dichotomously, i.e. as a PC10 � 8 mg/ml 
histamine. 
Statistics 
Differences in prevalence of rare alleles of SNPs between subjects with and without COPD 
or BHR were tested with X2 test and logistic regression. Additionally, we performed all 
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mentioned ana lyses stratified accord ing to smoking habits (never and ever smokers), s ince 
we expected the SOD effects to depend on smoking habits. For 2 50D3 SNPs we were not 
ab le to estimate the odds ratios for COPD and BHR for the homozygous mutant genotype 
due to the lack of (Arg213Gly), or low (G(-4466)T, n=3) numbers of subjects. 
In order to d isentangle the phenotypes COPD and BHR, subjects were classified into 4 
phenotypic groups accord ing to the presence of COPD and/or BHR ( i .e . :  'COPD-/BHR-', 
'COPD-/BHR+', 'COPD+/BHR-' and 'COPD+/BHR+') .  Mu ltinomia l  logistic regression, 
adjusted for packyears of smoking, was performed for al l SNPs separately, with the 4 
phenotypic groups as dependent variable. These ana lyses a l lowed us to pred ict if subjects 
with certain  genotypes were more l ikely to develop a COPD phenotype or a BHR 
phenotype. 
Linear regression ana lysis (adj usted for sex, height, age and packyears of smoking) was 
used to test whether the FEV1 or VC level d iffers between SOD genotypes at the last 
survey. Linear Mixed Effect models from the statistical package R (version 1.9.1) 30 were 
used to estimate longitud ina l  changes in l u ng function in the tota l cohort as wel l  as in the 
ever and never smokers subgroups (see onl ine supplement for deta i ls) .  Haplotype ana lysis 
was performed with HAPSTAT (version 3.0) software 31'32 (see on l ine supplement for 
detai ls) . Remain ing statistical ana lyses were performed using SPSS (version 12.0 .1 for 
Windows; SPSS, Ch icago, I L) .  P va lues<0.05 were considered to be significant (tested 2-
s ided) .  
RESULTS 
Study population and distribution of SOD SNPs 
The study popu lation characteristics and genotype frequencies a re shown in  table 1 .  A l l  
SNPs were d istributed accord ing to Hardy Weinberg Equ i l ibrium  in  the tota l popu lat ion 
and were not correlated with each other ( r2<0.27 for any SNP pa ir) .  The Phe131Cys 
substitution in 50D3 was not present in our  cohort. We found  no homozygote mutants for 
the Arg213Gly SNP in 50D3 in our  popu lation .  We identified respectively 3 and 5 
haplotypes in 50D2 and 50D3 occurring with a frequency >1% in the total population 
(table 54 in the onl ine supplement). 
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Table 1:  Characteristics of the sample of the Vlagtwedde-Vlaardingen cohort at the last survey 
Total population Ever smokers* 
n=l,390 n=945 
Males, n (%) 7 14 {51.4) 610 {64.6) 
Age in years, median (range) 52 {3 5-7 9) 50 {3 5-7 9)  
Packyears of smoking, median (range) 8 .0 {0-262.2) 1 8.8 (0 -262.2) 
FEV1 % predicted, mean {SD) 92.6 {15.3 ) 90 .6 (15.5) 
VC % predicted, mean (SD) 10 1 .8 ( 1 4.5) 100 .2 ( 1 4.0 )  
FEVJVC %, mean (SD) 7 3 .9 {8.7 ) 7 2.4 {9.2) 
COPD- GOLD stage II or higher, n (%) 167 (12.4) 1 40 (15.3 ) 
BHR- PC10S8 mg/ml histamine, n (%)
9 1 90 {46.5) 141 {50 .4) 
Genotype frequency (%heterozygotes / %homozygotes mutant) :  
50D2 Ala1 6Val : 49.6/23 .8 49.8/23 .6 
5OD2 C57 7 4T: 29.3 /4.5 28.8/5.2 
5OD3 Ala40 Thr: 43 .5/1 1 .9 42.0 /1 2 . 1  
50D3 Arg21 3 Gly: 3 .8/0 .0 4.1/0 .0 
5OD3 G{-4466)T: 8.6/0 .2 8.9/0 .3 
*sub-population of the total population 
§BHR test performed on a random sub-group (n=40 9) of the total population (n=l,3 90 )  
SD = standard deviation; BHR  = bronchial hyperresponsiveness; COPD = Chronic Obstructive Pulmonary Disease; 
GOLD = Global Initiative for Chronic Obstructive Lung Disease; FEV1 = Forced Expiratory Volume in 1 second; VC = 
Vital Capacity; PC10 = the histamine concentration causing an FEV1 decrease of 10% or more from baseline 
SOD SNPs and the presence of COPD 
The 50D2 C5774 T SNP was significantly associated with COPD in the total population and 
in ever smokers (table 2 and table S2 in supplementary data}, but not in never smokers 
(data not shown}. No significant associations were found for the other investigated SNPs 
(table 2}. The haplotype containing the 50D2 C5774 T SNP was associated with a significant 
higher odds for the presence of COPD (recessive effect; OR=2.1 [95% Cl=l.1-4 .0], p=0.02}, 
compared to the wild type haplotype (table S4 in the online supplement}. 
SOD SNPs and the presence of BHR 
The 50D2 C5774 T SNP was significantly associated with the presence of BHR in the 
random sub-group of the total population (n=409/1,390; table 2 and table S3 in 
supplementary data}. Mutant homozygotes had a significantly higher risk of having BHR 
compared to wild types. The Ala16Val substitution in SOD2 was borderline significantly 
associated with BHR (p=0.07 for mutant vs. wild type homozygotes, table 2}. Stratified 
analyses according to smoking showed no significant associations for these two SNPs. The 
haplotype containing the mutant allele of C5774 T SNP was associated with an increased 
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risk for BHR as compared to the wild type haplotype (additive effect; OR=l.7 [1.1-2.6], 
p=0.01; table 54 in the online supplement). 
The Ala40Thr SNP was significantly associated with BHR only in never smokers (OR for the 
presence of BHR Ala/Thr vs. Ala/Ala=2.84 [1.08-7.4 8]; and Thr/Thr vs. Ala/Ala 14 .4 0 [2.92-
71.08] adjusted for FEV1% predicted), but not in the total population and in ever smokers 
(table 2). 
SOD SNPs and the presence of COPD and/or BHR phenotype 
Two hundred and thirteen subjects had neither COPD nor BHR (COPD-/BHR-), 154 subjects 
had COPD-/BHR+, 6 subjects COPD+/BHR-, and 3 6  subjects had COPD+/BHR+. Subjects 
with the homozygous Ala16Val substitution in 5002 were most likely to be COPD-/BHR+ 
(OR=2.l [1.1-3 .8] for the Val/Val variant compared to Ala/Ala), indicating that the Ala16Val 
substitution was predictive for the presence of BHR and not for COPD or their 
combination. Likewise, subjects with the homozygous mutant 5002 C5774 T SNP were 
most likely to have COPD-/BHR+ (OR=3 .l [1.03 -9.51] for the homozygous mutant variant 
compared to the wild type). Haplotype analysis revealed that the only haplotype 
containing mutant alleles of both 5002 SNPs showed significantly increased odds ratio (OR 
for an additive effect=l.7 [1.2-2.6], p=0.01) for BHR in non-COPD subjects as compared to 
wild type haplotype. The polymorphisms in the 5003 gene were not associated with any 
of the 4 phenotypic outcome groups. 
SOD SNPs and the level of FEV1 or VC 
No significant differences between the SOD genotypes in relation to the level of FEV1 or VC 
were observed in the total population (see table 55 in the online supplement) or in the 
never or ever smokers subgroups (data not shown). Subjects homozygous for the G(-
4 4 66)T SNP in 5003 had borderline significantly lower VC (B (SE)= -532.2 ml (292.0), 
p=0.068), but not FEV1, compared to the homozygous wild type group (fig. 1). There were 
no homozygous 5003 G(-4 4 66)T SNP subjects in the never smokers. In ever smokers that 
were homozygous for the 5003 G(-4 4 66)T SNP we observed an effect size (i.e. -53 3 .2 ml 
(301.2), p=0.077) that was similar to that in the total cohort. 
-123 
Chapter 6 - SOD genetics in COPD & BHR 
Table 2: Odds ratios (95% Cl) for the presence of  COPD respectively BHR, in the total population and in ever 
smokers, according to SOD SNPs 
SNP MAF OR [Cl] (heterozygotes vs. wild type) OR [Cl] (homozygotes vs. wild type) 
5002 COPD in total population (n=l,390) 
Ala1 6Val 0.49 1 .05 [0.66-1 .67 ] 0.94 [0.62-1 .41 ] 
C57 7 4T 0.21 0.7 4 [0.50-1 . 1 1 ]  1.98 [1.04-3.78]* 
5003 
Ala40Thr 0.3 4 1 .03 [0. 7 2-1 .49] 0.59 [0.3 1 -1 . 1 3 ]  
Arg21 3 Gly 0.02 1 .66 [0.7 7 -3 .58] -
G(-4466)T 0.05 1 .25 [0.7 2-2. 1 4] -
5002 COPD in ever smokers (n=945) 
Ala1 6Val 0.48 0.93 [0.59-1 .46] 1 . 1 9  [0.7 1 -1 .98] 
C57 7 4T 0.21 0.7 5 [0.48-1 . 1 2] 2.37 [1.20-4.67]* 
5003 
Ala40Thr 0.3 3 1 . 1 8  [0.7 0-1 .7 8] 0.68 [0.3 4-1 .3 6] 
Arg21 3 Gly 0.02 1 .96 [0.89-4.3 6] -
G(-4466)T 0.05 1 .45 [0.82-2.58] -
5002 BHR in total population (n=409) 
Ala1 6Val 0.45 1 .24 [0.7 4-2.08] 1 .80 [0.97 -3 . 3 5]¥  
C57 7 4T 0.20 1 . 1 4  [0.61 -2.1 3 ]  3.21 [1.03-10.03]* 
5003 
Ala40Thr 0.3 2 1.01  [0.63 -1 .62] 1 .3 1  [0.63 -2.7 1 ]  
Arg21 3 Gly 0.01 0.3 3 [0.07 -1 .52] -
G(-4466)T 0.04 0.80 [0.3 6-1 .80] -
5002 BHR in ever smokers (n=280) 
Ala1 6Val 0.46 1 .62 [0.87 -3 .03 ] 1 .61 [0.7 6-3 .41 ] 
C57 7 4T 0.1 9 0.95 [0.54-1 .69] 2.97 [0.81 -1 0.98]§ 
5003 
Ala40Thr 0.3 2 0.67 [0.3 8-1 .21 ] 0.57 [0.24-1 .3 6] 
Arg21 3 Gly 0.01 0.48 [0.09-2.64] -
G(-4466)T 0.04 0.64 [0.25-1 .63 ] -
Logistic regression analysis with OR for COPD adjusted for packyears, and OR for BHR adjusted for packyears and 
FEV1% predicted. Significant associations are depicted in bold. 
*p<0.05 
¥p=0.07 
§p=0. 1 0 
BHR = bronchial hyperresponsiveness; SNP = single nucleotide polymorphism; MAF = minor allele frequency in 
the investigated group; OR = odds ratio; Cl = confidence interval; COPD = Chronic Obstructive Pulmonary Disease; 
SOD = Su peroxide Dismutase 
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SOD SNPs and longitudinal change in FEV1 
The annual FEV1 decline was similar in all genotype subgroups of the investigated SNPs 
{see table 56 in the online supplement}. Stratification according to smoking habits 
revealed that the 50D3 Arg213Gly substitution was associated with slower FEV1 decline in 
never smokers, e.g. 9.3 ml less decline per year in carriers of the Arg/Gly genotype while 
compared to the wild type {fig. 2}. The other SNPs were not associated with excess FEV1 
decline in stratified analyses. 
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Figure 2 .  Adjusted means for the annual change in FEV1 for the 50D3 Arg213 Gly genotypes in the total 
population and according to smoking habits 
10 Total cohort 
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FEV1 = Forced Expiratory Volume in 1 second; SOD = Superoxide Dismutase; Cl = Confidence Interval 
DISCUSSION 
Of all human tissues, the lungs are most directly and particularly exposed to noxious free 
radicals. Tobacco smoke and environmental air pollution are the major sources of these 
particles. Therefore, the redox balance regulation can be an important factor for the 
development of bronchial hyperresponsiveness, excess decline in lung function, and 
development of COPD. We showed that 50D2, containing the mutant allele of the C5774 T 
SNP, is a risk factor for bronchial hyperresponsiveness in the general population. 
Exclusively in subjects who had smoked, COPD was more prevalent in carriers of two 
copies of this mutant allele compared to wild type carriers. The 50D3 Arg213Gly 
substitution, that has previously been shown to be protective for COPD 18'21, was 
associated with slower FEV1 decline in never smokers only. Additionally our study confirms 
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a recently observed negative association of the G{-4 4 66}T 5003 SNP with lung VC level in 
the general population 22. 
Our finding is of interest since 5OD2 dysfunction and inactivation has been recently 
described ex vivo in bronchial epithelial cells derived from airways of asthmatic patients 9• 
This confirms the importance of 5OD2 in lung homeostasis where reactive oxygen species 
can impair epithelial ciliary function and increase airway smooth muscle contraction in 
response to histamine 4, which may contribute to the development of BHR. Our data 
suggest that this may also be the case in COPD. 
We found the mutant homozygosity of the 5002 SNP {C5774 T), located in intron 3 ,  to be a 
risk factor for the presence of COPD and BHR in the total population at the last survey. 
Although the role of SNPs localized in intrans is not clear yet, it is known that they may 
affect alternative splicing processes 33'34 which result in different aminoacid sequences in 
mature proteins. The main difference between the 5002 isoforms is the presence of an 
additional exon within the third intron 35, but the implication with respect to putative 
differences in activity between both isoforms is yet unknown. It is indeed confirmed that 
SOD2 isoforms formation may depend on genetic variations as this has been shown in 
vitro for a polymorphism {single base pair deletion) that is prevalent in African-Americans 
36
• This study concluded however that other {cis-acting) factors are necessary for switching 
between two isoforms in vivo. Thus it is also possible that C5774 T SNP is in high linkage 
disequilibrium with another {functional) SNP, which is actually responsible for the 
associations that we observed. 
Theoretically, the Ala16Val substitution could be of importance as well, since in vitro 
studies have shown impaired transport of Val16-SOD2 to the mitochondrion 12'13, and 
lower mitochondrial 5OD2 activity in leukocytes for the Val/Val genotype as compared to 
the other genotypes 14• We did not find an association of the Ala16Val SNP with either the 
presence of COPD or with lung function decline, which is in concordance with results of 
two previous studies performed 18'19• 
Bronchial responsiveness may be modulated by superoxide anion production 7 and BHR is 
a known risk factor for COPD development 5'6• Therefore impaired superoxide radical 
detoxification, caused by loss of SOD2 function, may increase the level of BHR and affect 
the development of COPD. Remarkably, subjects with homozygous variants of the 5002 
Ala16Val substitution or the 5002 C5774 T SNP showed increased odds ratios for having 
'pure BHR', which suggests it is indeed the phenotype BHR that is associated with these 
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50D2 SNPs, and the relation that we have found between C5774 T SNP and COPD is driven 
by the association with BHR. Out of 2 mutant 50D2 haplotypes only the one containing 
the mutant allele of the C5774 T SNP was associated with increased risk for BHR as 
compared to the wild type haplotype, which implies that this SNP, rather than Ala16Val 
substitution, is associated with the presence of BHR. 
Juul and colleagues 21 have shown prospectively and cross-sectionally a lower risk for 
COPD for the 50D3 Arg213Gly SNP heterozygotes while compared to the wild type. This 
has been confirmed by another cross-sectional study 18• The underlying mechanism of 
these associations may be explained by reduced proteolytic processing of mutated SOD3 
protein 37 and higher SOD3 level in blood plasma due to lower affinity to heparan sulphate 
in the extracellular matrix 20'38 • We additionally found that the protective effect of this SN P 
on longitudinal FEV1 change appears in never smokers. Therefore we hypothesize that 
there are other antioxidant-related genetic factors that additionally contribute to the FEV1 
change in smokers. Recently Dahl and colleagues reported that the G{-4 4 66)T {rs8192288) 
SNP, and particularly the homozygote mutant genotype, in 50D3 constitutes a risk factor 
for a low level of Forced Vital Capacity and more frequent COPD hospitalization in the 
Copenhagen City Heart Study 22• Interestingly in our study the same SNP was borderline 
significantly associated with low lung VC level, with a relatively large effect size. However 
we identified only 3 subjects carrying the risk {homozygous mutant) genotype and 
therefore we were not able to detect possible associations with FEV1 decline or estimate 
the odds ratio for COPD presence. 
There are some limitations to the study. It is conceivable that the low prevalence of the 
C5774 T SNP in 50D2 and especially of G{-4 4 66)T and Arg213 Gly in 50D3 may have 
negatively affected the power of our study. Therefore, we may have been unable to 
detect associations with BHR, FEV1 decline or with COPD in the general population or in 
ever smokers. Another study limitation is the fact that the Vlagtwedde-Vlaardingen cohort 
is a unique prospective study with measurements of both BHR and FEV1 at several time 
points over 25 years. Therefore we are not able to check for replication of our findings in 
another prospective cohort in order to reduce type I error {false positives). We 
additionally did not correct our p values for multiple comparisons. 
In summary, we conclude that SOD2 is an antioxidant enzyme in which variations in DNA 
sequence can play a role in the development of BHR. By showing the protective effect of 
the Arg213Gly SNP in 50D3 on the course of FEV1 in never smokers we provide another 
piece of the puzzle on the role of this substitution in pulmonary disease. Additionally, we 
- 128 -
Chapter 6 - SOD genetics in COPD & BHR 
provide supportive evidence for an association of G(-4 4 66)T (rs8192288) 50D3 SNP with 
the level of VC in the general population. Further studies are needed to confirm the 
possible role of SOD SNPs in COPD and BHR, and additional functional studies are 
warranted. 
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Online Data Supplement 
METHODS 
Subjects 
From all subjects information was collected on respiratory symptoms, smoking status, age, 
and sex by the Dutch version of the British Medical Council standardized questionnaire. 
Standardized FEV1 and VC (measured by slow inspiratory manoeuvre) measurements were 
performed every 3 years using a water-sealed spirometer (Lode Instruments, the 
Netherlands) according to the European Respiratory Society guidelines 1.  
Subjects with FEV1 lower than 1.5 L and those who could not perform a forced expiratory 
manoeuvre were excluded from responsiveness testing, as were subjects suffering from 
heart disease, hypertension, or acute respiratory infections. 
DNA extraction and genotyping 
Neutrophil depots from centrifuged blood samples were collected and stored at -20 °C. 
DNA was extracted with a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany) and 
checked for purity and concentration with a NanoDrop ND-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Wilmington, DE). We genotyped DNA 
samples of those subjects with more than 1,500 ng of isolated DNA available (n = 1,390). 
The G(-4 4 66)T (rs8192288) in 5003 was genotyped by K-Bioscience Ltd (Hoddesdon, UK) 
using their patent-protected competitive allele specific PCR system (KASPar). All the other 
SNPs were genotyped using Applied Biosystems TaqMan® SNP Genotyping Assays 
(Nieuwekerk aan de IJssel, The Netherlands) as described previously 2• Sequences of 
primers and probes used for genotyping are shown in table Sl. 
Statistics 
Linear Mixed Effects (LME) models were used to investigate the effect of 500s SNPs on 
the annual decline in FEV1 . Time was defined as the time in years relative to the first FEV1 
measurement and corresponding age. FEV1 measurements were included from the age of 
30 years, because an individual's maximal achieved lung function is assumed to have been 
reached before that age and lung function is considered to be either in the plateau or 
decline phase 3• Variables included in the model were sex, packyears of smoking, and the 
first available FEV1 after age 30 years and their interaction with time. 
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Haplotype analysis was performed with HAPSTAT (version 3 .0) software 4'5 • SOD 
haplotypes were analyzed cross-sectionally for additive, recessive and dominant effects on 
the BHR or COPD presence with the most prevalent haplotype set as a reference. 
TABLES 
Table S1: Sequences of primers and probes 
SNP Primers Probe 1 * Probe 2* 
50D2 Ala16Val rs4880 Applied Biosystems assay ID :  C 870 90 53 10 
Forward: 
50D2 ATGCCTGTMTCCCAGCTACTTG 
CTGAGACACAft.GM TT TGAGACAC§AGM TT 
C57 7 4T rs2842958 Reverse: 
CCTCCGCCTTTCAGGTTCAT 
Forward: 











50D3 Arg213 Gly rsl 7 99895 Applied Biosystems assay I D: C 230 7 50 6  10 
50D3 
Genotyped by the K-Bioscience company (UK) 
G(-4466)T rs8192288 
*Underlined bases indicate specific polymorphic site recognized by each probe 
Table S2: COPD prevalence in selected subgroups 
COPD COPD 
SNP MAF Genotype total population, P (2 df)* ever smokers group, P (Z df)* 
n [%f n {%f 
SODZ 
Ala/Ala 44 [12.S] 3 6  [15.1] 
rs4880 ,  Ala16Val 0 .49 Ala/Val 7 5  [11.7 ] 0 .7 4  6 1  [13 .9] 0 .41 
Val/Val 42 [13 .4] 3 8  [17 .9] 
C/C 110 [12.9] 92 [15.6] 
rs2842958, C57 7 4T 0 .21 C/T 3 8  [9.6] 0.01 3 1  [12.1] 0.008 
T/T 14 [23 .0 ]  14 [29.8] 
SOD3 
Ala/Ala 7 2  [12.8] 58 [14.6] 
rs253 6512, Ala58Thr 0 .3 4  Ala/Thr 68 [12.4] 0 .27 58 [16.2] 0 . 3 4  
Thr/Thr 12 [8.0 ]  11 [10 .5] 
rsl 7 99895, Arg213 Gly 0 .0 2  
Arg/Arg 154 [12.0 ]  
0 .20 
128 [14.7 ] 
0 .17 
Arg/Gly 9 [17 .6] 9 [23 . 1] 
G/G 148 [12.4] 122 [15.0 ]  
rs8192288, G{-4466)T 0 .0 5  G/T 18 [15.3 ] 0 .55 17 [20 .5] 0.3 2 
T/T 0 [O.O] 0 [O.O] 
§ within each genotype 
*in 12 tests with all genotypes (2 df); 1 df for 50D3 Arg213 Gly substitution 
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Table S3: BHR prevalence in selected subgroups 
SNP MAF Genotype BHR P (2 df)* BHR P (2 df)* 
total population, ever smokers 
n [%l group, 
n [%l 
S0D2 
0.45 Ala/Ala 48 [40.0] 3 4  [42.S] 
rs4880 , Ala1 6Val Ala/Val 88 [46.8] 0. 1 6  7 2  [54.5] 0.21 
Val/Val 47 [53 .4] 3 2  [53 .3 ] 
C/C 1 1 9  [44.6] 93 [49.7 ] 
rs2842958, C57 7 4T 0.20 C/T 52 [48.1 ] 0.07 3 4  [50.7 ] 0.29 
T/T 1 3  [7 2.2] 1 0  [7 1.4] 
S0D3 
Ala/Ala 84 [46.9] 7 0  [54.7 ] 
rs253 651 2, Ala40Thr 0.3 2  Ala/Thr 7 4  [45.1 ] 0.89 51 [49.0] 0.3 3 
Thr/Thr 21 [48.8] 1 3  [40.6] 
rs1 7 99895, Arg21 3 Gly 0.01  
Arg/Arg 1 84 [46.7 ] 
0.23 
1 3 5  [50.2] 
0.7 2 
Arg/Gly 3 [27 .3 ] 3 [42.9] 
G/G 1 7 5 [47.4] 1 3 0  [51 .6] 
rs8 1 92288, G(-4466)T 0.04 G/T 1 2  [3 7 .5] 0.28 9 [3 7 .5] 0.21 
T/T - -
§ within each genotype 
*in .:\. 2 tests with all genotypes (2 df); 1 df for 5003 Arg21 3 Gly and G(-4466)T substitutions 
MAF = minor allele frequency in the population tested for BHR; SOD = Superoxide Dismutase; BHR  = bronchial 
hyperresponsiveness; SNP = single nucleotide polymorphism 
Table S4: Additive effects of SOD haplotypes on the presence of COPD and BHR in the total population 
COPD BHR 
Haplotype§ Frequency [%] 
OR 95% CI p OR 95% CI p 
S0D2 
1 -0 28.5 0.97 0.7 2-1 .3 0  0.83 1 . 1 7  0.81 -1.7 0 0.40 
1 -1 1 9.9 1.05 0.7 8-1.41 0.7 5* 1 .7 2  1 . 1 4-2.59 0.01 
S0D3 
1 -0-0 27 .3 0.82 0.61 -1 . 1 0 0. 1 7 1 .22 0.86-1 . 7 4 0.26 
1 -0-1 4.4 1 .06 0.61 -1 .84 0.83 0.89 0.3 7 -2. 1 0 0.7 9  
1 -1 -0 1 .8 1.54 0.7 2-3 .3 0 0.28 0.3 7  0.0 8-1 . 7 5 0.21 
Haplotypes were analyzed in one model with the wild type haplotype (for both 5002 and 5003 wild type 
haplotype (frequency of 51 .6% and 66. 1% respectively) contains wild type allele of all SNPs) set as a reference. 
All analyses were adjusted for packyears smoked and additionally for FEV 1 % of predicted in the BHR analysis. 
§ 0/1 corresponds to the major/minor allele of SNPs in the following order: 
5002: Ala1 6Val - C57 7 4T 
5003: Ala40Thr - Arg21 3 Gly - G{-4466)T 
*for recessive effect: OR=2.l 95% Cl=l.1 -4.0, p=0.02 
FEV1 = Forced Expiratory Volume in 1 second; SOD = Superoxide Dismutase; Cl = confidence interval, OR=Odds 
Ratio 
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Table SS: Linear regression analysis on the level of FEV1 and VC 
FEV1 level in ml as compared to wild type VC level in ml as compared to wild type 
SNP MAF 
[95% Cl] [95% CI] 
Heterozygotes p 
Homozygotes 

























C57 7 4T [-7 .4- 100 .1 ] (-1 65.1 - 68.7 ] [-45.4 - 7 5.6] [-84.7 - 1 7 8.6] 
50D3 
rs253 651 2, 






0 .3 7  
1 9.7 
0 .67 
Ala40 Thr [-7 2.3 - 3 2.6] (-85.2 - 7 6.1 ] (-86.3 - 3 1 .8] (-7 1 .1 - 1 10 .S] 
rs1 7 99895, 
0 .0 2  
-61 .5 
0 .3 4  
-1 7 .0 
0 .81  
Arg21 3 Gly (-1 88.1 - 65.1 ] 
-
(-1 59.1 -1 25.1 ] 
- -
rs81 92288, 
0 .0 5  
-54.8 
0 .21 
-1 93 .4 
0 .46 
-3 3 .1 
0 .50 
-53 2.4 
0 .0 7  
G(-4466)T [-1 40 .7 - 3 1 .0 ]  (-70 6.9 - 3 20 .0 ]  (-1 28.9 - 62.6] (-1 10 5.2 - 40 .4] 
All analyses were adjusted for height, sex, age and packyears smoked. 
FEV1 = Forced Expiratory Volume in 1 second; MAF = minor allele frequency; SOD = Superoxide Dismutase; FEV1 = 
Forced Expiratory Volume in 1 second; SNP = single nucleotide polymorphism; Cl = confidence interval 
Table S6: LME models analysis on FEV1 decline 
Excess annual Excess annual FEVi 
SNP MAF 




heterozygotes, homozygotes mutant 
ml/yr [95% Cl]* ml/yr [95% Cl}* 
50D2 
rs4880 , Ala1 6Val 0 .49 
-0 .96 [-3 .26 -
0 .42 -0 .23 [-2.93 - 2.47 ] 0 .87 
1 .3 4] 
rs2842958, C57 7 4T 0 .2 1  0 .91 (-1 .22 - 3 .0 4] 0 .40 2.66 (-1 .84 - 7 .1 6] 0 .25 
50D3 
rs253 651 2, Ala40 Thr 0 .3 4  0 .0 5  (-2.0 5  - 2.1 5] 0 .96 0 .9 1  (-2.96 - 4.1 6] 0 .58 
rsl 7 99895, Arg21 3 Gly 0 .0 2  4.28 (-1 .40 - 9.96] 0 .1 4  - -
rs81 92288, G(-4466)T 0 .0 5  
-0 .97 (-4.68 -
0 .6 1  -1 1 .67 (-3 6.69 - 1 3 .3 5] 0 .3 6  
2.7 4] 
Negative values indicate faster FEV1 decline 
*compared to homozygotes wild type (reference) 
LME = Linear mixed effect; MAF = minor allele frequency; SOD = Superoxide Dismutase; FEV 1 = Forced Expiratory 
Volume in 1 second; SNP = single nucleotide polymorphism; Cl = confidence interval 
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To the Editors: 
Chappell et al. 1 recently found that several single nucleotide polymorphisms (SNPs} in the 
glutamate cysteine ligase (catalytic subunit; GCLC} and epoxide hydrolase 1 (EPHX1} do not 
associate with the presence or severity of chronic obstructive pulmonary disease (COPD}. 
We have previously shown in two independent population-based cohorts that the 
functional polymorphism rs17883901 and the trinucleotide GAG repeat in GCLC form 
unique genotype combinations that are associated with lower lung function in interaction 
with smoking 2• Chappell et al. did not study the latter variation in GCLC, nor the 
interaction between SNPs and smoking in relation to COPD severity, which is of special 
interest given the in vivo role of GCLC. They additionally studied SNPs in EPHX1, including 
nonsynonymous SNPs (nsSNPs} Tyr113 His and His139Arg that previously provided both 
positive and negative associations with COPD across studies and races 1'3-7. We aimed to 
extend these findings by showing the effects of EPHX1 SNPs on the level and change of 
forced expiratory volume in one second (FEV1} in the general population, and additionally 
investigated whether EPHX1 SNPs smoking interactions are associated with both 
outcomes, as was the case with GCLC. 
We genotyped five SNPs in EPHX1 (3 SNPs tagging the 5 kb promoter region: rs3753 658, 
rs10753 4 10 and rs2854 4 50, and 2 nsSNPs: rs105174 0 (Tyr113 His} and rs223 4922 
(His139Arg}} in a random sub-sample (n=l,152, tables 1 and 2} of the prospective, 
population-based Doetinchem cohort with DNA and spirometry available (n=3,224 } 2• 
Taqman assays (Applied Biosystems, Niewekerk aan de ljssel, the Netherlands} were used 
to genotype 2 nsSNPs 2• Promoter SNPs were genotyped by K-Bioscience Ltd (Hoddesdon, 
UK} with patent protected KASPar technology. SNPs and haplotypes were analyzed in 
additive, recessive and dominant models for their effect on: 
1. FEV1 level at the survey of 1998-2002 (table 1}, 
2. FEV1 change during 10-yr follow-up (surveys 1993 -1997 (n=l,152}, 1998-2002 
(n=l,152}, and 2003 -2007 (n=811}}, with linear mixed effect models (S-PLUS, 
version 7.0, TIBCO, Palo Alto, CA, USA} for SNPs 2• For data of the promoter and 
exon regions, haplotypes (>5% frequency} were compared to the remaining 
pooled haplotypes using linear regression analysis (haplo.stats, version 1.3 .1} 8 in 
the R environment 9, with FEV1 change defined using first and last FEV1 • 
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Table 1: Doetinchem cohort characteristics 
Time of the visit, years 1 999-200 3 
Total duration of follow-up (years)/ lO
R / 3 (2-3 ) 
/number of visits (median (range)) 
Males, n (%) 541 (47 .0 )  
Age in years, median (range) 49.9 {3 1 .2-70 .9) 
Height in cm, mean (SD) 1 7 2.6 (9.1 ) 
Smokers/Ex-smokers, n {%) 30 8 (26.7 ) / 47 3 {41 . 1 ) 
Packyears smoked, median (range): 
Total cohort 5.0 (0 .0 -84.0 ) 
Ever-smokers 1 2.5 (0 .00 4-84.0 ) 
FEV1 in liters, mean (SD) 3 .3 9  (0 .7 9) 
FEV1 change in ml/year, mean (SD) -26.2 {3 3 .4) 
Total EPHX1 SNPs call rate (%) 98.5 
#: applicable for the 70 .4% of subjects who additionally participated in the third survey (200 3 -200 7 ); the 
remainder of the cohort participated in the first ( 1 993-1 997 ) and the second (1 999-200 3 )  surveys only. 
FEV1= Forced Expiratory Volume in one second; EPHXl=epoxide hydrolase 1; SNP=Single Nucleotide 
Polymorphism 
Since EPHXl is a phase II detoxification enzyme and nsSNPs in EPHX1 are functional 10, 
these were tested statistically with an interaction term, i.e. pack-yrs x genotype/genotype 
combination/haplotype {defined as: slow {His113-His139+His113-Arg139 pooled); normal 
{Tyr113 -His139}; and fast {Tyr113 -Arg139)}. Interaction analysis of haplotype or genotype 
combinations contained two dummy variables and haplotype or genotype combinations 
were compared with each other. 
The study provided 80% power for detecting 158 ml difference in FEV1 level and 7 ml·y(
1 
in FEV1 change for the lowest prevalent SNP (i.e. rs107534 10} in an additive or dominant 
model {a=0.05, tested two-sided). 
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Table 2: Epoxide hydrolase 1 genotype characteristics 
Genotype characteristics 
rs10 7 53 410 
rs2854450 
rs3 7 53 658 
rs10 51 7 40 (Tyr1 1 3 His) 
rs223 4922 (His1 3 9Arg) 
Slow, n (%),i 
Normal, n (%)11 
Fast, n (%)11 
Heterozygotes n (%) 
240 (21 .2) 
3 60 (3 2.0 ) 
265 (23 .4) 
472 (41.3 ) 
3 7 7  (3 2.8) 
Homozygotes mutant n (%) MAF HWE test p value" 
1 3  ( 1 .2) 1 1.8 0.45 
42 (3.7) 1 9.8 0.73 
22 ( 1 .9) 1 3.6 0 .82 
83 (7.3 ) 27.9 0 .3 7  
55 (4.8) 21.2 0 .55 
40 2 (3 5.3 ) 
51 3 (45.0 ) 
225 ( 1 9.7 ) 
": for 1 degree of freedom Chi-squared test comparing the observed genotypes distribution with the expected as 
derived from the allele frequencies; ,i :  Tyr1 1 3 H is and Hisl3 9Arg genotype combinations defined as previously 
described ( 1 , 5, 6). 
HWE=Hardy Weinberg equilibrium; MAF=Minor Allele Frequency 
In our study all EPHX1 SNPs were non-correlated (r2<0.05 for any SNP pair}. Both FEV1 
level and FEV1 change were not significantly associated with any of the SNPs in any model 
(table 3 }  nor were they different between slow, normal and fast combinations of EPHX1 
genotypes. Four prevalent haplotypes were observed within the promoter (frequencies 
55.2%, 19.8%, 13.3% and 11.5%} and coding region (slow: 27.8% (21.9%+5.9%}; normal : 
56.8%; fast : 15.4%}, and none were significantly associated with FEV1 level or change. 
We observed no significant interactions between pack-yrs and nsSNPs or their 
combinations for either level or change in FEV1, nor was there a significant interaction 
with EPHX1 haplotypes and FEV1 level. The normal haplotype interacted with pack-yrs, 
providing 0.5 ml/year less FEV1 decline per pack-yr (SE=0.2, p=0.01} than the slow 
haplotypes pool in a dominant model (p>0.3 1  for recessive or additive model}. 
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Table 3: Effects of EPHXl genotypes on the level and change of forced expiratory volume in one second FEV 1 in 
the Doetinchem cohort• 
FEV1 level [ml]'II FEV1 change [ml/yrt 
SNP Heterozygotes Homozygotes mutant Heterozygotes Homozygotes mutant 
B 95% CI B 95% CI p 95% CI p 95% CI 
rs10 7 53 410 42.9 -24.4 - 1 10 .2 1 1 .4 -244.3 - 267 .0 0 .7 -3 .9 - 5.3 -4.2 -21 . 1 - 1 2.8 
rs2854450 43 . 1  - 1 6.1 - 10 2.4 -80 . 1 -224.5 - 64.4 3 .0 -1 . 1 - 7 .0 -0 .9 - 10 . 7  - 8.9 
rs3 7 53 658 -22.2 -86.9 - 42.5 -47 .2 -253 .6 - 1 59.2 -0 .8 -5.3 - 3 .7 -9.8 -23 .8 - 4.3 
rs10 51 7 40 
-1 3 .7 -70 .6 - 43 .1 -64.7 -1 7 2.2 - 42.8 -0 .4 -4.3 - 3 .5 -1 .2 -8.7 - 6.2 
(Tyr1 1 3 His) 
rs223 4922 
-20 .8 -7 9.6 - 3 8.1 -22.0 -1 50 .0 - 10 5.9 2.5 -1 .5 - 6.5 2.7 -6.0 - 1 1 .5 
(His1 3 9Arg) 
All between-genotype differences, including comparison of heterozygotes and homozygote mutant groups, were 
not significant (p>0 . 1 5  for both outcomes). n: n=l, 1 52; 'II: estimated for heterozygous and homozygous mutant 
genotypes as compared with wild-types using linear regression adjusted for age, sex, height and pack-yrs 
smoked; + : estimated for heterozygous and homozygous mutant genotypes as compared with wildtypes, using 
linear mixed effect model adjusted for age, sex, initial FEV1 level, pack-yrs smoked and their interaction with 
time. 
FEV1= Forced Expiratory volume in one second; EPHXl=epoxide hydrolase 1; SNP=Single Nucleotide 
Polymorphism; Cl=Confidence Interval 
We found no effect of genetic variations in EPHX1 on the level or change of FEV1 in the 
general population. Furthermore, there was no significant interaction between functional 
nsSNPs and pack-yrs in either outcome studied. Given the high number of tests performed 
(n=l08}, the single significant association of EPHX1 haplotype with FEV1 decline in 
interaction with smoking may be a spurious observation, and this needs replication. Our 
observations support and extend the previously reported negative results of Chappell et 
al. 1. Since a lower forced expiratory volume in one second level and accelerated forced 
expiratory volume in one second decline are both important indices of chronic obstructive 
pulmonary disease, EPHX1 does not likely play a role in the development of chronic 
obstructive pulmonary disease in Caucasians. 
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We provide supportive evidence for a role of the promoter polymorphism (GT-repeat} in 
heme oxygenase 1 (HO-1} in relation to lung function loss over time. This observation that 
has been made by Guenegou and colleagues in Caucasian population, and a call for 
replication of these results in a larger and independent cohort was made 1 • The relevance 
of H0-1 has been widely acknowledged 2• Chronic obstructive pulmonary disease (COPD} -
often a consequence of abnormally accelerated lung function decline 3 - has been widely 
studied in relation to H0-1 promoter GT-repeat, using a case control approach. So far 
these studies provided contradictory findings 4-7• 
We genotyped the H0-1 GT-repeat in our Dutch general population-based Vlagtwedde­
Vlaardingen cohort (n=l390, age median (range} : 52 (3 5-79}, 51% males, packyears 
median (range} : 9 (0-262}, 67.9% ever smokers}, that was followed for 25 years {1965-
1990} with forced expiratory volume in 1 s (FEV1} measurements every 3 years. We 
analyzed effects of this repeat on FEV1 change using linear mixed effect models as 
described previously 8• H0-1 GT-repeat polymorphism was genotyped using MegaBACE 
1000 (GE Healthcare, UK} system and alleles were defined as published previously (i.e. 
short (S}, medium (M}, long (L}} 1. We additionally extended our study to a separate 
analysis of all prevalent H0-1 genotypes, that is S/S (n=183 }, S/M (n=571}, S/L (n=70}, 
M/M (n=456}, and M/L+L/L genotypes pooled together (n=93 +7}. 
We found the M/L+L/L genotype-pool to constitute a risk factor for accelerated FEV1 
decline in the total population compared with any other genotype. The mean adjusted 
change in FEV1 for the M/L+L/L genotype-pool was -24.2 ml/year. S/L, S/S, S/M and M/M 
genotypes, provided respectively 6.3 (SE=2.8, p=0.025}, 3 .6 (SE=2.3 , p=0.120} 5.7 (SE=2.0, 
p=0.005}, and 4.9 (SE=2.0, p=0.017} ml/year less decline compared to the M/L+L/L pool. 
Since mentioned associations remained significant in ever-smokers and furthermore in 
heavy-smokers (packyears smoked>9; except for the M/M genotype where p=0.08} 
exclusively, we confirm an existence of the interaction between this polymorphism and 
smoking as observed previously 1. 
To our knowledge this is the first successful replication of a candidate polymorphism in 
relation to FEV1 decline in the general population. We additionally narrow the rik H0-1 
genotypes to the M/L+L/L pool. Furthermore, we confirm that GT-repeat variation in the 
H0-1 plays a particular role in smokers, which likely is related to the unique role of this 
gene in regulation of smoking-induced oxidative stress 2 • We believe that further studies 
on the H0-1 GT-repeat will provide more insight in the role of this gene in lung function 
loss and eventually in the pathogenesis of COPD. 
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ABSTRACT 
The level and course of lung function are genetically determined. A genome wide 
association study performed on the Framingham Heart Study identified Asn14 2Asp 
substitution in the Glutathione 5-Transferase Omega-2 (GSTO2) as a risk factor for a lower 
level of lung function in a general population. We aimed to replicate and extend this 
finding by investigating other polymorphisms in this region and study gene by smoking 
interactions. 
We genotyped seven Single Nucleotide Polymorphisms, tagging a cluster containing 
GSTOl and GST02 in the prospective population-based Doetinchem cohort (n=l,152). 
Effects of SNPs and haplotypes on lung function level and course were assessed with 
linear regression and linear mixed effect models. 
Two variations in the cluster, i.e. a minor haplotype and a Glu208Lys substitution in GSTOl 
were significantly (respectively p=0.031 and p=0.009 for an additive model) associated 
with lower FVC level. Additionally, Glu208Lys substitution associated with lower FEV1 level 
in heavy smokers exclusively. The Asn14 2Asp in GST02 was associated with lower FVC 
level in a recessive model (p=0.054 ). The major haplotype of the GST01/GST02 cluster 
was associated with slower FEV1 decline (p=0.04 9). 
This study suggests that variations in the GST01/GST02 cluster associate with the level 
and course of lung function in a general population. 
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INTRODUCTION 
Lung function is a heritable complex trait, determined by multiple genetic and 
environmental components and their mutual interactions. The recent genome wide 
association (GWA) study conducted in the Framingham Heart Study identified a 
nonsynonymous (Asn14 2Asp) Single Nucleotide Polymorphism (SNP) in the gene 
Glutathione 5-Transferase Omega-2 (GST02) as a risk factor for a lower mean level of 
Forced Expiratory Volume in 1 second (FEV1} and Forced Vital Capacity (FVC} 
1
. Another 
member of the same enzyme family, Glutathione S-Transferase Omega-1 (GSTOl} has 
been found in bronchoalveolar lavage fluid as well as in alveolar macrophages, especially 
in patients with very severe Chronic Obstructive Pulmonary Disease (COPD)2. Interestingly, 
GSTOl levels in induced sputum and lung homogenates are lower in COPD patients than in 
control smokers and non-smokers, which might be partially explained by decreased levels 
of alveolar macrophages in patients with severe COPD 2• Both GSTOl and GSTO2 possess 
thioltransferase activity and reduce dehydroascorbate and mono-/dimethylarsonate3,4. 
Reduction of the latter molecules is a rate-limiting step in the metabolism of arsenic, 
which is a toxic compound present also in tobacco smoke 3'5 • Therefore GSTOs are 
plausible candidates for genetic studies concerning lung function while above findings in 
the literature suggest a role for interaction with environmental factors like cigarette 
smoking. 
GST01 and GST02 are located adjacently on chromosome 10 and mRNA of both genes is 
present in the lung 6• Of interest, SNPs in GSTOs have functional significance. In the GST01 
the AGG deletion in the 5' splice donor site for exon 4 (completely tagged by rsll5094 38  
(Glu208Lys) SNP) was linked to an increased thioltransferase activity and lower heat 
GSTOl stability 6 while Ala14 0Asp substitution decreased activity of the enzyme 7• GSTO2 
variants Asn14 2Asp and the very rare Leul58 1 1e were associated with lower GSTO2 
expression in COS-1 cells in vitro 8• 
The current study performed in a prospective, population-based Dutch cohort set out to 
replicate the effect of polymorphic loci in the GST01/GST02 cluster on the level of lung 
function and investigated additional effects on the longitudinal course of lung function in 
the general population. It also aimed to assess whether these effects are modified by 
smoking. 
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METHODS 
Subjects 
Subjects from the Doetinchem cohort study 9, a prospective part of the larger MORGEN 
study 10, were included. A sub-sample (n=l,152, table 1) was randomly selected from the 
total cohort with spirometry tests and DNA available (n=3 ,224 ) as described previously 11• 
Between 1994 and 2007 subjects were studied for prebronchodilator FEV1 and FVC three 
times with 5-year intervals according to the European Respiratory Society (ERS) guidelines 
12• Maneuvers were performed with a heated pneumotachograph (Jaeger, Germany). 
Selection of tagging SNPs and genotyping 
We selected 7 SNPs tagging the whole cluster of GSTOl and GST02 (including 5kb regions 
flanking 5' end of GSTOl and 3 '  end of GST02) with an r2 threshold of 0 .8 and a minimum 
minor allele frequency of 1% for the Caucasian population (HapMap release 23a). All SNPs 
were genotyped by K-Bioscience (Hoddesdon, UK) using their patent protectep KASPar 
technology. 
Statistics 
Variations in the GST01/GST02 cluster were analyzed in general (heterozygotes and 
homozygotes mutant compared to homozygotes wild type), additive, recessive and 
dominant models for their effect on: 
FEV1 and FVC level at the survey of 1998-2002 using linear regression adjusted for 
age, sex, height and packyears smoked 
FEV1 decline during 10-year follow-up (surveys 1993-1997 (n=l,152), 1998-2002 
(n=l,152), and 2003-2007 (n=811)), with linear mixed effect (LME) models adjusted 
for sex, packyears smoked, age and FEV1 level at baseline and their interaction with 
time (defined in relation to age at baseline) 
Significant genetic effects and effects of functional SNPs were further tested for their 
interaction with smoking. The following interaction terms were considered: 
SNP by ever/never smoking status in the total population with adjustment for ever 
smoking status and genotypes and no adjustment for packyears smoked 
SNP by packyears smoked within ever smokers with adjustment for packyears 
smoked and genotypes 
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Table 1: Characteristics of the Doetinchem cohort (n=l,152) at the second survey 
Males, n {%) 541 (47.0) 
Age in years, median (range) 49.9 (31.2-70.9) 
Smokers/Ex-smokers, n (%) 308 (26.7) / 473 {41.1) 
Packyears smoked, median (range): 
Total cohort 5.0 (0.0-84.0) 
Ever-smokers 12.5 (0.004-84.0) 
FEV1 in liters, mean (SD) 3 .39 (0.79) 
FVC in l iters, mean (SD) 4.36 (1.01) 
FEV1 change in ml/year, mean (SD) -26.2 (33.4) 
The total SNPs call rate (%) 98.3 
GSTOl genotypes: Heterozygotes n (%) Homozygotes mutant n (%) MAF 
HWE test 
p value 
rs4925 (Alal40Asp) 500 (45.2) 96 {8.7} 31.3 0.10 
rsl1509438 (Glu208Lys) 63 (5.6) 1 (0.1) 2.9 1.00 
GST02 genotypes: 
rs17826034 480 {42.6) 92 (8.2 29.4 0.46 
rs10491045 106 (9.2) 1 (0.1) 4.7 0.53 
rs157077 571 (50.4) 213 (18.8) 44.0 a.so 
rs156697 (Asn142Asp) 506 (44.4) 141 (12.4) 34.6 0.57 
rs7085725 so (4.4) 3 (0.3} 2.5 0.06 
Unique haplotypes in the 
GST01/GST02 cluster: 
Haplotype A 574 (51.5) 250 (22.4) 48.2 0.32 
Haplotype C 191 (17.1) 9 {0.8) 9.4 0.96 
Haplotype G 47 (4.2) 1 (0.1) 2.2 0.83 
SNP = Single Nucleotide Polymorphism; FEV1 = Forced Expiratory Volume in 1 second; FVC = Forced Vital 
Capacity; SD = Standard Deviation; MAF = Minor Allele Frequency; HWE = Hardy-Weinberg Equilibrium; GST01 = 
G/utathione S-Transferase, Omega-1; GST02 = G/utathione S-Transferase, Omega-2 
Software 
Selection of tagging SNPs, linkage disequilibrium plot, haplotype frequencies and 
calculation of Hardy-Weinberg Equilibrium (HWE) p values were performed with 
Haploview (version 4.1) 13• Linear regression analysis was performed with SPSS (version 
16.0). LME models were performed with S-PLUS (version 7.0). Subjects with of 0, 1 or 2 
copies of certain haplotype were identified using PHASE software (version 2.1.1) with>95% 
probability 14'15• 
P values>0.05 were considered to be statistically significant (tested 2-sided). 
RESULTS 
All genotyped SNPs were found to be in HWE (table 1). We identified 7 haplotypes in the 
GST01/GST02 cluster and three of them (i.e. haplotypes A, C and G) were unique i.e. they 
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were not tagged by any genotyped SNP (table 2}. Of all genetic variation pairs, SNPs 
rs4 925 in GST01 and rs1782603 4 in GST02 had the highest correlation {r2=0.89, figure l}. 
Figure 1: Linkage disequilibrium plot { 100 ·r2) of genetic variations studied in the GST01/GST02 cluster 
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Table 2: Haplotypes identified in the GST01/GST02 cluster 
SNPs in the 
GST01/GST02 cluster* 
Haplotype Haplotype frequency [%] 
00 '<:I" 
M M '<:I" 
0 0 r-,. r-,. N O'l ID .-1 r-,. O'l 
0 N O'l 0 ID 
N L/'l 00 '<:I" r-,. ID 
.-1 r-,. 0 L/'l L/'l 0 
� � � � �  � 
A 0-0-0-0-0-0-0 49. 1  
B 1 -0 -1 -0 -1 -1 -0 29.2 
C 0-0-0-0-1-0-0 9.4 
D 0 -0 -0 -1 -0 -0 -0 4.8 
E 0 -1 -0 -0 -1 -1 -0 2.9 
F 0 -0 -0 -0 -1 -1 -1 2.4 
G 1-0-0-0-0-0-0 2.2 
Three unique haplotypes A, C and G are not tagged by any genotyped SNP and are depicted in bold. 
*0 /1 corresponds to wild type/mutant allele of SNPs in the GST01/GST02 cluster 
SNP = Single Nucleotide Polymorphism; GST01 = Glutathione 5-Transferase, Omega-1; GST02 = G/utathione 5-
Transferase, Omega-2 
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Effects on the level of FEV 1 
We found no significant association of any investigated variations in the GST01/GST02 
cluster with the level of FEV1 (table 3 ). Haplotype G was borderline significantly associated 
(p=0.056) with a lower FEV1 level in a dominant model (table 3 ). 
Effects on the level of FVC 
Two variations in the GST01/GST02 cluster i.e. SNP rs115094 38 and haplotype G were 
significantly associated with a lower FVC level in an additive (respectively 180.5 ml and 
160.8 ml lower FVC level per allele) and dominant models, while haplotype A was 
significantly associated with an 84 .9 ml higher FVC level in a dominant model (table 4 ). 
SNP rs156697 was associated (p=0.054 ) with a 94 .2 ml lower FVC level in a recessive 
model (table 4 ). 
Effects on FEV1 decline 
Haplotype A was significantly associated with a slower FEV1 decline in a recessive model, 
i.e. homozygotes mutant had 4 .5 ml/yr less accelerated FEV1 decline (SE=2.3 , p=0.04 9) as 
compared to other genotypes. The same haplotype was borderline significantly associated 
with slower FEV1 decline in an additive model (table 5). 
Table 3: Effects of GSTOl and GST02 variations on the level of FEV1 
Variation Heterozygotes Homozygote mutant Padditive Pdominant Prec�ssive 
B SE p B SE p 
rs4925 -2.4 29.5 0 .93 6 -48.5 51 .9 0 .3 50 0 .489 0 .7 28 0 .3 41 
rs1 1 50 943 8 -100 .9 60 .8 0 .0 97 -289.9 462.4 0 .53 1 0 .0 7 8  0 .0 85 0 .53 8 
rs1 7 8260 3 4  20 . 1  29.2 0 .491 -45.6 52.5 0 .3 85 0 .842 0 .7 3 4  0 .27 9 
rs10 4910 45 1 2.0 48.4 0 .80 4 -80 3 .2 463 .8 0 .0 84 0 .921 0 .93 6 0 .0 83 
rs1 570 7 7  26.3 3 2.0 0 .410 -9.8 40 .7 0 .81 1 0 .955 0 .587 0 .462 
rs1 56697 5.5 29.6 0 .853 -50 .2 44.4 0 .259 0 .428 0 .80 8  0 .20 5 
rs70 857 25 -5.2 67 .7 0 .93 9 8.5 270 .0 0 .97 5 0 .957 0 .947 0 .97 4 
Haplotype A 24.9 3 3 .4 0 .457 45.8 40 .1 0 .254 0 .252 0 .3 25 0 .3 81  
Haplotype C 28.2 3 6.8 0 .444 1 56.4 1 54.5 0 .3 1 1  0 .27 4 0 .3 47 0 .3 26 
Haplotype G -45.9 460 .6 0 .0 56 -1 3 1 .6 68.7 0 .921 0 .0 63 0 .0 56 0 .93 3 
Regression coefficient (B) in ml, its standard error (SE) and corresponding p value are given for heterozygous and 
homozygous mutant genotype as compared to wild type. Additionally, p values for additive, dominant and 
recessive genetic models are depicted. 
FEV1 = Forced Expiratory Volume in 1 second; GSTOl = G/utathione 5-Transferase, Omega-1; GST02 = 
Glutathione 5-Transferase, Omega-2 
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Table 4: Effects of GSTOl and GST02 variations on the level of FVC 
Variation Heterozygotes Homozygote mutant Paddltive Pdominant Precesslve 
B SE p B SE p 
rs4925 18.1 3 4.0 0 .594 -7 7 .1 59.9 0 .198 0 .551 0 .93 4 0 .13 4 
rs1150 943 8 -169.8 7 1.0 0.017 -67 7 .0 53 9.6 0 .210 0.009 0.012 0 .216 
rs17 8260 3 4  42.2 3 4.0 0 .214 -58.9 61.1 0 .3 3 6  0 .958 0 .426 0 .184 
rs10 4910 45 -1.9 56.4 0 .97 3 -7 59.1 540 .1 0 . 160 0 .7 56 0 .866 0 .160 
rs1570 7 7  50 .1 3 7 . 1 0 .17 7 -3 6.6 47 .2 0 .43 8 0 .666 0 .454 0 .100 
rs156697 30 .5 3 4.5 0 .3 7 6  -7 8.7 51.8 0 . 129 0 .428 0 .843 0 .0 54 
rs70 857 25 14.8 7 8.7 0 .850 49.2 3 14.0 0 .87 5 0 .812 0 .826 0 .87 7 
Haplotype A 90 .9 3 8.7 0.019 7 1.1 46.5 0 .126 0 . 10 3 0.021 0 .7 80 
Haplotype C 8.3 42.7 0 .845 158.5 17 9.2 0 .3 7 7  0 .597 0 .7 18 0 .3 81 
Haplotype G -158.9 7 9.7 0.046 -483 .6 53 4.1 0 .3 65 0.031 0.036 0 .3 7 4  
Significant p values are depicted in bold. 
Regression coefficient (B) in ml, its standard error (SE) and corresponding p value are given for heterozygous and 
homozygous mutant genotype as compared to wild type. Additionally, p values for additive, dominant and 
recessive genetic models are depicted. 
FVC = Forced Vital Capacity; GSTOl = Glutathione 5-Transferase, Omega-1; GST02 = G/utathione 5-Transferase, 
Omega-2 
Table 5: Effects of GSTOl and GST02 variations on FEV1 decline 
Variation Heterozygotes Homozygote mutant Padditive Pdominant Precessive 
B SE p B SE p 
rs4925 1.19 2.00 0 .550 -3 .98 3 .53 0 .261 0 .652 0 .851 0 . 17 8 
rs1150 943 8 -2.27 4.22 0 .591 -21.3 3 29.83 0 .47 5 0 .481 0 .53 1 0 .47 7 
rs17 8260 3 4  2.29 2.00 0 .253 -4.94 3 .63 0 . 17 4  0 .7 85 0 .556 0 .0 88 
rs10 4910 45 -3 .0 8  3 .3 3  0 .3 55 -50 .29 29.95 0 .0 93 0 .215 0 .27 9 0 .0 95 
rs1570 7 7  -0 .0 3 2.19 0 .990 -3 .98 2.80 0 .156 0 .20 6  0 .595 0 .10 6  
rs156697 0 .3 5  2.0 4 0 .864 -3 .45 3 .0 7  0 .262 0 .428 0 .80 1  0 .210 
rs70 857 25 -1.0 4 4.61 0 .822 -21. 3 5 17 .3 3 0 .218 0 .448 0 .60 5 0 .219 
Haplotype A 1.41 2.3 1 0 .543 5.49 2.7 8 0.049 0 .0 53 0 .426 0.049 
Haplotype C -0 .0 1 2.53 0 .995 -19.0 7 10 .70 0 .0 75 0 .47 8 0 .7 3 1  0 .0 7 5 
Haplotype G -0 .66 4.67 0 .888 4.94 30 .00 0 .869 0 .93 7 0 .911 0 .868 
Significant p values are depicted in bold. 
Negative parameter estimates (B) indicate faster FEV1 decline. 
Parameter estimate (B, table 5) in ml/yr, its standard error (SE) and corresponding p value are given for 
heterozygous and homozygous mutant genotype as compared to wild type. Additionally, p values for additive, 
dominant and recessive genetic models are depicted. 
FEV1 = Forced Expiratory Volume in 1 second; GSTOl = G/utathione 5-Transferase, Omega-1; GST02 = 
Glutathione 5-Transferase, Omega-2 
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Interaction with smoking 
There was a significant (p=0.02} interaction between rs11509438 SNP  and packyea rs 
smoked in the ana lysis concerning FEV1 l evel with in ever-smokers. The interactio n  term 
reflected that the detrimental effect of this SNP observed in the total population existed i n  
heavy smokers exclusively (subjects who smoked�12.5 packyears, i .e .  the median va lue i n  
ever smokers, figure 2 } .  No add itional sign ificant interactions between functiona l  SNPs o r  
SNPs/haplotypes with significant main effects a nd  packyears smoked or ever/never 
smoking status were observed .  
Figure 2 :  Level of FEV1 according to the rs1 1 50 943 8 (Glu20 8Lys) SNP i n  the GST01 and smoking status 
3.9 
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FEV1 = Forced Expiratory Volume in 1 second; SNP = Single Nucleotide Polymorphism; GST01 = Glutathione 5-
Transferase, Omega-1; Cl= Confidence Interval 
DISCUSSION 
I n  the cu rrent study we found that two ra re variations in the GST01/GST02 cluster 
negatively affect the level of FVC in the Dutch genera l  popu lation cohort, yet we d id  not 
rep l icate association of Asn142Asp in GSTO2 with lower lung function level reported in the 
Framingham Heart study 1. Furthermore we showed that the major hap lotype of this 
c luster has a protective effect on the level of FVC and longitud ina l  cou rse of FEV1. 
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We identified the rare haplotype and rsl15094 38  (Glu208Lys} SNP in GSTOl as a risk 
factor for low level of FVC, whereas effects on the level of FEV1 were not significant. 
Interestingly, our subsequent analysis revealed that the effect of the Glu208Lys 
substitution on the FEV1 level is more pronounced in heavy smokers. The Glu208Lys 
substitution completely tags the AGG deletion in 5' splice donor site for GSTOl exon 4 8, 
and the latter variation results in a higher thioltransferase GSTOl activity and lower heat 
stability 6• Our results suggest that, apart from the higher GSTOl activity towards thiol 
groups, AGG deletion or Glu208Lys substitution might impair GSTOl-mediated reduction 
of arsenic compounds in tobacco smoke. The second detrimental variation, i.e. the rare 
haplotype has an unknown function, yet might be in linkage disequilibrium with functional 
variations that were not investigated in the current study. 
We found seven haplotypes in the GST01/GST02 cluster in our population. Interestingly, 
the major one, prevalent in 4 9%, had a protective effect on the course of FEV1, i.e. the 
carriers of this haplotype had less accelerated FEV1 decline as compared to non-carriers. 
We additionally observed that this haplotype is significantly associated with a higher level 
of FVC. These findings may be due to an underlying biological mechanism since mutant 
variants of all investigated nonsynonymous and functional variations in both GSTOl and 
GST02 do not occur in a wild type haplotype. 
We cannot fully support the previously reported, highly significant association of the 
rsl56697 (Asn14 2Asp} SNP in the GST02 with a lower level of FEV1 and FVC in the 
Framingham Heart Study 1 . We observed a borderline significant association of this SNP 
with lower FVC level in a recessive model, whereas the associations with FEV1 level or 
decline were not significant. Interestingly, all significant associations found in the cross­
sectional FVC analysis showed similar, yet not significant, trends in FEV1 level analysis 
suggesting a restrictive, rather than obstructive, pattern of genetic effects. Similarly in the 
Framingham Heart Study Asn14 2Asp substitution showed relatively stronger association 
with the lower mean level of FVC than with the lower mean level of FEV1 (respectively 
p=9.8xlf
f6 and p=l.8x10-5 for additive effects} 1. 
In summary we identified three variations in the GST01/GST02 cluster affecting the level 
of FVC in a general population. The functional Glu208Lys SNP in GSTOl was associated 
with a lower FEV1 level in heavy smokers, while the major haplotype of the GST01/GST02 
cluster had protective effect on the longitudinal course of FEV1. 
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Chapter 10 
SUMMARY, CONCLUSIONS AND FUTURE PERSPECTIVES 
Summary of the findings 
The studies described in this thesis show that several polymorphic variations in genes 
involved in cellular pro-/anti-inflammatory and redox balance have a significant effect on 
lung function in the general population (table 1). Since lung function is a complex trait that 
is influenced by genetic and environmental factors, some biologically plausible gene by 
smoking and gene by dietary intake interactions have been investigated for the first time. 
Ultimately, certain genetic variations described in this thesis are biologically plausible 
candidates for future studies concerning lung function, smoking-related lung disorders 
and Chronic Obstructive Pulmonary Disease (COPD} in particular. 
Table 1: Genes and their polymorphic variants described in this thesis. 
Gene Chromosomal Role in vivo Previously reported Genetic findings 
position findings in COPD genetics described in the thesis 
Heme 22q12 Heme Presence of long variant of Genotypes with 
Oxygenase 1 breakdown to the GT promoter repeat medium and long or 
(HMOX1) carbon associated with accelerated with both long variants 
monoxide, free FEV1 decline in Caucasian of the GT promoter 
iron and heavy smokers and with repeat associated with 
biliverdin emphysema in Japanese; accelerated FEV1 
not associated with COPD decline 
and FEV1 decline in 
Caucasians in case-control 
studies 
Epoxide 1q42 Phase II Positive and negative No association of 
Hydrolase 1 detoxification associations regarding promoter or 
(EPHX1) enzyme nonsynonymous SNPs with nonsynonymous SNPs 
COPD across studies and with FEV1 level or 
races decline 
ATP-Binding 16p13 ATP-dependent Not studied 2 SNPs in the 3 '  region 
Cassette, trans-membrane associated with FEV1 
Subfamily C, transport of level and 1 SNP in 
Member 1 or glutathione intron 14 associated 
Multidrug conjugates and with FEV1 decline in the 
Resistance- organic anions Doetinchem and 
associated Vlagtwedde-
Protein 1 Vlaardingen cohorts 
(ABCC1 or 
MRP1) 
Glutamate- 6p12 Rate limiting step C(-129)T not associated C(-129)T SNP and 
Cysteine of glutathione with COPD in Chinese and Trinucleotide GAG 
Ligase, biosynthesis not in Caucasians Repeat associated with 
Catalytic lower level of lung 
Subunit (GCLC} function in interaction 
with smoking 
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Table 1 (continued): Genes and their polymorphic variants described in this thesis. 
Gene Chromosomal Role in vivo Previously reported Genetic findings 
position findings in COPD genetics described in the thesis 
Glutamate- lp22 Rate limiting step C(-588)T SNP associated C{-588)T SNP not 
Cysteine of glutathione with COPD in Chinese but associated with lung 
Ligase, biosynthesis not in Caucasians function level or decline 
Modifier 
Subunit (GCLM 
Sirtuin 1 10 q21 Deacetylation of Not studied No association with FEV1 
(SIRT1} histones and or VC level and nor with 
other proteins FEV1 decline 
(e.g. NFKB) 
Glutathione 5- 10 q24-q25 Metabolism of Not studied Glu20 8Lys associated 
Transferase, inorganic arsenic with lower FVC level and 
0mega-1 and vitamin C with lower FEV1 level in 
(GST01) heavy smokers in the 
Doetinchem cohort 
Glutathione 5- 10 q24-q25 Metabolism of Asn1 42Asp associated Asn1 42Asp borderline 
Transferase, inorganic arsenic with highly significant significantly associated 
0mega-2 and vitamin C negative effect on the with FVC, but not FEV1, 
(GST02} level of FEV1 and FVC in level in a recessive 
Framingham GWA study model 
Superoxide 6q25 Mitochondrial Ala1 6Val not associated lntronic SNP, but not 
0ismutase 2 synthesis of with COPD in Chinese and Ala1 6Val, associated 
(5002} peroxide from Caucasians with increased risk for 
superoxide anion BHR and COPD 
Superoxide 4p1 5 Extracellular Arg21 3 Gly associated Arg21 3 Gly associated 
0ismutase 3 synthesis of with lower risk for COPD with slower FEV1 decline 
(5003} peroxide from by two independent in never smokers but not 
superoxide anion studies; rs81 92288 in the associated with COPD; 
5' UTR associated with rs81 92288 in 5' UTR 
lower FVC level in Danish borderline significantly 
cohort associated with lower VC 
level 
Nuclear Factor 2q3 1 Transcription Promoter polymorphisms SNP in intron 1 
Erythroid 2- factor of not associated with COPD associated with lower 
Like 2 (NFE2L2) numerous in Japanese level of FEV1 in the 
antioxidant analysis of pooled 
enzymes Doetinchem and 
Vlagtwedde-Vlaardingen 
cohorts 
Kelch-Like Ech- 1 9p1 3 Cytosolic Not studied SNP in intron 3 
Associated repressor of associated with higher 
Protein 1 NFE2L2 level of FEV1 in the 




COPD=Chronic Obstructive Pulmonary Disease; FEV1=Forced Expiratory Volume in 1 second; FVC=Forced Vital 
Capacity; VC=Vital Capacity; UTR= Untranslated Region; SNP=Single Nucleotide Polymorphism 
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Chapter 2 describes a study investigating three functiona l  polymorphisms in a rate-l imiting 
enzyme of de nova antioxidant glutath ione (GSH) biosynthesis, i .e . G lutamate Cysteine 
Ligase (GCL) in  relation to the level and decl ine in lung function in the genera l popu lation. 
Add itiona l ly, this study took into account two important environmental determinants of 
lung function as potentia l  interactive factors, i .e. smoking and vitamin C intake. The 
selection of GCL polymorphisms for the study was based on the previously published  
functiona l  genetic stud ies showing an inh ibitory effect of  GAG Trinuc leotide Repeat, 
C(-588)T (rs41303970), and C{-129)T ( rs17883901) variations in the GCL subun its on the 
activity of gene promoter region or on the level of GCL's enzymatic product GSH in 
plasma .  Incorporation of smoking and vitamin C intake into the study was based on 
previous findings showing that GSH levels are increased in hea lthy smokers as compared 
to never smokers and that vitamin C is ab le to reduce GSH in the spontaneous reaction or 
in the enzymatic reaction in vivo. This study was performed in two independent Dutch 
cohorts and showed that polymorphisms in the cata lytic subun it of GCL ( i .e . GCLC gene) 
form un ique genotype combinations and are importantly contributing to a reduced lung 
function level via interaction with packyears smoked and particu larly in individua ls with 
low vitamin C intake. Inclusion of both genetic and environmenta l risk factors into the 
study provided possible strategies for neutra l iz ing harmfu l effects of smoking. This is due 
to the observation that especia l ly ind ivid ua ls with a low vitamin C intake experience 
harmfu l effects of smoking, and this effect is further enhanced by the presence of GCLC 
polymorphisms. 
The major scope of chapter 3 is on a pathway involved in the pro-/anti-inflammatory and 
redox balance in the lung in vivo. I n  this study we calcu lated intake of polyphenol ic 
compound resveratrol using 11 unique d ietary sources in the entire Doetinchem cohort 
(n=3,224). We add itiona l ly investigated separately major resveratro l sou rces, since it has 
been suggested that two of these, i .e . red wine and white wine, are associated with h igher 
level of FEV1 and FVC in the general popu lation 
1. We found a sign ificant beneficia l  effect 
of white wine intake, but not of red wine on the leve l of FEV1 in the entire Doetinchem 
cohort. I nterestingly this effect was sign ificantly more pronounced in subjects with more 
than 12.5 packyears smoked throughout l ife. In l ine with this resu lt we found that white 
wine consumption lowers the risk for mi ld  and moderate a i rway obstruction, as defined 
using Lower Limit of Normal ( LLN) FEV1 level and/or FEV1/FVC ratio .  This study add itiona l ly 
showed for the first time that resveratrol intake is associated with a h igher level of FVC, 
but not of FEV1 on a genera l population level .  However, since we d id not observe a n  
association between resveratrol intake a nd  LLN-defined a i rway obstruction, the relevance 
of resveratrol intake in relation to COPD and possibly other lung d isorders needs to be 
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addressed by subsequent studies. Since red wine contains a 4 -5 times higher resveratrol 
concentration than white wine, we concluded that resveratrol is probably not responsible 
for the observed beneficial effects of white wine on the level of lung function. Accordingly, 
Schunemann and colleagues found white wine to display a stronger effect on the level of 
FEV1 as compared to red wine in the cohort of New York residents 
1
. They suggested that 
health-promoting lifestyle factors associated with white wine drinking might be 
responsible for this observation, which implies a possible confounding effect of covariates 
that were not taken into account during the analysis. We additionally hypothesize that 
other polyphenolic compounds present in white wine may exert beneficial effect on lung 
function as well. Plausible candidates in this respect are tyrosol and hydroxytyrosol, 
polyphenolic white wine constituents with, similar to resveratrol, antioxidant and 
cardioprotective effects in vivo 2• Additionally, chapter 3 includes the analysis of four 
Single Nucleotide Polymorphisms (SNPs) tagging Sirtuin 1 (SIRT1), a deacetylase gene 
induced by resveratrol in vitro. Previous studies found lower expression of this gene in the 
lung tissue of COPD patients as compared to controls 3 and another in vivo study showed 
an anti-inflammatory effect of SIRTl, mediated by a direct interaction with NFKB 
transcription factor 4• We found no relation of any investigated variations in SIRT1 with 
either the level or course of FEV1 in the Doetinchem and Vlagtwedde-Vlaardingen cohorts. 
In order to increase the statistical power of our study we pooled both cohorts, but again 
we did not observe any significant genetic associations. Additional 5/RTl by smoking, or 
SIRT1 by resveratrol intake interaction analyses did not show that the effects of SIRT1 
variations on lung function are modified by these environmental factors in the general 
population. 
The study described in chapter 4 screened SNPs in Multidrug Resistance-associated 
Protein 1 (MRP1) affecting the level or change of FEV1 in the general population. MRPl is a 
membrane-bound pump responsible for a glutathione-dependent organic anion excretion 
(e.g. leukotriene C4 or NNAL-0-glucuronide, a cigarette smoke metabolite) from the cell in 
vivo 5• Therefore MRPl has been widely studied in the context of pharmacogenetics and 
cancer 6-9• Van der Deen and colleagues showed that MRPl is lower expressed in the 
bronchial epithelium of COPD patients, than in that of healthy controls, with a further 
expression decrement in more severe COPD stages 10• Leschziner and colleagues showed 
that 51 SNPs are required to tag the entire MRP1 gene in Caucasians 11• We selected 3 5  
MRP1 SNPs for genotyping, and tagged the remaining 1 6  SNPs using haplotypes 
constructed from genotyped SNPs. We additionally included two low-prevalent and 
functional nonsynonymous SNPs in MRP1. We found multiple SNPs in MRP1 associated 
with the FEV1 level and decline in the Doetinchem cohort, yet only 3 associations could be 
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directly replicated in the Vlagtwedde-Vlaardingen cohort. The 2 SNPs replicated for the 
effect on the level of FEV1 are located in the 3 '  region of MRP1 and form 3 (out of 4 
possible) haplotypes in the general population. Interestingly, haplotype analysis showed 
the same pattern of association with the level of FEV1 for all 3 haplotypes in both analyzed 
cohorts. Additionally, we identified one low prevalent genotype (i.e. homozygote mutant 
of the rs3 5621 SNP in intron 14 of MRP1) as a risk factor for a highly accelerated FEV1 
decline in both cohorts. The detrimental effect size due to this genotype as compared to 
the wild type, i.e. more than an additional 15.0 ml decline in FEV1 per year, is 3-4 times 
bigger than the effect of lifetime ever-smoking status. Thus, the association we found is 
certainly of clinical importance. In summary, the three SNPs in MRP1 replicated for their 
effect on the level or decline of FEV1 are plausible candidates for further studies on the 
development of COPD. Since MRPl is responsible for trans-membrane transport of 
organic anions, including clinical drugs, it is also of future interest to study functionality of 
these SNPs in the context of pharmacogenetics in established COPD. 
Chapter 5 describes a study concerning NFE2L2 and KEAP1, genes widely studied both in 
vitro and in vivo in the context of COPD 12'13 • However, to date there have not been 
genetic studies reporting on both genes and lung function in a general population. 
NFE2L2, and its cytosolic repressor KEAPl, regulate transcription of numerous antioxidant 
enzymes. We tagged both genes with eight SNPs and we additionally identified and 
studied two unique haplotypes, i.e. haplotypes not tagged by any genotyped SNP, in each 
gene. Additionally we established LD structure between tagging SNPs derived from 
HapMap and newly identified NFE2L2 promoter polymorphisms, including a Trinucleotide 
CGG Repeat (TNR) 14• Interestingly, besides the two, already known TNR alleles (i.e. 4 and 
5 CGG repeats) we observed also novel, yet very rare, alleles consisting of 2, 6, and 7 CGG 
repeats. We found no replicated association of any investigated SNPs or haplotypes with 
the level or decline of FEV1 between the Doetinchem and the Vlagtwedde-Vlaardingen 
cohorts. Pooling cohorts resulted in identification of 1 SNP in KEAPl and 1 SNP in NFE2L2 
associated with the level of FEV1, yet none of the investigated variations associated with 
FEV1 decline. Similarly, gene by gene interaction analysis, based on a direct biological 
interaction between the two genes, and gene by ever/never smoking status interaction 
analysis did not reveal significant associations in the pooled cohorts. In summary, we 
concluded that genetic variations in both KEAP1 and NFE2L2 might affect the level but not 
the change of FEV1 in the general population. However, given the relatively small 
prevalence and/or small effect size provided by these SNPs, the clinical relevance as well 
as replication of these findings needs to be addressed further. 
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Chapter 6 describes multiple lung function phenotypes in relation to SNPs in two genes 
belonging to Superoxide Dismutases (500s) family. SODs constitute a unique enzymatic 
system able to degrade noxious superoxide anion in vivo 15• Impairment of the 
mitochondrial superoxide dismutase (SOD2) activity was related to asthma 
pathophysiology 16, and extracellular superoxide dismutase (SOD3) was shown to protect 
lungs against oxidant-mediated injury 17'18 • The Arg213 Gly (rs1799895 }  substitution in 
50D3 has been associated with elevated SOD3 levels in human plasma 19 and with 
protection against COPD development by two independent studies involving Caucasian 
subjects 20•21 • It has also been shown that the rs8192288 SNP in the 50D3 5' Untranslated 
Region (UTR) constitutes a risk for more frequent COPD hospitalization and associates 
with a lower level of Forced Vital Capacity in two large Danish cohorts 22• Our study 
showed that the intronic C5774 T SNP (rs284 2958} in 50D2 was associated with the 
presence of bronchial hyperresponsiveness (BHR) and development of COPD in the 
Vlagtwedde-Vlaardingen cohort. Since both phenotypes (i.e. BHR and COPD) are 
correlated we performed a multinomial logistic regression analysis, which revealed that 
the C5774 T SNP is a risk factor for BHR in individuals without COPD. We additionally 
observed a significant association of the Arg213Gly substitution in 50D3 with slower FEV1 
decline in never-smokers exclusively, while the rs8192288 in 5' UTR of 50D3 was 
associated with borderline significantly lower Vital Capacity level. Eventually, our study 
extended previous findings concerning 50D3 gene and gave new insight into the role of 
50D2 variations in lung function of the general population. Given the low prevalence of 
most investigated SNPs in 50D2 and 50D3, our study could have been affected by low 
statistical power, possibly resulting in false negative findings. Therefore, future meta­
analyses regarding these SNPs in multiple cohorts are warranted. 
In chapter 7 SNPs in phase I I  detoxification enzyme Epoxide Hydrolase 1 (EPHXl) and their 
role in the level and change of FEV1 in the general population are described. Two 
prevalent, nonsynonymous and functional SNPs (i.e. rs105174 0 (Tyr113 His) and rs223 4 922 
(His139Arg)) in EPHXl previously showed both positive and negative associations with 
lung function and development of COPD across studies and races 23-28• We additionally 
studied three SNPs tagging the EPHXl promoter region, a region that is therefore 
hypothetically involved in the regulation of EPHXl transcription rate. We found no 
significant association of any investigated SNP in EPHXl with either of the phenotypes 
studied. We thus concluded that SNPs in EPHXl do not likely affect lung function and 
consequently COPD development in the general, Dutch population. Interestingly, a recent 
meta-analysis showed that non-synonymous variations in EPHXl affect COPD 
development in Asian, rather than in Caucasian populations, while the genotype 
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combinations of these SNPs, reflecting enzyme activity, associate with COPD 
independently from the race 29• 
Chapter 8 describes a study aiming to replicate a previously reported association between 
promoter GT repeat polymorphism in Heme Oxygenase 1 (HMOX1 )  and FEV1 decline in the 
general population. We defined HMOX1 promoter genotypes on the basis of number, and 
consequently the length, of GT repeats i.e. short, medium and long and for the first time 
analyzed all prevalent genotypes of this polymorphism. We found that subjects carrying 
medium and long or both long alleles of this repeat had an accelerated FEV1 decline as 
compared to the remaining genotypes. Furthermore, this association was observed in 
smokers and heavy smokers exclusively. We thus extended the previous findings of 
Guenegou and colleagues 30 by showing that heterozygotes carrying short and long GT 
repeat allele are not at risk for faster FEV1 decline. The underlying biological mechanism of 
the reported association may include transcription regulation of HMOX1 in response to 
pro-oxidant stimuli like hydrogen peroxide that depends on the number of promoter GT 
repeats 31• HMOXl is responsible for heme degradation in vivo. Products of heme 
breakdown, i.e. carbon monoxide, free iron and biliverdin display a variety of important 
functions in vivo including scavenging of reactive oxygen species, vasodilation, and anti­
inflammatory effects. In conclusion, as based on molecular studies, effects of GT repeat 
polymorphism in HMOX1 depend on the cellular redox status. Therefore, HMOX1 is a 
plausible candidate for studies focusing on disorders like COPD, where the pro­
/antioxidant balance is disturbed by smoking. Since results of previous case-control 
studies in COPD are not consistent and identified different risk alleles in HMOX1 25'27'31, it 
is of future interest to establish linkage disequilibrium (LD) structure of the HMOX1 
promoter, which may ultimately lead to identification of other HMOX1 variations 
associated with COPD. 
The final study in the thesis, described in chapter 9, investigated whether SNPs in the 
cluster containing Glutathione S-Transferases Omega (GSTOs) genes, i.e. GST01 and 
GST02, affect the level and course of lung function in the Doetinchem cohort. 
Nonsynonymous Asn14 2Asp (rs156697} substitution in the GST02 was among the top 
ranked SNPs in the 100K Genome Wide Association study conducted in the Framingham 
Heart Study concerning the mean level of FEV1 and FVC 
32
• Since GST02 is located 
adjacently to GST01 on chromosome 10, and the latter gene is lower expressed in lung 
tissue of COPD patients as compared to controls 33, we decided to study the entire GSTOs 
cluster. We found no association of any of the seven SNPs tagging this cluster with the 
- 165 -
Chapter 10 - Summary, conclusions and future perspectives 
level of FEV1. Interestingly three variations in the cluster were significantly associated with 
the level of FVC and a major haplotype in this locus, prevalent in 4 9%, constituted a 
protective factor for decline in FEV1 . Moreover, we found one functional SNP in GST01 
associated with the level of FEV1 in heavy smokers exclusively. This finding might be 
explained by participation of GSTOs in the rate-limiting step of detoxification of inorganic 
arsenic 34, a toxic cigarette smoke compound. Interestingly, all significant associations 
found in the cross-sectional FVC analysis showed similar, yet not significant, trends with 
the level of FEV 1, suggesting a restrictive, rather than obstructive pattern of these genetic 
effects. Similarly to the Framingham Heart Study, Asn14 2Asp substitution showed a 
relatively stronger association with a lower mean level of FVC than with a lower mean 
level of FEV1 (respectively p=9.8x10-
6 and p=1.8x10-5 for additive effects) 32• This SNP 
showed a borderline significant (p=0.054 ) association with a lower level of FVC, but not of 
FEV1 in a recessive model in the Doetinchem cohort. Overall, we could not fully confirm 
the association of this SNP with lung function level reported in the Framingham Heart 
Study. 
Conclusions 
Several studies described in this thesis characterized candidate genes that were proposed 
to play a role in COPD development, predominantly by case-control studies. Other studies 
described biologically plausible genetic candidates for the level or decline of lung function 
and COPD development in the general population. Inclusion of established environmental 
determinants of lung function such as smoking or vitamin C intake allowed studying, for 
the first time, certain gene by environment interactions. Such interactions are likely 
involved in COPD etiology and their existence is based on the fact that the effect of 
genetic variations may depend on certain environmental exposures, i.e. the effect of 
polymorphism might be more, or less, apparent in subjects exposed to the specific 
environmental factor. Therefore, variations in genes directly involved in detoxification of 
toxic cigarette smoke compounds are likely playing a minor or no role in subjects with no 
or a limited history of exposure to tobacco smoke. Consequently, polymorphisms affecting 
the function or the amount of mature antioxidant enzymes may have an abundant role in 
subjects who have smoked for many years. For example, the effects of functional 
variations in antioxidant genes GCLC and HMOX1 described in this thesis were more 
apparent in smokers and further in subjects with a higher cumulative amount of cigarettes 
smoked throughout life. Since other environmental factors than smoking have been linked 
to COPD development, it is tempting to speculate that there exist several other types of 
gene by environment interactions affecting lung function. Therefore, as based on the 
current knowledge concerning in vivo molecular pathways, two chapters in the thesis 
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incorporated ana lysis of genetic variations whi le taking into account their p laus ib le 
interaction with the intake of d ietary compounds vitamin C respectively resveratrol in 
relation to l ung function. One of the pitfa l ls in ana lyzing statistical interactions is certa in ly 
a decrement in the statistica l  power. Gene by environment interaction ana lysis req u ires 
exponentia l ly larger cohort sizes in  order to ach ieve the same statist ica l  power as  in  the 
stud ies investigating a single gene or a single environmenta l factor. Consequently, much 
larger cohort sizes are necessary for the detection of sign ificant genetic risk factor  in the 
cohort sub-samples, defined accord ing to the presence or absence of the exposu re. Th is 
observation refers a lso to the ana lysis of epistatic events, i .e .  SNP by SNP interactions, 
which u lt imately requires investigation of maxima l ly n ine genotype combinations derived 
from two non-l inked SNPs. Such ana lysis was performed in chapter 4 of this thesis, and we 
observed that some genotype combinations, and especia l ly those derived from low 
preva lent SNPs, are present in a minority of the population or are not present for a given 
popu lation size. Assumption of the significant contribution of gene by gene or gene by 
environment interactions to a certain phenotype is logica l ly fol lowed by a question about 
the contribution of more than two factors acting in an  interactive network. Therefore it is 
certain ly chal lenging, and a lso necessary, to hypothesize and ana lyze data on the 
interaction between many genes and many environmental factors s imu ltaneously. This 
requ i res large sample sizes that wi l l  l ike ly not exist in one research center or popu lation. 
Therefore, such projects requ i re a multi-cohort design, where data pool ing, achieved via 
e.g. mu lti-center col laboration or open-access datasets, a l lows significant increment in the 
statistical power of the study. 
Some stud ies described in the thesis a imed to rep l icate previously reported find ings while 
the others were conducted in two independent Dutch popu lation-based cohorts, which 
a l lowed verification and possib le repl ication of significant genetic find ings. The latter is 
cu rrent state of the art. Some chapters in this thesis lacked such repl ication (e.g. chapters 
concern ing GCLM, GST02 or MRPl genes), therefore these find ings cou ld be spu rious, and 
fa lse positive associations may have been obta ined by chance. However non-repl icated 
genetic find ings may have several other origins that need to be considered when 
interpreting resu lts from genetic association stud ies, and severa l of them will be d iscussed 
in the fol lowing sections of this chapter. 
Different cohorts and populations have often d ifferent h istories of exposure to 
environmental factors, which may cause that the effect of some variations becom ing more 
apparent in one, but less apparent in the other popu lation. For example, it is p laus ib le that 
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a gene responsible for drug transport has no phenotypic effect whatsoever in subjects not 
exposed to this drug. Contrary, variations in this gene may have a great contribution to a 
specific phenotype in subjects using the drug  on a daily basis. This example might be easily 
translated into the field of respiratory genetics, since different cohorts have different 
history of exposure to risk factors such as air pollution, tobacco smoking or environmental 
tobacco smoke in uterus, youth or adulthood, which ultimately may change the effect of 
genes involved in smoking-related pathways. This refers to the cohorts investigated in this 
thesis as well, i.e. the Doetinchem and the Vlagtwedde-Vlaardingen cohort, since smokers 
in the latter cohort on average smoked much more than smokers in the Doetinchem 
population. Another reason, which may contribute to non-replicated genetic findings is 
the statistical power provided by single cohorts to detect certain genetic effect. For 
example, the Vlagtwedde-Vlaardingen cohort has a higher power to study phenotypes like 
FEV1 decline as compared to the Doetinchem cohort, due to the longer follow-up time and 
higher number of FEV1 measurements in the participating subjects. To ensure that the 
obtained results do not represent either false positive or false negative findings it is 
therefore necessary to perform a meta-analysis on both populations under study. Analysis 
on the pooled datasets of the cohorts, as performed in chapter 2 and 4 of the thesis, 
increases the power of the study, and consequently decreases the number of spurious 
findings. However, false negative findings may still be present due to a low prevalence 
and/or small phenotypic effect of the SNP. 
Another way to reduce the number of non-replicated findings is an improvement of 
genotyping quality and the use of preferably the same phenotype definitions between the 
cohorts studied. In all chapters, validation of the genotyping quality has been performed 
by assessing deviation from Hardy-Weinberg Equilibrium, since it is expected that in 
general population samples such deviations should not occur. Additionally some DNA 
samples were checked for possible between-sample contaminations during genotyping of 
the tri- and more allelic markers and by additional genotyping of stock DNA samples. This 
allowed us to assume a validity of genotype calls obtained. Next to genotyping, there may 
be inconsistencies of phenotype definition between different studies, which may 
contribute to non-replication of genetic findings as well. Phenotyping mismatch concerns 
especially the definition of COPD that may vary between studies and might be defined 
based on lung function measurements using different spirometry protocols {e.g. post- or 
pre-bronchodilator measurements) and spirometers or different COPD subphenotypes 
{e.g. emphysema scores or COPD symptoms). For example, it is likely that the effect of 
functional variation in genes involved in destruction of lung parenchyma tissue will 
become more apparent in studies involving COPD patients with severe emphysema, as 
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compared to studies investigating COPD patients with no emphysematous characteristics, 
yet with respiratory symptoms like chronic cough or chronic phlegm production and 
airway obstruction. Moreover, the presence of airway obstruction is a prerequisite for a 
COPD diagnosis. However, this has been established that some individuals may have no 
signs of airway obstruction, yet do have emphysema as assessed by a chest tomography 
{CT} scan. This may also hamper a genetic analysis and the proof of significance. 
Future perspectives 
Research on the genetics of respiratory disorders is certainly a dynamic field of science 
and will intensify in the future. In the past decades, hypothesis driven candidate gene 
approaches were usually applied. Another strategy, aiming to identify genetic risk factors 
for complex diseases, has been studying the inheritance pattern and the segregation of 
genetic microsatellite markers in families with assessed quantitative {e.g. FEV1 level} or 
qualitative {e.g. COPD diagnosis} traits. Such approaches are applied in genome wide 
linkage studies that have been very successful in identifying genetic variants associated 
with rare, following Mendelian pattern of inheritance, disorders like sickle cell anemia or 
cystic fibrosis. The Boston early-onset COPD genome wide scan revealed a strong linkage 




• Further studies of this region 
pointed SERPINE2, a member of serine proteases inhibitors, as a positional candidate gene 
for COPD development 37• Five SNPs in SERPINE2 were associated with COPD or COPD 
phenotypes in the National Emphysema Treatment Trial and Boston Early-Onset COPD 
Study. However, a subsequent large case -control study did not confirm these 
associations, which could be due to a difference in the disease severity between cases 
included in those studies 38• 
The recent advances in genotyping technology facilitated genotyping of million or more 
SNPs in one DNA sample. The application of this technique, known as Genome-Wide 
Association {GWA} study, allows using a hypothesis-free approach in finding genetic 
variations predisposing for different complex disorders. The first reported GWA study on 
quantitatively defined lung function in the general population was performed on the 
Framingham study and identified SNPs in multiple genes not previously studied in the 
context of COPD or lung function genetics e.g. Small Nuclear Ribonucleoprotein 
Polypeptide N in relation to the decline in FEV 1 or Rhomboid Domain Containing 1 in 
relation to the level of FEV1. Interestingly, the only one nonsynonymous SNP {Asn14 2Asp} 
among the most significant SNPs in the cross-sectional lung function analysis is located in 
the Glutathione 5-Transferase Omega 2 (GST02}, a gene coding antioxidant enzyme 
involved in the metabolism of inorganic arsenic and vitamin C. GST02 is located adjacently 
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to GSTOl on chromosome 10, and both enzymes contain well characterized functional 
polymorphisms. GSTOl is present in the bronchoalveolar lavage fluid and abundantly 
present in alveolar macrophages, and especially in patients with very severe COPD 33• 
Interestingly, the GSTOl level is lower in induced sputum or lung homogenates of COPD 
patients as compared to smokers or non-smokers, which might be partially explained by 
decreased levels of alveolar macrophages in patients with severe COPD 33• 
Recent genome wide association studies identified alpha/beta-nicotinic acetylcholine 
receptors cluster (CHRNA3, CHRNAS, and CHRNB4) on chromosome 15 as a susceptibility 
locus for lung cancer and nicotine dependence 39.4°, thus likely involved in COPD 
development as well. Another study found that there are two haplotypes, conferring 
protective and respectively harmful effects on nicotine addiction, at this locus 41• 
A subsequent study provided evidence for an association of nonsynonymous (Asp3 98Asn) 
rs16969968 SNP in CHRNAS with COPD, independently of lung cancer and smoking 42• 
A GWA study on COPD performed in four independent populations confirmed 15q25 locus 
as a region associating with COPD with a substantial population attributable risk of 
approximately 12% for the top-ranked SNP 43 • Based on the strength of the association, it 
has been concluded that the rs803 4 191 or the synonymous rs1051730 SNP in CHRNA3 are 
more likely to be causal variants as compared to the highly, but not completely, linked 
Asp3 98Asn substitution in CHRNAS. Furthermore, this GWA study proposed Hedgehog 
Interacting Protein (HHIP) as a gene likely involved in COPD development, yet the 
observed associations of SNPs in HHIP did not reach the strict levels of GWA significance. 
Interestingly the parallel GWA study on the FEV1/FVC ratio in the Framingham Heart Study 
identified four SNPs nearby HHIP (yet not linked with HHIP variations) associated with the 
presence of airway obstruction measured both quantitatively and qualitatively 44• The 
hedgehog pathway participates in lung branching during lung development 45, which 
might provide a biological explanation for highly significant associations of SNPs located 
near and within HHIP with FEVi/FVC ratio and development of COPD. 
It is therefore of future interest whether associations of both, 15q25 and 4 q3 1, loci can be 
extended and replicated by other independent studies, involving other respiratory 
phenotypes like FEV1 decline and cohorts of different ethnicities. The association of 15q25 
region with COPD certainly requires further investigation in the context of phenotypic 
causality, i.e. whether this region and most likely CHRNAs locus associates with COPD 
development via nicotine addiction exclusively or via yet unknown biological mechanisms. 
It is also of interest to perform genetic association studies while taking into account 
possible comorbidities, which refers especially to the 15q25 locus associated with both 
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lung cancer and COPD. Importantly, COPD is an independent risk factor for the squamous 
cell lung carcinoma and the incidence of lung cancer correlates with the degree of airway 
obstruction 46• Therefore it is possible, that shared genetic component, like genetic 
variations in the CHRNA locus on chromosome 15, predispose for lung cancer via causative 
association with COPD or with a degree of nicotine dependence. 
Consequently, as based on the postulated in vivo role of HHIP, it is of great importance to 
study this gene in the context of lung growth that should be preferably assessed in cohorts 
followed from birth up to the plateau phase in lung development and further, in the 
general-population-based prospective cohorts of adults, with lung function in a decline 
phase. 
Hypothesis-free approaches such as GWA studies are required to identify novel genetic 
factors in studies focused on lung function and smoking-related lung disorders. Such an 
approach is used in the ongoing COPACETIC study, consisting of a large discovery cohort of 
COPD cases and controls without COPD yet with a comparable amount of packyears and 
additionally five replication cohorts from different European countries 47• The availability 
of CT scans as well as spirometry measurements in the COPACETIC study will lead to a 
distinction of COPD subphenotypes such as emphysema, or airway obstruction without 
emphysematous changes in relation to genetic variations. Ultimately this approach might 
result in a reduction of false positive and false negative findings, due to phenotypic 
mismatch. Moreover it may help to better understand why some individuals smoke and 
develop severe emphysema, and why others develop mild airway obstruction only. 
The identification of genetic risk factors for complex disorders requires subsequent 
functional studies in order to better understand biological mechanisms underlying the 
identified associations. The recent study concerning functionality of 15q25 locus showed 
that rsl6969968 SNP influence CHRNAS mRNA transcripts level in normal lung tissue from 
adenocarcinoma patients 48, which provides a basic explanation for previously observed 
associations in GWA studies. Another example of functional genetic studies preceding and 
following epidemiological associations concerns polymorphisms in the S' region of GCLC 
gene, described in chapter 1 of this thesis. Both variations in the 5' GCLC region, i.e. 
Trinucleotide GAG repeat and the rs17883901 (C{-129}T} SNP, have functional significance 
as shown by multiple studies, yet none of these studies investigated the effect of both 
variations simultaneously 49-51 • This certainly requires attention since these polymorphisms 
are in strong LD, and form 4 haplotypes (out of 6 theoretical assuming the absence of LD} 
in the Caucasian population. Therefore it is of interest to focus on haplotypes rather than 
single polymorphisms when assessing the in vitro role of variations in S' GCLC region. The 
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role of variants in a promoter region, such as those in the GCLC, may be investigated with 
a reporter vectors system (figure 1). Using this approach the expression of the reporter 
gene (e.g. firefly luciferase) is quantified for each 5' GCLC haplotype, containing 
polymorphisms of interests and additionally all putative regulatory elements 52 required 
for constitutive gene expression. Subsequent transfection of reporter vectors to lung­
derived cell line like A54 9 allows determining expression of reporter gene according to 
specific 5' GCLC haplotype. Ultimately such a study assesses the difference in a 
transcriptional activity provided by different, yet naturally occurring, GCLC haplotypes in 
vitro. Moreover this system may be used for a molecular explanation of the observed gene 
by environment interactions, since exogenous stimulants like a cigarette smoke extract or 
cytokines can be added to transfected cell cultures and subsequently can induce or 
decrease activity of the promoter studied. 
Figure 1: Reporter vector containing 4.2 kb of 5' GCLC 
haplotype 
The map of 4.2 kb 5' GCLC haplotype cloned into the pGL3 -
basc vector (Promega, UK) using Hindlll and Ncol restriction 
sites. Positions of HapMap-derived SNP (rs67 590 8) and two 
remaining and functional polymorphisms are indicated. 
Arrows indicate position of luciferase gene (/uc+) used for 
expression quantification and 6-/actamase gene (Amp') 






( ... )CCc:TBGGCA( •• ) 
rsl7883901: 
( ••. )AACTG!GACC( ..• ) 
Neal Trinucleotide GAG Repeat: 
( ... IGAGGAGGAGGAGGAGGAGGAG\nsGAGlnsGAG( ..• I 
Candidate gene studies, including those described in this thesis, are required for a more 
complete understanding of crucial biological pathways in the lung. Due to the complexity 
of lung function genetics, these studies may provide apparently contrasting results. This 
emphasizes the necessity of analyzing gene by environment interactive components, 
replication of results, and meta-analysis of independent studies. Eventually, all these steps 
may lead to a robust estimate of the effect of genetic variation on the analyzed 
phenotype. The constant improvement of high throughput genotyping arrays, like those 
used in GWA studies, will allow in the nearest future identification of novel genetic 
variations with relatively high significance (i.e. small p-values), which affect lung growth, 
timing and speed of lung function decline and development of COPD. The worldwide 
efforts of scientists in meta-analyses of data will subsequently contribute to mapping 
variations with lower penetrance, yet with still significant and clinically relevant effects. 
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Other genomic techniques, like whole genome resequencing arrays, which have not been 
yet performed in the context of COPD, are additionally required to characterize genetic 
background of COPD in more detail. Such an approach will facilitate identification of yet 
unknown and/or very rare mutations predisposing for COPD, and subsequent functional 
genetic studies should explain a biological mechanisms behind identified associations. All 
the above can be eventually be used for a more accurate prediction of COPD development 
and subsequent disease progression at an individual level, and may contribute to a 
personalized, thus more effective, therapy in COPD. This might ultimately lead to a 
decrease in worldwide burden of COPD and COPD-related mortality. 
Importantly, changes in DNA sequence are not the only one affecting genomic 
transcription machinery. It is known that multiple epigenetic events contribute to the 
expression and function of genes and proteins. Promoter DNA methylation and histone 
deacetylation are well-known examples of epigenetic phenomena that may silence or 
enhance gene expression. Gene methylation status has already been shown to be 
important in diseases with complex etiology like lung cancer, as well as in diseases where 
a single DNA region determines disease onset like in the Prader-Willi syndrome. However 
the nature of epigenetic events in respiratory system and COPD pathology remains 
uncovered and still needs to be addressed. 
In summary, genetic determinants of lung function and predisposition to COPD are related 
in complex structures including environmental and endogenous factors that are still 
largely unknown. The meta-analyses of data from multiple cohorts, and advances in high­
throughput genotyping technology will certainly contribute to the identification of novel 
genes with a varying disease penetrance. The novel techniques will allow studying the 
genome, including the epigenome, more deeply and will shed new light on the role of 
genes in the function of the human lung. 
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De in dit proefschrift beschreven studies tonen aan dat verschillende polymorfe 
genetische variaties die betrokken zijn bij de cellulaire pro- en anti-inflammatoire - en 
redoxbalans een significant effect hebben op de longfunctie van de algehele bevolking {zie 
tabel 1 in de Engelse summary). Omdat de longfunctie een complex systeem is dat 
be"invloed wordt door genetische en omgevingsfactoren, hebben we enkele biologisch 
plausibele interacties tussen genen en roken en tussen genen en dieet voor het eerst 
onderzocht. 
Hoofdstuk 2 beschrijft een onderzoek waarbij drie functionele polymorfismes in een 
enzym dat bij de biosynthese van de novo antioxidant glutathion betrokken is, i.e. 
Glutamate Cysteine Ligase (GCL), zijn onderzocht in relatie tot het longfunctieniveau en de 
afname daarvan in de algehele populatie. Daarbij is rekening gehouden met twee 
belangrijke omgevingsfactoren die mogelijk van invloed zijn op de longfunctie, namelijk 
roken en vitamine C-inname. Dit onderzoek werd uitgevoerd bij twee onafhankelijke 
Nederlandse cohorten. Uit het onderzoek bleek dat polymorfismes in de katalytische 
subunit van GCL {namelijk het GCLC gen) unieke genotypecombinaties vormen die in 
belangrijke mate bijdragen aan een verminderde longfunctie, in combinatie met het 
aantal pakjaren gerookte sigaretten {1 pakjaar is het roken van 1 pakje sigaretten per dag, 
gedurende een jaar lang) en vooral bij personen met een lage vitamine C-inname. Het 
betrekken van zowel genetische risicofactoren als die van de omgeving bij het onderzoek 
leverde mogelijke strategieen op om het nadelige effect van roken te neutraliseren. 
Hoofdstuk 3 beschrijft een proces dat onderdeel is van de pro- en anti-inflammatoire - en 
redoxbalans in de long in vivo. In deze studie hebben we de inname van de 
polyfenolverbinding resveratrol berekend. Daarnaast hebben we belangrijke 
resveratrolbronnen apart onderzocht, omdat verondersteld wordt dat twee hiervan, 
namelijk rode en witte wijn, zijn geassocieerd met een betere longfunctie in de algehele 
bevolking. Het bleek dat witte wijn wel, maar rode wijn geen significant positief effect had 
op het FEV1 {Forced Expiratory Volume in 1 second)- niveau in het hele Doetinchem­
cohort. Opvallend genoeg was dit effect het grootst bij personen die gedurende hun hele 
leven meer dan 12,5 pakjaren hadden gerookt. Dit resultaat sloot aan bij onze 
bevindingen dat consumptie van witte wijn de kans op lichte en gemiddelde 
luchtwegobstructie verlaagt. Het onderzoek wees tevens voor het eerst uit dat 
resveratrolinname gerelateerd is aan een toename van FVC, maar niet van FEV1 in de 
algehele bevolking. Omdat de resveratrolconcentratie in rode wijn vier tot vijf keer zo 
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hoog is als in witte wijn, concludeerden we dat resveratrol waarschijnlijk niet 
verantwoordelijk is voor de waargenomen positieve effecten van witte wijn op de 
longfunctie. Hoofdstuk 3 bevat tevens een analyse van vier Single Nucleotide 
Polymorphisms (SNPs} van Sirtuin 1 (SIRTl}, een deacetylase-gen dat door resveratrol in 
vitro wordt opgewekt. Er was geen samenhang te vinden tussen de onderzochte variaties 
in SIRTl en het niveau of het verloop van de FEV1 in de Doetinchem- en Vlagtwedde­
Vlaardingen-cohorten. Als we de beide cohorten samengevoegden, met als doel om de 
statistische power te verhogen, vonden we ook geen significante genetische associaties. 
In het onderzoek dat in hoofdstuk 4 wordt beschreven, zijn SNPs in Multidrug Resistance­
associated Protein 1 {MRPl} en hun invloed op FEV1 in de algehele bevolking onderzocht. 
MRPl is een membraangebonden pomp die verantwoordelijk is voor de uitscheiding van 
glutathion-afhankelijke organische anionen (bijv. leukotriene C4 of NNAL-O-glucuronide, 
een metaboliet van sigarettenrook} van de eel in vivo. We hebben 3 5  MRPl SNPs 
geselecteerd voor genotypering en nog eens 16 SNPs getagged, daarbij gebruikmakend 
van haplotypes geconstrueerd uit de gegenotypeerde SNPs. Verschillende SNPs in MRPl 
bleken geassocieerd met het FEV1-niveau en de afname daarvan in het Doetinchem­
cohort, maar slechts drie associaties konden rechtstreeks gerepliceerd warden in het 
Vlagtwedde-Vlaardingen cohort. De twee SNPs die gerepliceerd werden voor het effect op 
het FEV1 -niveau bevinden zich in de 3 '-regio van MRPl. Bovendien hebben we een minder 
gangbaar genotype ge°identificeerd (namelijk de homozygote mutant van de rs3 5621 SNP 
in intron 14 van MRPl} als een risicofactor voor een versnelde afname van FEV1 in beide 
cohorten. Het nadelige effect van dit genotype in vergelijking met wild type, i.e. een extra 
afname van 15,0 ml FEV1 per jaar, is drie tot vier keer grater dan het effect van ooit roker 
zijn geweest. Daarom is het verband dat we hebben gevonden van klinisch belang. 
Hoofdstuk 5 beschrijft een onderzoek omtrent NFE2L2 en KEAPl, genen die zowel In vitro 
als in vivo uitgebreid onderzocht zijn in de context van COPD. Tot nu toe is er echter geen 
genetisch onderzoek gedaan naar beide genen in relatie tot elkaar en hun effect op de 
longfunctie in de algehele bevolking. NFE2L2 en zijn cytosolische repressor KEAPl 
reguleren de transcriptie van verschillende antioxidante enzymen. We hebben beide 
genen getagged met acht SNPs, maar vonden geen gerepliceerd verband tussen de 
onderzochte SNPs of haplotypes en het FEVrniveau of afname ervan in het Doetinchem­
cohort of in het Vlagtwedde-Vlaardingen-cohort. Het samenvoegen van de cohorten 
leidde tot de identificatie van twee SNPs in KEAPl en NFE2L2 die verband hielden met het 
FEV1 -niveau, maar geen van de onderzochte variaties was geassocieerd met een afname 
van FEV1. Ook bleken er geen significante associaties te bestaan in de samengevoegde 
- 178 
Nederlandse samenvatting 
cohorten na analyse van gen-gen interacties, of gen-roken interacties. Samenvattend 
concluderen we dat genetische variaties in zowel KEAPl als NFE2L2 het niveau van FEV1 in 
de algehele bevolking wel zouden kunnen be'invloeden maar niet de verandering ervan. 
Hoofdstuk 6 beschrijft verscheidene longfunctie-fenotypes in relatie tot SNPs in twee 
genen die behoren tot de groep van 5uperoxide 0ismutases (5OOs). 500s vormen een 
uniek enzymatisch systeem dat schadelijke superoxide anionen in vivo kan afbreken. De 
Arg213Gly (rs1799895}-substitutie in 5003 wordt in verband gebracht met bescherming 
tegen het ontwikkelen van COPD, terwijl het rs8192288 SNP in de 5003 5' Untranslated 
Region het risico met zich meebrengt vaker wegens COPD in het ziekenhuis te warden 
opgenomen en in verband wordt gebracht met een lagere FVC (Forced Vitale Capacity) in 
twee grate Deense cohorten. Ons onderzoek heeft aangetoond dat het intronische 
C5774 T SNP (rs284 2958} in 5002 gerelateerd is aan de aanwezigheid van BHR (Bronchial 
Hyperresponsiveness) en de ontwikkeling van COPD in het Vlagtwedde-Vlaardingen 
cohort. Omdat beide fenotypes (BHR en COPD) gecorreleerd zijn, hebben we een 
multinomial logistic regressie-analyse uitgevoerd, waaruit bleek dat de C5774 T SNP een 
risicofactor is voor BHR bij mensen zonder COPD. We ontdekten tevens een significante 
samenhang van de Arg213Gly-substitutie in 5003 met een langzamere FEV1-afname 
uitsluitend bij mensen die nooit gerookt hebben, terwijl het rs8192288 SNP in de 5003 5' 
UTR gerelateerd was met een, net niet significante, lagere FVC. 
In hoofdstuk 7 warden SNPs in fase II detoxificatie-enzym Epoxide Hydrolase 1 (EPHXl) en 
hun invloed op het niveau van en veranderingen in FEV1 in de algehele populatie 
beschreven. Twee prevalente, non-synonymous en functionele SNPs (namelijk rs105174 0 
(Tyr113 His) en rs223 4 922 (His139Arg)) in EPHXl bleken zowel positieve als negatieve 
associaties te hebben met longfunctie en het ontwikkelen van COPD in verschillende 
onderzoeken en rassen. Tevens hebben we drie SNPs onderzocht die het EPHXl 
promoter-gebied taggen. We hebben geen significante associaties gevonden tussen de 
onderzochte SNPs in EPHXl en een van beide onderzochte fenotypes. De conclusie was 
dan oak dat SNPs in EPHXl waarschijnlijk geen invloed hebben op de longfunctie en dus 
oak niet op het ontstaan van COPD in de algehele Nederlandse bevolking. 
Hoofdstuk 8 beschrijft een onderzoek met als doel het repliceren van een eerder 
aangetoonde associatie tussen promoter GT repeat polymorphism in Heme 0xygenase 1 
(HM0Xl) en FEV1-afname in de algehele populatie. We hebben een versnelde FEV1-
afname gevonden bij mensen met een middellange en een lange of met twee lange allelen 
van deze repeat in vergelijking met de overige genotypes. Bovendien werd dit verband 
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uits lu itend aangetoond bij rokers en bij zware rokers. Omdat de resu ltaten van vroegere 
case-control stud ies op het gebied van COPD niet consistent zijn en er versch i l lende risico­
a l le len in HMOXl zij n  gevonden, is het belangrijk voor toekomstig onderzoek om de 
l inkage d isequ i l ibri um  {LD)-structuur  vast te ste l len van de  HMOXl promoter, wat 
uiteindel ijk  kan le iden to de identificatie van andere HMOXl-variaties d ie verband houden 
met COPD.  
Tot slot is in hoofdstuk 9 van d it proefschrift beschreven of SNPs in het Glutathione 5-
Transferases Omega (GSTOs) cl uster {name l ijk GSTOl en G5TO2) de longfunctie 
be"invloeden in het Doetinchem cohort. De non-synonymous Asn142Asp {rs156697)­
substitutie in GST02 bleek een van de belangrijkste SNPs te zijn in de 100K Genome Wide 
Association stud ie, u itgevoerd in het kader van de Fram ingham Heart Study aangaande 
het gemiddelde n iveau van FEV1 en FVC. Omdat GST02 naast GSTOl op chromosoom 10 
l igt, en de  expressie van het laatstgenoemde gen voor wat betreft longweefsel lager is bij 
COPD patienten dan  bij een controlegroep, besloten we het he le cluster van GSTOs te 
onderzoeken. Geen van de zeven SNPs was geassocieerd met het FEV1 -niveau. Orie 
va riaties van het c luster hadden een significante associatie met het FVC-niveau en een 
belangrijk haplotype in d it locus, dat in  49% van de geva l len voorkomt, bl ijkt een 
beschermende factor te zijn voor afname van FEV
1
. Net als in  de Framingham Heart Study, 
l iet Asn142Asp substitutie een relatief sterkere associatie z ien met een lager gemidde ld 
niveau  van FVC dan  met een lager gemidde ld n iveau van FEV1 {respectieve l ijk  p=9,8x10· 
en p=1,8x10"5 voor een add itief efffect) .  Deze SNP l iet een associatie (p=0.054) z ien met 
een lager niveau  van FVC, maar niet van FEV1 in een recessief model in het Doetinchem 
cohort. U iteinde l ij k  konden we het verband van d it SNP met de  longfunctie zoals 
gerapporteerd in de  Framingham Heart Study n iet vol led ig bevestigen . 
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